BioMedLib Search Engine
[ goto HOMEPAGE ]
Search the biomedical literature, for the most relevant articles.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
b cell small lymphocytic lymphoma 2005:2010[pubdate] *count=100
1175 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
b cell small lymphocytic lymphoma
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 1175
1.
Esteghamati A, Khalilzadeh O, Ashraf H, Zandieh A, Morteza A, Rashidi A, Meysamie A, Nakhjavani M:
Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007).
Metabolism
; 2010 Dec;59(12):1730-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Physical activity is correlated with
serum leptin
independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007).
Reports on the relationship between
leptin
and physical activity (PA) at the population
level
are scarce.
The present study examined the relationship between
serum leptin
concentrations and PA in a nationally representative sample of 3001 Iranian adults aged 25 to 64 years.
Serum leptin
was measured with an enzyme-linked immunosorbent assay.
After adjustment for age, area of residence, smoking, body mass index, and waist circumference, total PA (r = -0.129, P = .038 in men and r = -0.226, P = .006 in women), the duration of vigorous-intensity activity (r = -0.120, P = .044 in men and r = -0.154, P = .019 in women), the duration of moderate-intensity activity (r = -0.114, P = .047 in men and r = -0.160, P = .018 in women), and time spent on sedentary behaviors (r = 0.194, P = .014 in men and r = -0.204, P = .007 in women) were significantly correlated with
serum leptin
.
In both sexes, participants in higher categories of PA had significantly lower
serum leptin levels
.
In conclusion, our results demonstrated an inverse association between
leptin
concentrations and PA independent of age, sex, smoking, and body adiposity.
Our results point to the regulatory effects of PA on
serum leptin
.
[MeSH-major]
Exercise.
Leptin
/ blood. Obesity / physiopathology. Population Surveillance
Genetic Alliance.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Exercise and Physical Fitness
.
MedlinePlus Health Information.
consumer health - Obesity
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
(PMID = 20580780.001).
[ISSN]
1532-8600
[Journal-full-title]
Metabolism: clinical and experimental
[ISO-abbreviation]
Metab. Clin. Exp.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Leptin
2.
Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P:
Prognostic significance of serum adipokine levels in colorectal cancer patients.
Anticancer Res
; 2009 Aug;29(8):3321-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic significance of
serum
adipokine
levels
in colorectal cancer patients.
BACKGROUND: Adipokines may significantly influence the growth and proliferation of tumor stroma and
malignant
cells within.
Reduced adiponectin and increased
leptin serum levels
were found in colorectal cancer (CRC) patients.
Recently, it has been demonstrated that tumor necrosis factor-alpha (TNF-alpha) is able to induce dose-dependent changes in
serum
adipokine
levels
.
MATERIALS AND METHODS: Baseline
leptin
, adiponectin and TNF-alpha
levels
were analyzed in 90 patients with histologically diagnosed primary or newly diagnosed metastatic CRC treated at 'Tor Vergata' Clinical Center and followed up for a median period of 3 years.
RESULTS:
Serum leptin levels
were higher in CRC patients than in controls (p<0.0001).
Conversely,
serum
adiponectin
levels
were lower in CRC patients than in controls (p<0.0001).
Leptin
inversely correlated with adiponectin (p<0.005).
The
leptin
/adiponectin (L/A) ratio was eight-fold greater in CRC compared to controls (p<0.0001).
CONCLUSION:
Serum
adipokine
levels
might have a role in the biology of CRC and the combined measurement of
leptin
and adiponectin
levels
might provide useful prognostic information in the management of patients with CRC.
[MeSH-minor]
Adiponectin / blood. Adult. Aged. Case-Control Studies. Female. Follow-Up Studies. Humans.
Leptin
/ blood. Male. Middle Aged.
Neoplasm
Recurrence, Local / blood.
Neoplasm
Recurrence, Local / pathology.
Neoplasm
Recurrence, Local / surgery. Prognosis. Survival Rate. Treatment Outcome. Tumor Necrosis Factor-alpha / blood
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19661351.001).
[ISSN]
1791-7530
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / Leptin; 0 / Tumor Necrosis Factor-alpha
3.
Bhat GK, Plant TM, Mann DR:
Relationship between serum concentrations of leptin, soluble leptin receptor, testosterone and IGF-I, and growth during the first year of postnatal life in the male rhesus monkey, Macaca mulatta.
Eur J Endocrinol
; 2005 Jul;153(1):153-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Relationship between
serum
concentrations of
leptin
, soluble
leptin
receptor, testosterone and IGF-I, and growth during the first year of postnatal life in the male rhesus monkey, Macaca mulatta.
OBJECTIVES: Subnormal
leptin levels
in low birth weight infants may allow for catch-up growth during infancy.
Scant data are available that relate growth with circulating
leptin
during normal infancy in primates.
The current study objective was to examine the association between
serum leptin
, its soluble receptor (sOB-R), testosterone and IGF-I concentrations, and body weight during infancy in male rhesus monkeys.
DESIGN: Hormone
levels
were assessed longitudinally in animals (n = 7) from birth until 1 year of age.
RESULTS: Body weight increased during the first 6 months of life and was strongly correlated with rising IGF-I
levels
and, as IGF-I plateaued and then declined during the second half of the year, body weight gain decelerated.
In contrast,
leptin levels
declined gradually with age during the first year of life in conjunction with increasing body weight.
There was no association between body weight gain and
serum leptin levels
or between
serum
testosterone and
leptin
values.
Since sOB-R
levels
also declined with
leptin
values, it does not appear that
levels
of bioavailable
leptin
changed during infancy.
CONCLUSIONS: The data do not support the contention that
leptin
regulates growth during infancy, but the close association between IGF-I
levels
and body weight suggested that this hormone may regulate growth in infant male monkeys.
The failure to observe an association between
serum
testosterone and
leptin
concentrations suggested that
leptin
is not involved in the activation of the hypothalamic-pituitary -testicular axis during this developmental period.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
TESTOSTERONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15994757.001).
[ISSN]
0804-4643
[Journal-full-title]
European journal of endocrinology
[ISO-abbreviation]
Eur. J. Endocrinol.
[Language]
ENG
[Grant]
United States / NIGMS NIH HHS / GM / GM08248; United States / NICHD NIH HHS / HD / HD08610; United States / NICHD NIH HHS / HD / HD13254; United States / NICHD NIH HHS / HD / HD41749; United States / NCRR NIH HHS / RR / RR03024
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
England
[Chemical-registry-number]
0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 3XMK78S47O / Testosterone; 67763-96-6 / Insulin-Like Growth Factor I
Advertisement
4.
Kojima M, Sakurai S, Shimizu K, Itoh H:
B-cell cutaneous lymphoid hyperplasia representing progressive transformation of germinal center: a report of 2 cases.
Int J Surg Pathol
; 2010 Oct;18(5):429-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
B-
cell
cutaneous lymphoid hyperplasia representing progressive transformation of germinal center: a report of 2 cases.
The authors report histomorphologic, immunophenotypic, and genotypic findings of 2 cases of B-
cell
CLH demonstrating progressive transformation of germinal center (PTGC).
PTGC was characterized by enlarged but
well
-circumscribed follicles without clear demarcation of the germinal center and mantle zone, which contained a predominance of
small
lymphocytes
and variable numbers of centrocytes, centroblasts, and immunoblasts.
However, there were no centroblasts and immunoblasts resembling
lymphocytic
and/or histiocytic Reed-Sternberg
cell
variants in nodular
lymphocyte
-predominant Hodgkin
lymphoma
(NLPHL) in either lesion.
These unusual CLHs should be
differentiated
from the primary cutaneous marginal zone B-
cell lymphoma
, primary cutaneous follicular
lymphoma
, particularly "floral variant," or NLPHL.
To avoid overdiagnosis and overtreatment, immunophenotypic and genotypic studies are required along with careful
morphologic
examination.
[MeSH-major]
B-
Lymphocytes
/ pathology.
Cell
Transformation, Neoplastic / pathology. Germinal Center / pathology. Pseudolymphoma / pathology. Skin Diseases / pathology
[MeSH-minor]
Aged. Biomarkers / metabolism.
Diagnosis
, Differential. Female. Fluorescent Antibody Technique, Direct. Humans. Immunophenotyping.
Lymphoma
, B-
Cell
, Marginal Zone /
diagnosis
.
Lymphoma
, Follicular /
diagnosis
. Male. Middle Aged. Skin Neoplasms /
diagnosis
MedlinePlus Health Information.
consumer health - Skin Conditions
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18815203.001).
[ISSN]
1940-2465
[Journal-full-title]
International journal of surgical pathology
[ISO-abbreviation]
Int. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers
5.
Grønbaek K, Ralfkiaer U, Dahl C, Hother C, Burns JS, Kassem M, Worm J, Ralfkiaer EM, Knudsen LM, Hokland P, Guldberg P:
Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms.
Mod Pathol
; 2008 May;21(5):632-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Frequent hypermethylation of DBC1 in
malignant
lymphoproliferative neoplasms.
Here, we examined DBC1 at 9q33.1
as a
potential target in lymphomagenesis.
DBC1 is a putative tumor suppressor that has been shown to be involved in the regulation of
cell
growth and programmed
cell
death.
DBC1 was hypermethylated in 5 of 5 B-
cell
-derived
lymphoma cell
lines, 41 of 42
diffuse
large B-
cell
lymphomas
, 24 of 24 follicular
lymphomas
, 5 of 5 mantle
cell
lymphomas
, 4 of 4
small lymphocytic
lymphomas
, 1 of 2 lymphoplasmacytoid
lymphomas
, and in 12 of 12 acute lymphoblastic leukemias, but was unmethylated in 1 case of splenic marginal zone
lymphoma
, in 12 of 12 multiple myelomas, in 24 of 24 reactive
lymph
nodes, and in 12 of 12 samples of blood
lymphocytes
from random donors.
DBC1 hypermethylation was associated with transcriptional silencing in
lymphoma cell
lines, and reexpression of this gene could be induced by treatment with the demethylating agent, 5-aza-2'-deoxycytidine.
Our data suggest that hypermethylation of the DBC1 promoter region is a frequent event during the development of lymphoproliferative malignancies, and that DBC1 hypermethylation may serve
as a
marker for these cancers.
[MeSH-minor]
Aged. CpG Islands / genetics. DNA,
Neoplasm
/ genetics. Humans. Middle Aged. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18264085.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DBC1 protein, human; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins
6.
Krcmár J, Kotolová H, Veselá L, Csöllei J, Gonec T, Karpísek M, Bartosová L, Necas J:
[Study of a newly synthesized substance with a potential to stimulate beta3-adrenergic receptors].
Ceska Slov Farm
; 2006 May;55(3):120-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The effects of six-week oral administration of the newly synthesized substance B496 (methyl-4-[2-[2-hydroxy-3-(4-ethylcarbamoyl)phenoxyprophyl]amino]etyl)-phenoxyacetate hydrochloride) on
serum
glucose, triglycerides, total cholesterol, and
leptin levels
were studied in male Wistar rats fed with a high-fat diet.
The results indicated a significant reduction in
serum
glucose
levels
(-26 %, p<0,01), triacylglyceride
levels
(-21 %, p<0,05) and
leptin levels
(-43 %, p<0,01).
Further the effect of a single intraperitoneal dose (1 mg/kg) of B496 and BRL-37344 on
serum leptin levels
in the C57Bl/6J mouse was investigated.
Administration of BRL-37344 resulted in a significant decrease in
serum leptin levels
(-55 %, p<0,001).
[MeSH-major]
Adrenergic beta-Agonists / pharmacology.
Leptin
/ blood. Receptors, Adrenergic, beta-3 / drug effects
Hazardous Substances Data Bank.
CHOLESTEROL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16838489.001).
[ISSN]
1210-7816
[Journal-full-title]
Ceská a Slovenská farmacie : casopis Ceské farmaceutické spolecnosti a Slovenské farmaceutické spolecnosti
[ISO-abbreviation]
Ceska Slov Farm
[Language]
cze
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Czech Republic
[Chemical-registry-number]
0 / Adrenergic beta-Agonists; 0 / B496 compound; 0 / Blood Glucose; 0 / Ethanolamines; 0 / Leptin; 0 / Phenoxyacetates; 0 / Receptors, Adrenergic, beta-3; 0 / Triglycerides; 114333-71-0 / BRL 37344; 97C5T2UQ7J / Cholesterol
7.
Becker DJ, Sevilla DW, O'Connor O:
Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in a patient with hepatitis C virus.
Acta Haematol
; 2010;123(2):77-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Concurrent and apposed hepatocellular carcinoma and
small lymphocytic lymphoma
/chronic
lymphocytic
leukemia in a patient with hepatitis C virus.
A patient with chronic hepatitis C virus (HCV) presented to our clinic with a hepatic mass
as well
as lymphocytosis.
Biopsy of the hepatic mass revealed apposed hepatocellular carcinoma (HCC) and
small lymphocytic lymphoma
(
SLL
)/chronic
lymphocytic
leukemia (CLL).
Dramatic examples of
lymphoma
regression during treatment with antiviral medication in chronic HCV patients have suggested an etiologic role for HCV in lymphomagenesis.
A growing body of research seeks to clarify the details of the interaction between HCV and B-
cell
lymphomas
.
This case of adjacent
SLL
/CLL and HCC is the first published
diagnosis
of these two diseases in the liver at one time, and the only published example of the physical apposition of any
lymphoma
and HCC.
[MeSH-major]
Carcinoma, Hepatocellular / virology. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ virology. Liver Neoplasms / virology
[MeSH-minor]
Aged. Hepatitis C, Chronic / complications. Hepatitis C, Chronic /
diagnosis
. Humans. Male
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
Genetic Alliance.
consumer health - Hepatitis
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 S. Karger AG, Basel.
(PMID = 20029171.001).
[ISSN]
1421-9662
[Journal-full-title]
Acta haematologica
[ISO-abbreviation]
Acta Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Switzerland
8.
Wang X, Yuling H, Yanping J, Xinti T, Yaofang Y, Feng Y, Ruijin X, Li W, Lang C, Jingyi L, Zhiqing T, Jingping O, Bing X, Li Q, Chang AE, Sun Z, Youxin J, Jinquan T:
CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells.
J Immunol
; 2007 Sep 1;179(5):2880-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CCL19 and CXCL13 synergistically regulate interaction between
B cell
acute
lymphocytic
leukemia CD23+CD5+ B Cells and CD8+ T cells.
However, the interaction between
malignant
B and T cells remains to be fully elucidated.
In a previous study, we have reported that ligation of CCL19-CCR7 and CXCL13-CXCR5 activates paternally expressed gene 10 (PEG10), resulting in an enhancement of apoptotic resistance in B-
cell
acute
lymphocytic
leukemia (B-ALL) CD23+CD5+ B cells.
Here, we report that B-ALL CD23+CD5+ B cells produce IL-10 at high
level
, which can be further elevated by costimulation with CCL19 and CXCL13.
CCL19/CXCL13-activated B-ALL CD23+CD5+ B cells, in turn, increase IL-10 expression in syngeneic CD8+ T cells in a
B cell
-derived IL-10-dependent manner and requiring a
cell
-
cell
contact.
Moreover, using a short hairpin RNA to knockdown PEG10, we provide direct evidence that increased expression of PEG10 in B-ALL CD23+CD5+ B cells is involved in
malignant
B-T
cell
interaction, contributing to the up-regulation of IL-10 expression,
as well
as to the impairment of cytotoxicity of syngeneic CD8+ T cells.
Thus,
malignant
B-ALL CD23+CD5+ B cells play an immunoregulatory role in controlling different inflammatory cytokine expressions.
[MeSH-major]
B-
Lymphocytes
/ immunology. Burkitt
Lymphoma
/ immunology. CD8-Positive T-
Lymphocytes
/ immunology. Chemokine CCL19 / physiology. Chemokine CXCL13 / physiology. Immunologic Surveillance / immunology
[MeSH-minor]
Adolescent. Adult. Antigens, CD5 / analysis. Child. Child, Preschool. Cytotoxicity, Immunologic. Female. Humans. Interleukin-10 / metabolism. Male. Middle Aged. Proteins / antagonists & inhibitors. Proteins / genetics. Proteins / metabolism. RNA,
Small
Interfering / pharmacology. Receptors, IgE / analysis. Up-Regulation
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
J Immunol. 2007 Nov 15;179(10):7184
(PMID = 17709502.001).
[ISSN]
0022-1767
[Journal-full-title]
Journal of immunology (Baltimore, Md. : 1950)
[ISO-abbreviation]
J. Immunol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD5; 0 / CXCL13 protein, human; 0 / Chemokine CCL19; 0 / Chemokine CXCL13; 0 / PEG10 protein, human; 0 / Proteins; 0 / RNA, Small Interfering; 0 / Receptors, IgE; 130068-27-8 / Interleukin-10
9.
Brown JR:
Inherited predisposition to chronic lymphocytic leukemia.
Expert Rev Hematol
; 2008 Oct;1(1):51-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Inherited predisposition to chronic
lymphocytic
leukemia.
Inherited susceptibility to chronic
lymphocytic
leukemia (CLL) has been recognized for decades.
Approximately 10% of individuals with CLL report a family history of CLL or a related lymphoproliferative
disorder
, and genetic predisposition is the best understood risk factor for CLL.
Monoclonal B-
cell
lymphocytosis (MBL) has been identified recently
as a
likely precursor to CLL; it is found in the general population with increasing age and enriched in unaffected relatives of individuals with familial CLL.
Studies of MBL
as well
as mouse models of CLL may lead to better understanding of early CLL pathogenesis that is relevant to familial predisposition.
To date, the identification of genes that predispose to familial CLL has been slow, primarily due to the relatively few families available for study, the
small
size of those families and disease causation most likely by multiple genes that each confer smaller risks.
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2002 Jul 15;100(2):635-9
[
12091358.001
]
[Cites]
Leukemia. 2002 Jul;16(7):1229-32
[
12094247.001
]
[Cites]
Leuk Res. 2002 Sep;26(9):791-4
[
12127552.001
]
[Cites]
Blood. 2002 Aug 1;100(3):1100-1
[
12150154.001
]
[Cites]
Blood. 2002 Oct 1;100(7):2289-90
[
12239136.001
]
[Cites]
Br J Haematol. 1997 Apr;97(1):107-12
[
9136948.001
]
[Cites]
Immunity. 1997 Nov;7(5):703-13
[
9390693.001
]
[Cites]
Leukemia. 1998 Nov;12(11):1696-8
[
9823943.001
]
[Cites]
Am J Hum Genet. 1999 Jul;65(1):265-9
[
10364544.001
]
[Cites]
Leukemia. 1999 Oct;13(10):1497-500
[
10516748.001
]
[Cites]
Nat Rev Genet. 2005 Oct;6(10):756-65
[
16205715.001
]
[Cites]
N Engl J Med. 2005 Oct 27;353(17):1793-801
[
16251535.001
]
[Cites]
Lancet Oncol. 2006 Jan;7(1):27-38
[
16389181.001
]
[Cites]
Int J Immunogenet. 2006 Feb;33(1):21-4
[
16426238.001
]
[Cites]
Leukemia. 2006 Feb;20(2):280-5
[
16341048.001
]
[Cites]
Cytometry B Clin Cytom. 2007 Sep;72(5):344-53
[
17266153.001
]
[Cites]
Cytogenet Genome Res. 2007;118(1):8-12
[
17901694.001
]
[Cites]
Int J Cancer. 2007 Nov 15;121(10):2260-6
[
17583571.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3326-33
[
17687107.001
]
[Cites]
Nat Genet. 2007 Nov;39(11):1315-7
[
17934461.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):690-700
[
18021083.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):701-8
[
18021084.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):724-9
[
18021087.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):762-71
[
18021089.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):774-9
[
18021091.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):645-57
[
17941951.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):809-19
[
17941952.001
]
[Cites]
Br J Haematol. 2007 Dec;139(5):744-52
[
17961188.001
]
[Cites]
J Clin Oncol. 2007 Dec 1;25(34):5448-57
[
17968022.001
]
[Cites]
Nat Genet. 2008 Mar;40(3):281-3
[
18264098.001
]
[Cites]
Nat Genet. 2008 May;40(5):631-7
[
18372901.001
]
[Cites]
Nat Genet. 2008 May;40(5):623-30
[
18372905.001
]
[Cites]
Nat Genet. 2008 May;40(5):616-22
[
18385676.001
]
[Cites]
Blood. 2008 Jun 15;111(12):5446-56
[
18216293.001
]
[Cites]
Blood. 2008 Jun 15;111(12):5691-3
[
18424666.001
]
[Cites]
N Engl J Med. 2008 Aug 7;359(6):575-83
[
18687638.001
]
[Cites]
Leuk Res. 2009 Jan;33(1):162-5
[
18556064.001
]
[Cites]
Br J Haematol. 1999 Dec;107(3):616-24
[
10583268.001
]
[Cites]
Blood. 2000 Feb 15;95(4):1413-9
[
10666219.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3028-33
[
10716693.001
]
[Cites]
Eur J Haematol. 2000 Aug;65(2):114-7
[
10966171.001
]
[Cites]
Mol Cell. 2000 Aug;6(2):395-407
[
10983986.001
]
[Cites]
Blood. 2000 Dec 1;96(12):3982-4
[
11090088.001
]
[Cites]
N Engl J Med. 2000 Dec 28;343(26):1910-6
[
11136261.001
]
[Cites]
Blood. 2001 Apr 1;97(7):2098-104
[
11264177.001
]
[Cites]
Int J Cancer. 2001 Apr 15;92(2):203-7
[
11291046.001
]
[Cites]
Cancer. 2001 Sep 1;92(5):1325-30
[
11571749.001
]
[Cites]
Leuk Lymphoma. 2001 Jun;42(1-2):99-108
[
11699227.001
]
[Cites]
Lancet. 2002 Mar 30;359(9312):1114-9
[
11943260.001
]
[Cites]
Blood. 2002 Jun 1;99(11):4216-8
[
12010828.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60
[
12011454.001
]
[Cites]
Blood. 2002 Jul 15;100(2):603-9
[
12091354.001
]
[Cites]
Br J Haematol. 2002 Dec;119(3):713-5
[
12437649.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
[
12434020.001
]
[Cites]
Cancer Causes Control. 2002 Nov;13(9):791-5
[
12462543.001
]
[Cites]
Leuk Lymphoma. 2002 Oct;43(10):1987-90
[
12481897.001
]
[Cites]
Cytometry B Clin Cytom. 2003 Mar;52(1):1-12
[
12599176.001
]
[Cites]
Br J Haematol. 2003 Jun;121(6):866-73
[
12786797.001
]
[Cites]
Leuk Res. 2003 Oct;27(10):973-5
[
12860021.001
]
[Cites]
Blood. 2004 Mar 15;103(6):2337-42
[
14630808.001
]
[Cites]
Cancer Res. 2004 Apr 1;64(7):2424-33
[
15059895.001
]
[Cites]
J Natl Cancer Inst. 2004 May 5;96(9):673-82
[
15126604.001
]
[Cites]
Leukemia. 2004 Jun;18(6):1162-3
[
15085160.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1065-7
[
15184265.001
]
[Cites]
Semin Hematol. 2004 Jul;41(3):201-6
[
15269880.001
]
[Cites]
Blood. 2004 Sep 15;104(6):1850-4
[
15161669.001
]
[Cites]
Cancer Cell. 2004 Oct;6(4):399-408
[
15488762.001
]
[Cites]
N Engl J Med. 1987 May 21;316(21):1289-94
[
3574400.001
]
[Cites]
Leuk Res. 1991;15(5):305-14
[
2046383.001
]
[Cites]
Cancer Res. 1992 Jan 15;52(2):437-43
[
1370214.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80
[
1454823.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12530-4
[
7809072.001
]
[Cites]
Blood. 1996 Jun 15;87(12):4990-7
[
8652811.001
]
[Cites]
Am J Hum Genet. 1996 Nov;59(5):990-8
[
8900225.001
]
[Cites]
Leuk Res. 2005 Jan;29(1):59-61
[
15541476.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16600-5
[
15545599.001
]
[Cites]
N Engl J Med. 2005 Apr 21;352(16):1667-76
[
15843669.001
]
[Cites]
Cancer. 2005 May 1;103(9):1906-15
[
15779016.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1245-50
[
15894680.001
]
[Cites]
Leukemia. 2005 Jun;19(6):1025-8
[
15800670.001
]
[Cites]
J Natl Cancer Inst. 2005 Jul 20;97(14):1088-9; author reply 1093-5
[
16030308.001
]
[Cites]
J Natl Cancer Inst. 2005 Jul 20;97(14):1089-90; author reply 1093-5
[
16030309.001
]
[Cites]
J Natl Cancer Inst. 2005 Jul 20;97(14):1090-1; author reply 1093-5
[
16030310.001
]
[Cites]
J Natl Cancer Inst. 2005 Jul 20;97(14):1091-2; author reply 1093-5
[
16030311.001
]
[Cites]
J Natl Cancer Inst. 2005 Jul 20;97(14):1092-3; author reply 1093-5
[
16030312.001
]
[Cites]
Br J Haematol. 2005 Aug;130(3):325-32
[
16042682.001
]
[Cites]
Am J Hum Genet. 2005 Sep;77(3):420-9
[
16080117.001
]
[Cites]
J Immunol. 2005 Oct 1;175(7):4309-19
[
16177071.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
[
16166262.001
]
[Cites]
J Natl Cancer Inst. 2005 Oct 5;97(19):1466-74
[
16204696.001
]
[Cites]
Int J Cancer. 2006 Apr 1;118(7):1831-5
[
16217763.001
]
[Cites]
J Clin Oncol. 2006 Feb 20;24(6):983-7
[
16432079.001
]
[Cites]
Br J Haematol. 2006 Apr;133(1):59-61
[
16512829.001
]
[Cites]
Leukemia. 2006 Apr;20(4):728-9
[
16437141.001
]
[Cites]
Semin Oncol. 2006 Apr;33(2):195-201
[
16616066.001
]
[Cites]
Nat Genet. 2006 Jun;38(6):659-62
[
16715099.001
]
[Cites]
Blood. 2006 Jul 15;108(2):638-44
[
16574953.001
]
[Cites]
Haematologica. 2006 Aug;91(8):1117-20
[
16885053.001
]
[Cites]
Blood. 2006 Aug 15;108(4):1334-8
[
16670263.001
]
[Cites]
Leuk Res. 2006 Dec;30(12):1573-6
[
16581122.001
]
[Cites]
Blood. 2007 Feb 1;109(3):916-25
[
17047154.001
]
[Cites]
Blood. 2007 Feb 1;109(3):1202-10
[
17053054.001
]
[Cites]
Int J Cancer. 2007 Mar 1;120(5):1099-102
[
17131330.001
]
[Cites]
Br J Haematol. 2007 Apr;137(2):173-5
[
17391501.001
]
[Cites]
Nat Genet. 2007 May;39(5):645-9
[
17401363.001
]
[Cites]
Nat Genet. 2007 May;39(5):631-7
[
17401366.001
]
[Cites]
Cell. 2007 Jun 1;129(5):879-90
[
17540169.001
]
[Cites]
Blood. 2007 Jun 15;109(12):5079-86
[
17351108.001
]
[Cites]
Leuk Lymphoma. 2007 Jun;48(6):1087-91
[
17577771.001
]
[Cites]
Nature. 2007 Jun 28;447(7148):1087-93
[
17529967.001
]
[Cites]
Nat Genet. 2007 Aug;39(8):977-83
[
17603485.001
]
[Cites]
Nat Genet. 2007 Aug;39(8):984-8
[
17618284.001
]
(PMID = 19802369.001).
[ISSN]
1747-4094
[Journal-full-title]
Expert review of hematology
[ISO-abbreviation]
Expert Rev Hematol
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / K23 CA115682-03; United States / NCI NIH HHS / CA / K23 CA115682-04; None / None / / K23 CA115682-03; United States / NCI NIH HHS / CA / CA115682-01; United States / NCI NIH HHS / CA / K23 CA115682; United States / NCI NIH HHS / CA / CA115682-04; United States / NCI NIH HHS / CA / K23 CA115682-01; United States / NCI NIH HHS / CA / CA115682-02; United States / NCI NIH HHS / CA / K23 CA115682-02
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
[Keywords]
NOTNLM ; association / familial chronic lymphocytic leukemia / linkage / lymphocytosis / monoclonal B cell
10.
Jose VJ, Mariappan P, George PV, Selvakumar, Selvakumar D:
Serum leptin levels in acute myocardial infarction.
Indian Heart J
; 2005 Jan-Feb;57(1):39-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Serum leptin levels
in acute myocardial infarction.
BACKGROUND: Several studies have shown an association of
serum leptin levels
with cardiovascular diseases.
The present study was undertaken to assess
levels
of
serum leptin
in patients presenting with acute ST segment elevation myocardial infarction.
The
serum leptin levels
in patients with myocardial infarction was 6.51 +/- 6.76 ng/ml versus 2.86 +/- 2.22 ng/ml in controls.
In the multivariate analysis the odds ratio for
serum leptin
with myocardial infarction was 1.45 with a 95% confidence interval of 1.2 to 1.8.
CONCLUSIONS: Our results suggest that
serum leptin level
is elevated in patients with acute ST segment elevation myocardial infarction.
[MeSH-major]
Leptin
/ blood. Myocardial Infarction / blood
MedlinePlus Health Information.
consumer health - Heart Attack
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15852893.001).
[ISSN]
0019-4832
[Journal-full-title]
Indian heart journal
[ISO-abbreviation]
Indian Heart J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Chemical-registry-number]
0 / Leptin
11.
Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, Pruneri G, Orlando L, Martinelli G:
Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients.
Leuk Lymphoma
; 2010 Aug;51(8):1485-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Rituximab and subcutaneous cladribine in chronic
lymphocytic
leukemia for newly diagnosed and relapsed patients.
The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic
lymphocytic
leukemia (CLL).
Forty-three patients with active CLL or
small lymphocytic lymphoma
received rituximab 375 mg/m(2) on day 1 and cladribine 0.1 mg/kg subcutaneously on days 2-6.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ drug therapy.
Neoplasm
Recurrence, Local / drug therapy. Salvage Therapy
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
CLADRIBINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20578816.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Equilibrative Nucleoside Transporter 1; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; 0 / SLC29A1 protein, human; 0 / cif nucleoside transporter; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
12.
Xiao C, Su ZL, Wu QL, Gao HY, Fang JC, Xia ZJ, Guan ZZ:
[Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
Zhonghua Bing Li Xue Za Zhi
; 2005 Jan;34(1):22-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinical and pathological reassessment of 493 cases of non-Hodgkin'
s lymphomas
according to current WHO
classification
of lymphoid neoplasms].
OBJECTIVE: To investigate the clinical and pathological features of non-Hodgkin's
lymphoma
(NHL) and to evaluate the applicability of the new WHO
classification
of lymphoid neoplasms.
METHODS: According to the new WHO
classification
, a total of 500 cases of non-Hodgkin's
lymphoma
diagnosed during the period 1992 - 2003 were reviewed and reappraised with their morphological, immunological and clinical characteristics.
RESULTS: Among 500 cases previously diagnosed
as lymphomas
, 493 cases (98.6%) were confirmed to be NHL, of which B-
cell
neoplasms was 69.0% and T/NK-
cell
neoplasms 29.8%.
Overall, 6 subtypes including
diffuse
large B-
cell lymphoma
(DLBCL), follicular
lymphoma
(FL), unspecified peripheral T-
cell lymphoma
(PT-un), precursor T-lymphoblastic
lymphoma
(T-LBL), extranodal marginal zone B-
cell lymphoma
of MALT
type
(MALT) and B-
small lymphocytic lymphoma
(B-
SLL
) were among the most common subtypes.
In pediatric and young patient populations, the most common subtypes were LBL, DLBCL and Burkitt's
lymphoma
.
Marginal zone B-
cell lymphoma
and
SLL
demonstrated the best prognosis, LBL and PT-un both the worst, whereas DLBCL and FL had an intermediate prognosis, however, subgrouping of FL according to WHO
classification
did not reveal a significant survival difference (P > 0.05).
CONCLUSIONS: Basing upon the results of a comprehensive survey on the
morphologic
features, immunophenotyping and clinical data of the above cases, the new WHO
classification
of lymphoid neoplasms is practical and easily applicable for routine pathological evaluation of lymphoproliferaive disorders and in guiding the clinical management.
[MeSH-major]
Lymphoma
, Non-Hodgkin /
classification
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Burkitt
Lymphoma
/ epidemiology. Burkitt
Lymphoma
/ pathology. Child. Child, Preschool. China / epidemiology. Female. Humans. Killer Cells, Natural.
Lymphoma
, B-
Cell
/
classification
.
Lymphoma
, B-
Cell
/ epidemiology.
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
, Follicular /
classification
.
Lymphoma
, Follicular / epidemiology.
Lymphoma
, Follicular / pathology.
Lymphoma
, Large B-
Cell
,
Diffuse
/ epidemiology.
Lymphoma
, Large B-
Cell
,
Diffuse
/ pathology.
Lymphoma
, T-
Cell
/
classification
.
Lymphoma
, T-
Cell
/ pathology. Male. Middle Aged. Prognosis. Retrospective Studies. World Health Organization
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15796877.001).
[ISSN]
0529-5807
[Journal-full-title]
Zhonghua bing li xue za zhi = Chinese journal of pathology
[ISO-abbreviation]
Zhonghua Bing Li Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
13.
Teixeira PF, Cabral MD, Silva NA, Soares DV, Braulio VB, Couto AP, Henriques JL, Costa AJ, Buescu A, Vaisman M:
Serum leptin in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition.
Thyroid
; 2009 May;19(5):443-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Serum leptin
in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition.
BACKGROUND: The relationship between thyroid status, including subclinical hypothyroidism (SH) and
serum leptin
is controversial or uncertain.
Therefore we evaluated
serum leptin
in SH and overt hypothyroidism (OH) and determined the effects of levothyroxine (LT(4)) replacement on
serum leptin
in these disorders.
METHODS:
Serum leptin
, thyrotropin (TSH), free thyroxine, insulin, glucose, and body composition parameters were compared in 55 SH, 20 OH, and 28 euthyroid (EU) pre- and postmenopausal women.
In addition, the effect of LT(4) treatment on
serum leptin
in SH and OH was assessed.
RESULTS: The mean +/- SD (median)
serum leptin
concentrations in the OH and SH groups were higher than in the EU group (35.1 +/- 27.2 [33.0] and 36.6 +/- 21.9 [30.6] ng/mL, respectively, vs. 23.2 +/- 19.3 [17.9] ng/mL, p = 0.011), but the difference was only significant in postmenopausal women.
In premenopausal women there was no correlation between
leptin
, BMI, or FMI and
serum
TSH
levels
(r(s) = 0.009, p = 0.474; r(s) = 0.043, p = 0.367; r(s) = 0.092, p = 0.232).
In the postmenopausal women, the partial correlation coefficient between TSH and
leptin
was present, even when controlling for BMI (r(s) = 0.297, p = 0.042) and FMI (r(s) = 0.275, p = 0.050).
LT(4) treatment was associated with a reduction of
serum leptin
concentrations in the OH group (p = 0.008).
In SH group there were no differences between LT(4) replacement or no treatment, since a fall in
serum leptin levels
was detected in both SH subgroups, despite a more pronounced fall with LT(4) use.
CONCLUSIONS:
Serum leptin
concentrations are elevated in postmenopausal women with SH or OH.
A relationship between thyroid status and
serum leptin
is further supported by the fact that LT(4) treatment, to restore the EU status, reduced
serum leptin levels
in OH in the absence of significant effects on BMI.
In women, hypothyroidism influences either
leptin
secretion or degradation and this effect is more pronounced in postmenopausal than in premenopausal women.
[MeSH-major]
Body Composition. Hormone Replacement Therapy. Hypothyroidism / drug therapy.
Leptin
/ blood. Postmenopause / blood. Premenopause / blood. Thyroxine / therapeutic use
MedlinePlus Health Information.
consumer health - Hormone Replacement Therapy
.
MedlinePlus Health Information.
consumer health - Hypothyroidism
.
Hazardous Substances Data Bank.
LEVOTHYROXINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19415994.001).
[ISSN]
1557-9077
[Journal-full-title]
Thyroid : official journal of the American Thyroid Association
[ISO-abbreviation]
Thyroid
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Blood Glucose; 0 / Insulin; 0 / Leptin; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine
14.
Oumeish OY, Oumeish I, Tarawneh M, Salman T, Sharaiha A:
Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature.
Int J Dermatol
; 2006 Mar;45(3):306-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's
lymphoma
developing into chronic
lymphocytic
leukemia: the first case reported in the literature and review of the literature.
A 56-year-old married female presented in May 1998 with a 5-month history of xanthelasma of the eyelids, followed 4 months later by two enlarged
lymph
nodes of the left side of the neck and three of the left axilla.
In July 1998, computed tomography (CT) scans of the chest and abdomen with contrast medium showed pretracheal, bilateral axillary, right retrochural, paracaval, aortocaval, and para-aortic
lymph
node enlargement.
These findings were suggestive of
lymphoma
.
One cervical and two left axillary
lymph
nodes were excised.
They revealed total replacement of the nodular architecture by
a diffuse
proliferation of mature lymphoid cells having
small
nuclei and a crumbled chromatin pattern, and very rare mitosis.
It was concluded from the
lymph
node biopsies that these changes were typical of non-Hodgkin's
lymphoma
,
diffuse
and
small cell
type
, of low-grade malignancy.
The bone marrow picture was consistent with
diffuse
,
well
-
differentiated
non-Hodgkin's
lymphoma
, developing into chronic
lymphocytic
leukemia (CLL).
Endoscopy showed antral-
type
gastric mucosa exhibiting mild chronic gastritis.
Skin biopsy from a fresh lesion on the back showed
a diffuse
inflammatory
cell
infiltrate with collections of histiocytic cells.
The blood picture also showed monoclonal IgG paraprotein (3170 mg/dL) of the kappa light chain
type
.
The patient was treated by the oncologist for her
lymphoma
, and was given Cytoxan, prednisolone, endoxan, Leukeran, and melphalan.
She also responded to Leukeran at a dose of 5 mg daily for 5 days every month for 6 months, and showed regression in the size of the
lymph
nodes.
[MeSH-major]
Granuloma / pathology. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ etiology.
Lymphoma
, Non-Hodgkin / complications. Necrobiotic Disorders / pathology. Paraproteinemias / etiology. Xanthomatosis / pathology
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
Genetic Alliance.
consumer health - Xanthogranuloma
.
Hazardous Substances Data Bank.
MELPHALAN
.
Hazardous Substances Data Bank.
CHLORAMBUCIL
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16533236.001).
[ISSN]
0011-9059
[Journal-full-title]
International journal of dermatology
[ISO-abbreviation]
Int. J. Dermatol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
15.
Gadzinowski J, Kowalska K, Vidyasagar D:
Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO.
J Perinatol
; 2008 Dec;28 Suppl 3:S56-66
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment of MAS with PPHN using combined therapy:
SLL
, bolus surfactant and iNO.
In this study, thirteen infants with
diagnosis
of MAS and PPHN were first treated with conventional respiratory support.
Then between 2 and 22h of life they were randomized either to bolus surfactant treatment (n=6) or surfactant lung lavage (
SLL
, n=7) treatment.
The results showed that infants treated with
SLL
had significant improvements in oxygenation, decreases in MAP and A-a gradients.
In conclusion these data show no advantage of
SLL
therapy over bolus surfactant treatment in infants with MAS complicated by PPHN.
Hazardous Substances Data Bank.
NITRIC OXIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19057612.001).
[ISSN]
1476-5543
[Journal-full-title]
Journal of perinatology : official journal of the California Perinatal Association
[ISO-abbreviation]
J Perinatol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
0 / Pulmonary Surfactants; 31C4KY9ESH / Nitric Oxide
16.
Holland-Cunz S, Göppl M, Rauch U, Bär C, Klotz M, Schäfer KH:
Acquired intestinal aganglionosis after a lytic infection with varicella-zoster virus.
J Pediatr Surg
; 2006 Mar;41(3):e29-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
She underwent multiple laparotomies in which histological sections of the entire
small
intestine could be obtained.
A more detailed immunohistochemical analysis using neuronal (PGP, enolase), glial (S100), and
lymphocytic
(LCA) antibodies demonstrated a nearly complete neuronal loss.
[MeSH-major]
Enteric Nervous System / pathology. Enteric Nervous System / virology. Herpes Zoster / complications. Intestinal Diseases / etiology. Intestine,
Small
/ innervation
[MeSH-minor]
Child, Preschool. Female. Humans. Ileus / etiology. Immunocompromised Host. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ complications
MedlinePlus Health Information.
consumer health - Shingles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16516611.001).
[ISSN]
1531-5037
[Journal-full-title]
Journal of pediatric surgery
[ISO-abbreviation]
J. Pediatr. Surg.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
17.
Aldoss IT, Blumel SM, Bierman PJ:
The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma.
Cancer Manag Res
; 2009;1:155-65
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The role of bendamustine in the treatment of indolent non-Hodgkin
lymphoma
.
There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin
lymphoma
(NHL).
This agent has a high degree of activity against a variety of tumor
cell
lines.
Clinically, bendamustine has demonstrated activity against indolent NHL, chronic
lymphocytic lymphoma
, multiple myeloma and mantle
cell lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2008 Sep 20;26(27):4473-9
[
18626004.001
]
[Cites]
Anticancer Drugs. 2005 Sep;16(8):871-7
[
16096436.001
]
[Cites]
J Clin Oncol. 2009 Feb 10;27(5):812-26
[
19103723.001
]
[Cites]
Ther Clin Risk Manag. 2008 Aug;4(4):727-32
[
19209254.001
]
[Cites]
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
[
19474385.001
]
[Cites]
Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6
[
2456618.001
]
[Cites]
Biochim Biophys Acta. 1972 Dec 22;287(3):386-9
[
4629776.001
]
[Cites]
Semin Oncol. 2002 Aug;29(4 Suppl 13):12-4
[
12170426.001
]
[Cites]
N Engl J Med. 2005 Feb 3;352(5):441-9
[
15689582.001
]
[Cites]
J Clin Oncol. 2002 Aug 1;20(15):3262-9
[
12149300.001
]
[Cites]
Blood. 2005 Dec 1;106(12):3725-32
[
16123223.001
]
[Cites]
J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12
[
16402269.001
]
[Cites]
J Clin Oncol. 2006 Sep 1;24(25):4143-9
[
16896003.001
]
[Cites]
Cancer Chemother Pharmacol. 2007 May;59(6):759-70
[
16957931.001
]
[Cites]
Anticancer Drugs. 2007 Jun;18(5):587-95
[
17414628.001
]
[Cites]
J Clin Oncol. 2007 May 20;25(15):1986-92
[
17420513.001
]
[Cites]
Leukemia. 2007 Nov;21(11):2316-23
[
17597807.001
]
[Cites]
Leuk Lymphoma. 2007 Jul;48(7):1299-306
[
17613757.001
]
[Cites]
J Cancer Res Clin Oncol. 2008 Feb;134(2):245-53
[
17653574.001
]
[Cites]
Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 1:S13-7
[
18282361.001
]
[Cites]
Blood. 2008 Jul 15;112(2):330-9
[
18451308.001
]
[Cites]
J Cancer Res Clin Oncol. 2009 Feb;135(2):227-34
[
18719942.001
]
[Cites]
Blood. 2008 Oct 1;112(7):2596-7
[
18809766.001
]
[Cites]
Anticancer Drugs. 1996 Jun;7(4):415-21
[
8826610.001
]
[Cites]
J Clin Oncol. 1997 Mar;15(3):1110-7
[
9060552.001
]
[Cites]
Pharmazie. 1985 Nov;40(11):782-4
[
4095129.001
]
[Cites]
J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9
[
12458340.001
]
[Cites]
Semin Oncol. 2002 Aug;29(4 Suppl 13):4-11
[
12170425.001
]
[Cites]
Blood. 2005 Feb 15;105(4):1417-23
[
15494430.001
]
[Cites]
J Clin Oncol. 2005 May 20;23(15):3383-9
[
15908650.001
]
[Cites]
J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12
[
16088404.001
]
[Cites]
J Clin Oncol. 2005 Oct 20;23(30):7565-73
[
16186600.001
]
[Cites]
J Clin Oncol. 2005 Nov 1;23(31):7985-93
[
16204016.001
]
[Cites]
J Cancer Res Clin Oncol. 2006 Feb;132(2):99-104
[
16292542.001
]
[Cites]
Br J Cancer. 2007 Jun 4;96(11):1692-8
[
17486132.001
]
[Cites]
J Clin Oncol. 2008 Jan 10;26(2):211-7
[
18056679.001
]
[Cites]
Clin Cancer Res. 2008 Jan 1;14(1):309-17
[
18172283.001
]
[Cites]
J Clin Oncol. 2008 Jan 10;26(2):204-10
[
18182663.001
]
[Cites]
Leukemia. 2002 Oct;16(10):2096-105
[
12357363.001
]
[Cites]
Lancet. 2003 Aug 16;362(9383):516-22
[
12932382.001
]
[Cites]
Leuk Lymphoma. 2004 Sep;45(9):1821-7
[
15223642.001
]
[Cites]
Leuk Lymphoma. 2004 May;45(5):911-3
[
15291348.001
]
[Cites]
Leuk Lymphoma. 2004 Dec;45(12):2445-9
[
15621757.001
]
[Cites]
Haematologica. 2001 May;86(5):485-93
[
11410411.001
]
[Cites]
Anticancer Drugs. 2001 Oct;12(9):725-9
[
11593053.001
]
[Cites]
Haematologica. 2002 Jan;87(1):33-43
[
11801463.001
]
[Cites]
Leuk Lymphoma. 2002 Feb;43(2):327-31
[
11999564.001
]
[Cites]
J Cancer Res Clin Oncol. 2002 May;128(5):271-8
[
12029443.001
]
[Cites]
Blood. 2008 Dec 15;112(13):4824-31
[
18799723.001
]
(PMID = 21188134.001).
[ISSN]
1179-1322
[Journal-full-title]
Cancer management and research
[ISO-abbreviation]
Cancer Manag Res
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
New Zealand
[Other-IDs]
NLM/ PMC3004665
[Keywords]
NOTNLM ; Treanda / alkylating agent / bendamustine / chronic lymphocytic lymphoma / indolent non-Hodgkin lymphoma
18.
Dey P, Amir T, Al Jassar A, Al Shemmari S, Jogai S, Bhat M G, Al Quallaf A, Al Shammari Z:
Combined applications of fine needle aspiration cytology and flow cytometric immunphenotyping for diagnosis and classification of non Hodgkin lymphoma.
Cytojournal
; 2006;3:24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Combined applications of fine needle aspiration cytology and flow cytometric immunphenotyping for
diagnosis
and
classification
of non Hodgkin
lymphoma
.
AIMS AND OBJECTIVES: In this present study we have evaluated the feasibility of sub-
classification
of non-Hodgkin's
lymphoma
(NHL) cases according to World Health Organization's (WHO)
classification
on fine needle aspiration cytology (FNAC) material along with flow cytometric immunotyping (FCI) as an adjunct.
Both cytologic findings and FCI data were interpreted together to diagnose and sub-classify NHL according to WHO
classification
.
The cases were classified on FNAC as predominant
small
cells (12), mixed
small
and large cells (5) and large cells (26).
In five cases a suggestion of NHL was offered on FNAC material and these cases were labeled as NHL not otherwise specified (NHL-
NOS
).
With the help of combined FCI and FNAC, it was possible to sub-classify 38 cases of NHL (79%) according to WHO
classification
.
Combined FNAC and FCI data helped to diagnose 9 cases of
small lymphocytic lymphoma
(
SLL
), 2 cases of mantle
cell lymphoma
(MCL), 4 cases of follicular
lymphoma
(FL), 17 cases of
diffuse
large
B lymphoma
(DLBL) and 6 cases of lymphoblastic
lymphoma
.
Histopathology
diagnosis
was available in 31 cases of NHL out of which there were 14 recurrent and 17 cases of primary NHL.
Out of 15 DLBL cases diagnosed on FCI and FNAC, histology confirmed 14 cases and one of these cases was diagnosed as Burkitt's
lymphoma
on histology.
Cases of FL (4),
SLL
(3) and MCL (2) were
well
correlated with histopathology.
Histology
diagnosis
was given as DLBL (1),
SLL
(1), anaplastic large
cell lymphoma
(1) and FL transformed into large
cell
NHL (1).
Considering histopathology as gold standard, diagnostic specificity of combined FNAC and FCI was 100% (31/31) and sensitivity in sub-
classification
was 83.8% (26/31).
CONCLUSION: FNAC combined with FCI may be helpful in accurately sub-classifying NHL according to WHO
classification
.
Many of the subtypes of NHL such as FL and MCL which were previously recognized
as a
pure
morphologic
entity can be diagnosed by combined use of FNAC and FCI.
Other ancillary investigations such as chromosomal changes,
cell
proliferation markers etc. may be helpful in this aspect.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Diagn Cytopathol. 1998 Oct;19(4):274-8
[
9784991.001
]
[Cites]
Blood. 1999 Jun 1;93(11):3601-9
[
10339464.001
]
[Cites]
Histopathology. 2000 Jan;36(1):69-86
[
10632755.001
]
[Cites]
J Clin Pathol. 2000 Jun;53(6):451-7
[
10911803.001
]
[Cites]
Arch Pathol Lab Med. 2000 Dec;124(12):1792-9
[
11100059.001
]
[Cites]
Diagn Cytopathol. 2001 Apr;24(4):229-32
[
11285616.001
]
[Cites]
Diagn Cytopathol. 2002 Apr;26(4):251-6
[
11933272.001
]
[Cites]
Diagn Cytopathol. 2002 Dec;27(6):340-2
[
12451563.001
]
[Cites]
Diagn Cytopathol. 2003 Apr;28(4):191-5
[
12672094.001
]
[Cites]
Diagn Cytopathol. 1992;8(5):551-2
[
1396035.001
]
[Cites]
Cancer. 2005 Dec 25;105(6):432-42
[
16222688.001
]
[Cites]
Diagn Cytopathol. 1996 Nov;15(4):352-7
[
8982596.001
]
[Cites]
Blood. 1996 Sep 1;88(5):1771-9
[
8781434.001
]
[Cites]
Cancer. 1990 Jan 1;65(1):72-7
[
2293872.001
]
[Cites]
Cytopathology. 2006 Oct;17(5):275-87
[
16961657.001
]
[Cites]
Acta Cytol. 1990 May-Jun;34(3):329-36
[
2343687.001
]
[Cites]
Acta Cytol. 1984 May-Jun;28(3):337-45
[
6587711.001
]
[Cites]
Diagn Cytopathol. 1995 May;12(3):201-7
[
7621714.001
]
[Cites]
Acta Cytol. 1993 Sep-Oct;37(5):745-6
[
8362592.001
]
[Cites]
Histopathology. 1994 Dec;25(6):517-36
[
7698729.001
]
(PMID = 17069647.001).
[ISSN]
1742-6413
[Journal-full-title]
CytoJournal
[ISO-abbreviation]
Cytojournal
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC1634871
19.
Vassallo J, Bousquet M, Quelen C, Al Saati T, Delsol G, Brousset P:
CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma.
J Clin Pathol
; 2007 May;60(5):573-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CD5-positive
diffuse
large
B cell lymphoma
arising from a CD5-positive follicular
lymphoma
.
Follicular
lymphoma
(FL) is
a neoplasm
originating from germinal centre cells, corresponding to 25-40% of non-Hodgkin'
s lymphomas
.
Transformation into
diffuse
large
B cell lymphoma
(DLBCL) occurs in about one-third of cases.
CD5 is expressed in B-chronic lymphoid leukaemia/
small lymphocytic lymphoma
and mantle
cell lymphoma
, but can rarely be expressed in conjunction with CD10 in
well
-documented cases of FL.
In this report one case of grade 1 FL is described, which transformed into a DLBCL 6 months after initial
diagnosis
, with both tumours expressing CD5.
[MeSH-major]
Antigens, CD5 / metabolism.
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
, Follicular / pathology.
Lymphoma
, Large B-
Cell
,
Diffuse
/ pathology
[MeSH-minor]
Adult. Antigens,
Neoplasm
/ metabolism. Disease Progression. Female. Humans
Genetic Alliance.
consumer health - Follicular Lymphoma
.
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):1-11
[
10937042.001
]
[Cites]
Am J Clin Pathol. 2005 Aug;124(2):182-90
[
16040287.001
]
[Cites]
Am J Clin Pathol. 2000 Dec;114(6):912-21
[
11338480.001
]
[Cites]
Arch Pathol Lab Med. 2001 Jul;125(7):951-3
[
11419985.001
]
[Cites]
Am J Clin Pathol. 2002 Feb;117(2):291-300
[
11863226.001
]
[Cites]
Am J Clin Pathol. 2002 Oct;118(4):589-98
[
12375647.001
]
[Cites]
Am J Clin Pathol. 2003 Feb;119(2):218-30
[
12579992.001
]
[Cites]
Int J Biochem Cell Biol. 2004 Nov;36(11):2105-11
[
15313456.001
]
[Cites]
J Clin Pathol. 1992 Nov;45(11):1018-22
[
1280654.001
]
[Cites]
Blood. 1994 Sep 1;84(5):1361-92
[
8068936.001
]
[Cites]
Br J Haematol. 1996 Sep;94(4):676-84
[
8826892.001
]
[Cites]
J Clin Pathol. 1997 Jan;50(1):16-21
[
9059349.001
]
[Cites]
J Clin Oncol. 1997 Apr;15(4):1587-94
[
9193357.001
]
[Cites]
Mol Pathol. 1998 Dec;51(6):333-8
[
10193514.001
]
[Cites]
Mod Pathol. 2000 Dec;13(12):1269-79
[
11144922.001
]
(PMID = 17513519.001).
[ISSN]
0021-9746
[Journal-full-title]
Journal of clinical pathology
[ISO-abbreviation]
J. Clin. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD5; 0 / Antigens, Neoplasm
[Other-IDs]
NLM/ PMC1994527
20.
Lurie DM, Milner RJ, Suter SE, Vernau W:
Immunophenotypic and cytomorphologic subclassification of T-cell lymphoma in the boxer breed.
Vet Immunol Immunopathol
; 2008 Sep 15;125(1-2):102-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunophenotypic and cytomorphologic subclassification of T-
cell lymphoma
in the boxer breed.
The boxer breed is at high risk for developing
lymphoma
and, in contrast to the general canine population, is predisposed to the T-
cell
variant of the disease.
The purpose of this study was to more accurately classify
lymphoma
in this breed.
Clinical, cytomorphologic and immunophenotypic data were examined in 43 boxers with
lymphoma
.
Lymphomas
were classified as multicentric (n=29), mediastinal (n=6) and intestinal (n=8).
Of the 40 immunophenotyped samples, 34 (85%) were T-
cell
, 5 (12.5%) were B-
cell
and 1 was a non-B-
cell
non-T-
cell lymphoma
.
Immunophenotypic subtyping was done on prospectively collected T-
cell lymphoma
samples (n=22) to differentiate CD4 (helper) from CD8 (cytotoxic) T-
cell
origin
as well
as to determine the T-
cell
receptor (TCR) expression (TCRalphabeta vs. TCRdeltagamma).
Cytomorphologic analysis was done on the same 22 samples using the World Health Organization (WHO)
classification
scheme.
According to this scheme, 17/22 samples were classified as lymphoblastic, 2/22 as large
cell
peripheral T-
cell lymphoma
-not otherwise specified (PTCL-
NOS
), 2/22 as large granular
lymphoma
(LGL) high-grade and 1/22 as
small lymphocytic
.
The results of this study indicate that
lymphoma
in the boxer breed is a disease comprised predominantly of TCRalphabeta+, CD4+ (helper) T-cells with lymphoblastic (high-grade) morphology.
[MeSH-major]
Dog Diseases /
classification
.
Lymphoma
, T-
Cell
/
classification
.
Lymphoma
, T-
Cell
/ veterinary
[MeSH-minor]
Animals. Antigens, CD4 / blood. Antigens, CD4 / immunology. Antigens, CD8 / blood. Antigens, CD8 / immunology. Biopsy, Fine-Needle / veterinary. Dogs. Female. Genetic Predisposition to Disease. Immunohistochemistry / veterinary. Immunophenotyping / veterinary. Kaplan-Meier Estimate. Male. Prospective Studies. Receptors, Antigen, T-
Cell
, alpha-beta / blood. Receptors, Antigen, T-
Cell
, alpha-beta / immunology. Receptors, Antigen, T-
Cell
, gamma-delta / blood. Receptors, Antigen, T-
Cell
, gamma-delta / immunology. Retrospective Studies
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18579219.001).
[ISSN]
0165-2427
[Journal-full-title]
Veterinary immunology and immunopathology
[ISO-abbreviation]
Vet. Immunol. Immunopathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
21.
Jahan S, Zinnat R, Hassan Z, Biswas KB, Habib SH:
Gender differences in serum leptin concentrations from umbilical cord blood of newborn infants born to nondiabetic, gestational diabetic and type-2 diabetic mothers.
Int J Diabetes Dev Ctries
; 2009 Oct;29(4):155-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gender differences in
serum leptin
concentrations from umbilical cord blood of newborn infants born to nondiabetic, gestational diabetic and
type
-2 diabetic mothers.
To investigate gender differences, if any, in
leptin
concentrations from umbilical cord blood of new born infants of mothers with
type
2 diabetes mellitus (DM), gestational diabetes mellitus (GDM), and Non diabetic (ND) at delivery.
Serum leptin
concentrations were measured in 105 newborns (53 males and 52 females in the three groups).
Pearson correlation coefficient was used to explore the relationship between
serum leptin
concentrations and anthropometric measures of the fetus and their mother.
Both
Serum leptin level
and
serum C
-peptide was measured by chemiluminescence based ELISA.
The median range of
leptin
concentration in cord blood was ND group: Male [13.91 (3.22 - 47.63)], Female [16.88 (2 - 43.65)]; GDM group: Male [32 (7 - 76.00)], Female [36.73 (4.80 - 81.20)]; DM group: Male [20.90 (2 -76.00)], Female [32 {2.58 - 80.67)].
Cord
serum leptin levels
correlated with birth weight(r=0.587, p=0.0001), ponderal index (PI) (r=.319, p=0.024)of the babies and body mass index (BMI) (r=-0.299, p=0.035) of their mothers but did not correlate with gestational age, cord
serum C
-peptide concentration or placental weight at delivery.
Leptin
concentrations were higher in the female fetus in comparison to the male fetus.
We found that there are very strong associations between cord
leptin
concentrations at delivery and birth weight, ponderal index of the baby, body mass index of the mothers with
Type
2 DM.
We also found that high
leptin levels
could represent an important feedback modulator of substrate supply and subsequently for adipose tissue status during late gestation or adipose tissue is the major determinant of circulating
leptin levels
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biochem Biophys Res Commun. 1995 Sep 25;214(3):1260-7
[
7575539.001
]
[Cites]
Eur J Endocrinol. 2001 Jul;145(1):53-8
[
11415852.001
]
[Cites]
Science. 1995 Jul 28;269(5223):546-9
[
7624778.001
]
[Cites]
Nature. 1994 Dec 1;372(6505):425-32
[
7984236.001
]
[Cites]
N Engl J Med. 1996 Feb 1;334(5):292-5
[
8532024.001
]
[Cites]
Pediatrics. 1996 Aug;98(2 Pt 1):201-3
[
8692618.001
]
[Cites]
Nat Med. 1996 Sep;2(9):949-50
[
8782440.001
]
[Cites]
J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7
[
8784109.001
]
[Cites]
J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13
[
8923837.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Apr;82(4):1293-300
[
9100610.001
]
[Cites]
J Clin Endocrinol Metab. 1997 May;82(5):1642-4
[
9141565.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Sep;82(9):2849-55
[
9284709.001
]
[Cites]
Eur J Endocrinol. 1997 Dec;137(6):655-8
[
9437232.001
]
[Cites]
Diabetes. 1998 May;47(5):847-50
[
9588462.001
]
[Cites]
Science. 1995 Jul 28;269(5223):540-3
[
7624776.001
]
(PMID = 20336197.001).
[ISSN]
1998-3832
[Journal-full-title]
International journal of diabetes in developing countries
[ISO-abbreviation]
Int J Diabetes Dev Ctries
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC2839129
[Keywords]
NOTNLM ; Newborn infants / Serum leptin / Type 2 Diabetic / Umbilical cord blood / gestational diabetes mellitus / non diabetic
22.
Kojima M, Yamanaka S, Yoshida T, Shimizu K, Murayama K, Ohno Y, Itoh H, Motoori T, Masawa N, Nakamura S:
Histological variety of floral variant of follicular lymphoma.
APMIS
; 2006 Sep;114(9):626-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Histological variety of floral variant of follicular
lymphoma
.
To further clarify the histopathological findings of the floral variant of follicular
lymphoma
(FVFL), we studied 13 Japanese cases.
Two histological subtypes of neoplastic follicles of FVFL have been described: (i) A macrogerminal center pattern where the mantle zone
lymphocytes
were invaginated into the neoplastic germinal center, often reminiscent of a floral design. (ii) A microgerminal center pattern where the massive invasion of mantle zone
lymphocytes
resulted in almost complete breakage of the neoplastic follicles.
In the former pattern, the neoplastic germinal center usually contained large clusters of tumor cells, whereas in the latter,
small
clusters of up to 20 tumor cells or isolated tumor cells were observed in the neoplastic germinal centers.
Moreover, occasional tumor cells showed a
lymphocytic
and/or histiocytic Reed-Sternberg
cell
(L&H cells)-like morphology.
The overall histological findings of the macrogerminal center are similar to those of florid progressive transformation of germinal center (PTGC), whilst the microgerminal center pattern is similar to that of nodular
lymphocyte
-predominant Hodgkin
lymphoma
.
Initially, the differential
diagnosis
between FVFL and florid PTGC was emphasized.
However, the present study indicates that nodal marginal zone B-
cell lymphoma
possessing floral follicles and nodular
lymphocyte
-predominant Hodgkin
lymphoma
should be added to the differential
diagnosis
of FVFL.
The germinal center B-
cell
nature of FVFL is most clearly recognizable by immunohistochemistry, though histological appearance alone may cause some diagnostic problems.
[MeSH-major]
Lymph
Nodes / pathology.
Lymphoma
, Follicular / pathology
[MeSH-minor]
Adult. Aged. Antigens, CD / analysis.
Diagnosis
, Differential. Female. Germinal Center / pathology. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Oligonucleotides. RNA, Viral / analysis
Genetic Alliance.
consumer health - Follicular Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16948815.001).
[ISSN]
0903-4641
[Journal-full-title]
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
[ISO-abbreviation]
APMIS
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antigens, CD; 0 / Oligonucleotides; 0 / RNA, Viral
23.
El-Ferzli GT, Philips JB 3rd, Bulger A, Ambalavanan N:
A pumpless lung assist device reduces mechanical ventilation-induced lung injury in juvenile piglets.
Pediatr Res
; 2009 Dec;66(6):671-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The objective is to test the effect of the LAD on pulmonary histopathology in juvenile piglets with acute lung injury caused by saline lung lavage (
SLL
) followed by intermittent mandatory ventilation (IMV).
Three- to 4-wk-old piglets were randomized to no intervention (control group),
SLL
alone (
SLL
group),
SLL
+ IMV (IMV group), or
SLL
+ IMV + LAD (LAD group) (n = 6 per group).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Chest. 1989 Oct;96(4):849-51
[
2676391.001
]
[Cites]
Early Hum Dev. 2008 Nov;84(11):709-16
[
18930613.001
]
[Cites]
J Thorac Cardiovasc Surg. 1993 May;105(5):823-32
[
7683735.001
]
[Cites]
J Thorac Cardiovasc Surg. 1994 Mar;107(3):838-48; discussion 848-9
[
8127113.001
]
[Cites]
J Pediatr. 1994 Jul;125(1):104-10
[
7517446.001
]
[Cites]
Perfusion. 1994;9(4):265-9
[
7981464.001
]
[Cites]
J Paediatr Child Health. 1995 Apr;31(2):105-11
[
7794609.001
]
[Cites]
Anesthesiology. 1995 Oct;83(4):710-20
[
7574050.001
]
[Cites]
J Pediatr. 1996 Jan;128(1):109-17
[
8551400.001
]
[Cites]
ASAIO J. 1994 Jul-Sep;40(3):M728-31
[
8555610.001
]
[Cites]
Lancet. 1996 Jul 13;348(9020):75-82
[
8676720.001
]
[Cites]
Pediatr Pulmonol. 1996 Oct;22(4):263-70
[
8905887.001
]
[Cites]
J Paediatr Child Health. 1997 Jun;33(3):202-8
[
9259293.001
]
[Cites]
Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1058-65
[
9351603.001
]
[Cites]
ASAIO J. 1997 Sep-Oct;43(5):M821-4
[
9360161.001
]
[Cites]
Pediatr Pulmonol Suppl. 1997;16:51
[
9443195.001
]
[Cites]
Ann Thorac Surg. 2000 Feb;69(2):351-6
[
10735662.001
]
[Cites]
N Engl J Med. 2000 May 4;342(18):1301-8
[
10793162.001
]
[Cites]
Intensive Care Med. 2000 Sep;26(9):1334-42
[
11089761.001
]
[Cites]
J Thorac Cardiovasc Surg. 2001 Mar;121(3):542-51
[
11241090.001
]
[Cites]
Biol Neonate. 2001 Jul;80(1):74-80
[
11474154.001
]
[Cites]
Ann Thorac Surg. 2001 Sep;72(3):899-904
[
11570380.001
]
[Cites]
ASAIO J. 2001 Sep-Oct;47(5):486-91
[
11575823.001
]
[Cites]
J Pediatr. 2001 Oct;139(4):478-86
[
11598592.001
]
[Cites]
Am J Respir Crit Care Med. 2001 Oct 1;164(7):1154-60
[
11673202.001
]
[Cites]
Pediatr Res. 2002 Sep;52(3):387-92
[
12193673.001
]
[Cites]
Ann Thorac Surg. 2002 Oct;74(4):1011-6; discussion 1017-8
[
12400738.001
]
[Cites]
Pediatr Res. 2003 Feb;53(2):245-53
[
12538782.001
]
[Cites]
Crit Care Med. 2003 Mar;31(3):885-92
[
12627001.001
]
[Cites]
Eur Respir J Suppl. 2003 Aug;42:2s-9s
[
12945994.001
]
[Cites]
Respir Physiol Neurobiol. 2004 Jan 15;139(2):167-77
[
15123000.001
]
[Cites]
Anesthesiology. 2004 Sep;101(3):722-8
[
15329597.001
]
[Cites]
Minerva Pediatr. 2004 Aug;56(4):373-80
[
15457135.001
]
[Cites]
JAMA. 1986 Aug 15;256(7):881-6
[
3090285.001
]
[Cites]
Am J Respir Crit Care Med. 1998 Jan;157(1):294-323
[
9445314.001
]
[Cites]
Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1332-47
[
9563759.001
]
[Cites]
J Pharmacol Toxicol Methods. 1998 Aug;40(2):101-7
[
10100499.001
]
[Cites]
Clin Chest Med. 2006 Dec;27(4):601-13; abstract viii
[
17085249.001
]
[Cites]
Clin Physiol Funct Imaging. 2007 Mar;27(2):67-90
[
17309528.001
]
[Cites]
J Pediatr. 2007 Jul;151(1):10-5
[
17586183.001
]
[Cites]
Neonatology. 2007;92(1):19-25
[
17596733.001
]
[Cites]
Intensive Care Med. 2007 Aug;33(8):1423-33
[
17563879.001
]
[Cites]
Am J Respir Crit Care Med. 2007 Sep 15;176(6):575-81
[
17641159.001
]
[Cites]
Crit Care Med. 2008 Jan;36(1):183-7
[
18090370.001
]
[Cites]
Int J Mol Med. 2008 Apr;21(4):513-9
[
18360698.001
]
[Cites]
J Perinatol. 2008 May;28 Suppl 1:S47-56
[
18446178.001
]
[Cites]
Ann Thorac Surg. 2008 Aug;86(2):410-7; discussion 417
[
18640306.001
]
[Cites]
BMC Pulm Med. 2008;8:10
[
18625067.001
]
[Cites]
J Pediatr Surg. 1992 Jan;27(1):40-3
[
1552442.001
]
(PMID = 19687779.001).
[ISSN]
1530-0447
[Journal-full-title]
Pediatric research
[ISO-abbreviation]
Pediatr. Res.
[Language]
ENG
[Grant]
United States / NICHD NIH HHS / HD / HD046513-02; United States / NICHD NIH HHS / HD / K08 HD046513; United States / NHLBI NIH HHS / HL / R01 HL092906; United States / NICHD NIH HHS / HD / K08 HD046513-02
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS149422; NLM/ PMC2796292
24.
McElroy C, Velilla R, Chaudhary H, Al-Abbadi MA:
Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature.
Diagn Cytopathol
; 2009 Jan;37(1):48-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fine-needle aspiration
diagnosis
of squamous
cell
carcinoma in
a lymph
node involved with
small lymphocytic lymphoma
: case report and review of the literature.
Diagnosis
of two distinct
malignant
entities existing concurrently and at the same location (synchronous malignancy) by fine- needle aspiration (FNA) is unusual but may occur.
Small lymphocytic lymphoma
/chronic
lymphocytic
leukemia (
SLL
/CLL) in particular is associated with an increased incidence of secondary tumor, likely due to associated immunodeficiency.
Co-occurrence of some carcinomas such as squamous
cell
carcinoma (SCC), may show especially aggressive behavior.
A 57-year-old Caucasian male presented with recurrent upper extremity lymphedema and
diffuse
lymphadenopathy of the axillary and cervical regions.
FNA of a large cervical
lymph
node was diagnostic for both atypical
lymphocytic
proliferation and SCC.
Flow cytometric analysis showed the atypical
lymphocytic
proliferation to be positive for CD5, CD23, CD19, CD20, HLA-DR, CD38, and the population was kappa light chain restricted.
These cells were negative for CD-10 and FMC-7 antigens, suggesting a phenotype of B-
cell
SLL
/CLL.
We report a rare occurrence of metastatic SCC to
a lymph
node infiltrated by
SLL
/CLL.
The
diagnosis
was achieved by a combination of cytomorphologic examination of FNA smears, immunohistochemical staining of
cell
block material, and flow cytometry on the sample obtained by FNA.
To the best of our knowledge, only three cases of SCC metastasis to
SLL
/CLL diagnosed by FNA have been reported in the English literature.
[MeSH-major]
Carcinoma, Squamous
Cell
/
diagnosis
. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/
diagnosis
.
Lymph
Nodes / pathology. Neoplasms, Multiple Primary /
diagnosis
. Oropharyngeal Neoplasms / pathology
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 Wiley-Liss, Inc.
(PMID = 18973126.001).
[ISSN]
1097-0339
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Number-of-references]
16
25.
Wang YH, Huang TS, Liang HW, Su TC, Chen SY, Wang TD:
Fasting serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury.
Arch Phys Med Rehabil
; 2005 Oct;86(10):1964-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fasting
serum levels
of adiponectin, ghrelin, and
leptin
in men with spinal cord injury.
OBJECTIVES: To measure
serum levels
of adiponectin, ghrelin, and
leptin
in men with spinal cord injury (SCI) and to investigate possible correlations between these
serum levels
and various factors, such as body mass index (BMI), age, injury
level
, and duration of injury.
MAIN OUTCOME MEASURES:
Serum levels
of adiponectin, ghrelin, and
leptin
and BMI.
RESULTS:
Serum leptin levels
in subjects with SCI (mean, 7.0+/-0.5 mg/mL) [corrected] were significantly higher than those in able-bodied controls (mean, 4.7+/-0.6 mg/mL) [corrected] (P<.01).
The group with tetraplegia had higher
serum leptin levels
than the group with paraplegia, but this did not reach a statistically significant
level
(8.2+/-1.1 ng/mL vs 6.4+/-0.5 mg/mL [corrected] P=.097).
There were significant differences in
serum leptin levels
among the 3 groups by 1-way analysis of variance (P=.008).
Serum
adiponectin
levels
in subjects with SCI (7.1+/-0.5 mg/mL) [corrected] were higher than those in able-bodied controls (5.6+/-0.5 mg/mL) [corrected] but this was not statistically significant (P=.08).
In contrast,
serum levels
of ghrelin in subjects with SCI (302.0+/-17.5 pg/mL) were similar to those in the controls (264.0+/-27.0 pg/mL) (P=.24).
Serum leptin levels
correlated positively with BMI (SCI, r=.698, P<.001; controls, r=.782, P<.001), whereas
serum
adiponectin (SCI, r=-.527, P<.001; controls, r=-.315, P=.057) and ghrelin (SCI, r=-.368, P<.001; controls, r=-.447, P=.006)
levels
correlated negatively with the BMI in both subjects with SCI and controls.
CONCLUSIONS: Men with SCI have significantly higher
serum leptin levels
than able-bodied controls, and
serum leptin levels
correlated with the degree of neurologic deficit.
Men with SCI had a tendency toward higher
serum
adiponectin
level
than able-bodied controls.
Serum levels
of ghrelin in men with SCI were similar to those of controls.
[MeSH-major]
Leptin
/ blood. Peptide Hormones / blood. Spinal Cord Injuries / blood
MedlinePlus Health Information.
consumer health - Spinal Cord Injuries
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Arch Phys Med Rehabil. 2007 May;88(5):688
(PMID = 16213239.001).
[ISSN]
0003-9993
[Journal-full-title]
Archives of physical medicine and rehabilitation
[ISO-abbreviation]
Arch Phys Med Rehabil
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Ghrelin; 0 / Leptin; 0 / Peptide Hormones
26.
Richmond J, Bryant R, Trotman W, Beatty B, Lunde J:
FISH detection of t(14;18) in follicular lymphoma on Papanicolaou-stained archival cytology slides.
Cancer
; 2006 Jun 25;108(3):198-204
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
FISH detection of t(14;18) in follicular
lymphoma
on Papanicolaou-stained archival cytology slides.
BACKGROUND: The t(14;18)(q32;q21) translocation is present in about 85% of follicular
lymphomas
(FL) and can be identified using fluorescence in situ hybridization (FISH).
The authors proposed FISH for FL using Papanicolaou-stained archival cytology material
as a
practical ancillary technique for diagnosing FL.
METHODS: Cases included 35 FL, 6
small lymphocytic
lymphomas
/chronic
lymphocytic
leukemias (
SLL
/CLL), 4 mantle
cell
lymphomas
(MCL), 4 marginal zone
lymphomas
(MZL), 1 lymphoplasmacytic
lymphoma
(LPL), and 10 reactive lymphoid tissues (RLT).
This series shows a sensitivity of 81% and specificity of 100% for detecting the t(14;18) translocation
as a
diagnostic tool in FL.
[MeSH-major]
Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics.
Lymphoma
, Follicular / pathology. Translocation, Genetic
[MeSH-minor]
Biopsy, Fine-Needle. Humans. In Situ Hybridization, Fluorescence. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/
diagnosis
. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ genetics. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ pathology. Lymphoid Tissue / pathology.
Lymphoma
, Mantle-
Cell
/
diagnosis
.
Lymphoma
, Mantle-
Cell
/ genetics.
Lymphoma
, Mantle-
Cell
/ pathology. Staining and Labeling
Genetic Alliance.
consumer health - Follicular Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16671111.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
27.
Alexander C, Cochran CJ, Gallicchio L, Miller SR, Flaws JA, Zacur H:
Serum leptin levels, hormone levels, and hot flashes in midlife women.
Fertil Steril
; 2010 Aug;94(3):1037-43
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Serum leptin levels
, hormone
levels
, and hot flashes in midlife women.
OBJECTIVE: To examine the associations between
serum leptin levels
, sex steroid hormone
levels
, and hot flashes in normal weight and obese midlife women.
MAIN OUTCOME MEASURE(S):
Serum leptin
and sex steroid hormone
levels
.
RESULT(S): Correlation and regression models were performed to examine associations between
leptin levels
, hormone
levels
, and hot flashes.
Leptin levels
were associated with BMI, with "ever experiencing hot flashes" (questionnaire), with hot flashes within the last 30 days, and with duration of hot flashes (>1 year, P=.03).
Leptin
was positively correlated with testosterone, free testosterone index, and free estrogen index and inversely associated with
levels
of sex hormone-binding globulin.
In women with a body mass index>or=30 kg/m2,
leptin levels
no longer correlated with testosterone
levels
.
CONCLUSION(S):
Serum leptin levels
are associated with the occurrence and duration of hot flashes in midlife women; however, no correlation was found between
leptin
and
serum
estradiol.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
[Cites]
J Clin Endocrinol Metab. 1995 Aug;80(8):2354-8
[
7629229.001
]
[Cites]
Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):772-80
[
8456878.001
]
[Cites]
N Engl J Med. 1996 Feb 1;334(5):292-5
[
8532024.001
]
[Cites]
Maturitas. 1996 Apr;23(3):301-5
[
8794424.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Jan;82(1):318-21
[
8989281.001
]
[Cites]
Endocrinology. 1997 Feb;138(2):847-50
[
9003026.001
]
[Cites]
Br J Obstet Gynaecol. 1997 Aug;104(8):923-33
[
9255084.001
]
[Cites]
Endocrinology. 1998 Feb;139(2):551-8
[
9449624.001
]
[Cites]
J Clin Endocrinol Metab. 1998 Feb;83(2):453-9
[
9467557.001
]
[Cites]
Clin Exp Obstet Gynecol. 1997;24(3):163-6
[
9478308.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2541-6
[
9482922.001
]
[Cites]
Menopause. 1998 Spring;5(1):43-51
[
9689194.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Feb;84(2):428-34
[
10022396.001
]
[Cites]
Ginekol Pol. 1999 Jan;70(1):1-7
[
10349800.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7047-52
[
10359836.001
]
[Cites]
Endocrine. 1999 Feb;10(1):19-23
[
10403567.001
]
[Cites]
Semin Reprod Med. 2005 May;23(2):117-25
[
15852197.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E166-71
[
15741239.001
]
[Cites]
Am J Obstet Gynecol. 2005 Aug;193(2):347-51
[
16098853.001
]
[Cites]
Am J Obstet Gynecol. 2005 Oct;193(4):1353-60
[
16202725.001
]
[Cites]
Alcohol Alcohol. 2005 Nov-Dec;40(6):563-8
[
16087658.001
]
[Cites]
Maturitas. 2006 Jan 20;53(2):217-25
[
15913927.001
]
[Cites]
Maturitas. 2006 Jan 20;53(2):133-43
[
16368467.001
]
[Cites]
Obstet Gynecol. 1994 Jul;84(1):29-34
[
8008318.001
]
[Cites]
Maturitas. 2006 Jun 20;54(3):260-9
[
16423474.001
]
[Cites]
Clin Endocrinol (Oxf). 2006 Jul;65(1):125-31
[
16817831.001
]
[Cites]
Climacteric. 2007 Feb;10(1):27-37
[
17364602.001
]
[Cites]
Fertil Steril. 2007 Jun;87(6):1483-6
[
17276432.001
]
[Cites]
Obesity (Silver Spring). 2007 Sep;15(9):2217-24
[
17890489.001
]
[Cites]
Am J Epidemiol. 2008 Jan 1;167(1):78-85
[
17881385.001
]
[Cites]
Maturitas. 2008 Feb 20;59(2):149-57
[
18280066.001
]
[Cites]
Fertil Steril. 2008 Oct;90(4):1161-8
[
18304548.001
]
[Cites]
Int J Biometeorol. 1999 Nov;43(3):99-109
[
10639901.001
]
[Cites]
J Womens Health Gend Based Med. 2001 Jan-Feb;10(1):67-76
[
11224946.001
]
[Cites]
Am J Hum Biol. 2001 Jul-Aug;13(4):453-64
[
11400216.001
]
[Cites]
Obstet Gynecol. 2001 Sep;98(3):391-7
[
11530118.001
]
[Cites]
Maturitas. 2002 Jan 30;41(1):69-77
[
11809345.001
]
[Cites]
J Pediatr Endocrinol Metab. 2001;14 Suppl 6:1417-29
[
11837495.001
]
[Cites]
Atherosclerosis. 2002 Apr;161(2):455-62
[
11888531.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Oct;87(10):4522-7
[
12364429.001
]
[Cites]
Obstet Gynecol. 2003 Feb;101(2):264-72
[
12576249.001
]
[Cites]
Am J Epidemiol. 2004 Jun 15;159(12):1189-99
[
15191936.001
]
[Cites]
Endocrinology. 2004 Jul;145(7):3115-21
[
15059958.001
]
[Cites]
J Gen Intern Med. 2004 Jul;19(7):740-6
[
15209587.001
]
[Cites]
Clin Endocrinol (Oxf). 1985 Mar;22(3):293-312
[
3884189.001
]
[Cites]
Ann Clin Biochem. 1985 Sep;22 ( Pt 5):489-97
[
4062218.001
]
[Cites]
J Clin Endocrinol Metab. 1987 Apr;64(4):723-9
[
3818901.001
]
[Cites]
Int J Obes. 1989;13(1):1-9
[
2703288.001
]
[Cites]
Metabolism. 1991 Jan;40(1):101-4
[
1984562.001
]
[Cites]
Nat Med. 1995 Nov;1(11):1155-61
[
7584987.001
]
(PMID = 19476935.001).
[ISSN]
1556-5653
[Journal-full-title]
Fertility and sterility
[ISO-abbreviation]
Fertil. Steril.
[Language]
ENG
[Grant]
United States / NIA NIH HHS / AG / R01 AG018400-02; United States / NIA NIH HHS / AG / AG18400; United States / NIA NIH HHS / AG / R01 AG018400-03; United States / NIA NIH HHS / AG / R01 AG018400-05A2; United States / NIA NIH HHS / AG / R01 AG018400-01A1; United States / NIA NIH HHS / AG / R01 AG018400-06; United States / NIA NIH HHS / AG / R01 AG018400; United States / NIA NIH HHS / AG / R01 AG018400-04
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Gonadal Steroid Hormones; 0 / Leptin
[Other-IDs]
NLM/ NIHMS109122; NLM/ PMC3939020
28.
Barth TF, Barth CA, Kestler HA, Michl P, Weniger MA, Buchholz M, Möller P, Gress T:
Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma.
J Pathol
; 2007 Feb;211(3):305-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Transcriptional profiling suggests that secondary and primary large B-
cell
lymphomas
of the gastrointestinal (GI) tract are blastic variants of GI marginal zone
lymphoma
.
The pathogenetic relationship of marginal zone B-
cell lymphoma
(MALT
lymphoma
) of the gastrointestinal (GI) tract and eventually co-existing aggressive B-
cell lymphoma
and primary aggressive B-
cell lymphoma
remains to be elucidated.
The RNA of laser-microdissected cells was isolated and amplified from
small
and/or large
cell
compartments of eight MALT
lymphomas
(
small cell lymphoma
, SCL), 14 GI
diffuse
large B-
cell
lymphomas
(large
cell lymphoma
, LCL), and ten GI B-
cell
lymphomas
with composite
small
and large
cell
compartments (ComL) and expression analyses were performed using cDNA arrays.
Hierarchical cluster analysis clearly separated SCL and LCL and the
small
and large
cell
compartments of ComL.
Likewise, cluster analysis with all samples of SCL, LCL, and ComL yielded two main '
small cell
' and 'large
cell
' branches.
Furthermore, 60 genes were differentially expressed between SCL and LCL, and 82 genes between the
small
and large
cell
components of ComL; 26 genes were discriminators in both settings.
Use of the profiles of ComL as training sets for class prediction resulted in 95% accuracy for the
classification
of SCL and LCL.
Collectively, the data strongly suggest that both secondary and primary aggressive B-
cell
lymphomas
of the GI tract are blastic marginal zone
lymphomas
.
[MeSH-major]
Gastrointestinal Neoplasms / genetics. Gene Expression Profiling.
Lymphoma
, B-
Cell
/ genetics.
Lymphoma
, Large B-
Cell
,
Diffuse
/ genetics. Oligonucleotide Array Sequence Analysis. Transcription, Genetic
[MeSH-minor]
Genetic Markers. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ genetics. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ pathology. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
(PMID = 17152084.001).
[ISSN]
0022-3417
[Journal-full-title]
The Journal of pathology
[ISO-abbreviation]
J. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Genetic Markers
29.
Kramer CK, von Mühlen D, Barrett-Connor E:
Does leptin predict incident hypertension in older adults?
Clin Endocrinol (Oxf)
; 2010 Aug;73(2):201-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Does
leptin
predict incident hypertension in older adults?
OBJECTIVE:
Leptin
is associated with blood pressure (BP) in experimental and cross-sectional studies, but only one previous prospective study of middle-aged men has reported the association between
leptin
and incident hypertension.
We examined the association of
leptin levels
with incident hypertension in a population-based study of older men and women.
POPULATION: Participants were 602 community-dwelling older adults with normal baseline BP
levels
who attended a research clinic visit between 1984 and 1987 and again 4.4 years later (mean age was 66.2 +/- 11.4; 60.6% were men; mean body mass index (BMI) 24.9 +/- 3.4 kg/m(2)).
Leptin
was measured by radioimmunoassay.
Baseline
serum leptin levels
were higher in participants who developed hypertension compared to persistent normotensives [median (25th-75th range)] [8.8(5-16) vs 7(4-11) ng/ml, P = 0.002].
In logistic regression models,
leptin
(log-transformed) predicted incident hypertension before and after adjustments for baseline age, BMI, systolic BP, total cholesterol, medications, and previous cardiovascular disease (OR 1.75 95% CI 1.17-2.61, P = 0.006).
CONCLUSION: Higher
leptin levels
were independently associated with increased odds of incident hypertension in older adults.
MedlinePlus Health Information.
consumer health - High Blood Pressure
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hypertension. 2009 Mar;53(3):473-9
[
19204185.001
]
[Cites]
J Clin Endocrinol Metab. 2008 Oct;93(10):3922-6
[
18682500.001
]
[Cites]
J Clin Endocrinol Metab. 2009 Apr;94(4):1137-44
[
19174500.001
]
[Cites]
Am J Hypertens. 2009 May;22(5):577-80
[
19229195.001
]
[Cites]
Hypertension. 2009 Jun;53(6):965-72
[
19398660.001
]
[Cites]
J Vasc Res. 2009;46(6):609-17
[
19571581.001
]
[Cites]
Diabetes Care. 2000 Jan;23(1):57-63
[
10857969.001
]
[Cites]
Hypertens Res. 2000 Jul;23(4):303-10
[
10912765.001
]
[Cites]
Int J Obes Relat Metab Disord. 2001 Jan;25(1):121-5
[
11244467.001
]
[Cites]
Metabolism. 2001 Mar;50(3):325-9
[
11230786.001
]
[Cites]
Clin Exp Hypertens. 2001 May;23(4):357-68
[
11349826.001
]
[Cites]
J Neuroendocrinol. 2001 Oct;13(10):913-21
[
11679060.001
]
[Cites]
J Clin Invest. 2002 Oct;110(8):1093-103
[
12393845.001
]
[Cites]
Obes Res. 2003 Jan;11(1):160-6
[
12529499.001
]
[Cites]
JAMA. 2003 May 21;289(19):2560-72
[
12748199.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31
[
14557461.001
]
[Cites]
Nephron. 1976;16(1):31-41
[
1244564.001
]
[Cites]
Prev Med. 1976 Jun;5(2):207-15
[
935073.001
]
[Cites]
Am J Epidemiol. 1980 Jun;111(6):705-12
[
7386445.001
]
[Cites]
Hypertension. 1997 Sep;30(3 Pt 2):619-23
[
9322991.001
]
[Cites]
Hypertension. 1998 Jan;31(1 Pt 2):409-14
[
9453337.001
]
[Cites]
Eur J Pharmacol. 2005 Aug 22;518(2-3):175-81
[
16054621.001
]
[Cites]
J Hypertens. 2006 May;24(5):789-801
[
16612235.001
]
[Cites]
J Clin Endocrinol Metab. 2007 Feb;92(2):532-41
[
17118991.001
]
[Cites]
Am J Clin Nutr. 2009 Mar;89(3):991S-997S
[
19176740.001
]
(PMID = 20148909.001).
[ISSN]
1365-2265
[Journal-full-title]
Clinical endocrinology
[ISO-abbreviation]
Clin. Endocrinol. (Oxf)
[Language]
ENG
[Grant]
United States / NIA NIH HHS / AG / AG028507-03; United States / NIDDK NIH HHS / DK / R01 DK031801-15; United States / NIA NIH HHS / AG / R01 AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-13S1; United States / NIA NIH HHS / AG / AG007181-13S1; United States / NIA NIH HHS / AG / R01 AG028507-02; United States / NIA NIH HHS / AG / R01 AG007181; United States / NIA NIH HHS / AG / AG07181; United States / NIDDK NIH HHS / DK / R01 DK031801; United States / NIA NIH HHS / AG / AG007181-13; United States / NIA NIH HHS / AG / R01 AG007181-13; United States / NIDDK NIH HHS / DK / R01 DK031801-16; United States / NIDDK NIH HHS / DK / DK31801; United States / NIA NIH HHS / AG / R01 AG028507-03; United States / NIA NIH HHS / AG / AG028507-02; United States / NIA NIH HHS / AG / AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-14; United States / NIA NIH HHS / AG / R37 AG007181; United States / NIA NIH HHS / AG / R01 AG028507; United States / NIA NIH HHS / AG / AG028507
[Publication-type]
Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Leptin
[Other-IDs]
NLM/ NIHMS175266; NLM/ PMC2891171
30.
Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH, Llorca J:
Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.
Clin Exp Rheumatol
; 2009 Mar-Apr;27(2):222-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Anti-TNF-alpha therapy does not modulate
leptin
in patients with severe rheumatoid arthritis.
OBJECTIVE: The adipocytokine
leptin
regulates weight centrally and participates in the regulation of the immune and inflammatory responses.
In the present study we investigated whether inflammation, obesity or both of these characteristics are potential determinants of circulating
leptin
concentrations in a group of RA patients on periodical treatment with the TNF-alpha-blocker-infliximab due to severe disease.
We also assessed whether the infusion of infliximab may alter circulating
leptin
concentrations in patients with severe RA.
Serum leptin levels
were determined immediately prior to and after infliximab infusion.
RESULTS: There was a positive correlation between body mass index of RA patients and baseline
serum level
of
leptin
(rho=0.665, p<0.001).
Apart from a significant correlation with VCAM-1 (rho=0.349, p=0.04), no significant correlations between baseline
leptin levels
and the age at the time of the study or at the onset of the disease, disease duration, ESR and CRP
levels
, DAS28, lipids, insulin sensitivity, adhesion molecules, resistin, adiponectin, ghrelin or the cumulative prednisone dose at the time of the study were found.
Leptin levels
did not change upon infliximab infusion (p=0.48).
CONCLUSION: In RA patients on TNF-alpha blocker treatment, circulating
leptin levels
are unrelated to disease activity but constitute a manifestation of adiposity.
The beneficial effect of anti-TNF-alpha therapy on cardiovascular mortality in RA does not seem to be mediated by reduction in
serum levels
of
leptin
.
[MeSH-major]
Antibodies, Monoclonal / therapeutic use. Arthritis, Rheumatoid / blood. Arthritis, Rheumatoid / drug therapy.
Leptin
/ blood. Obesity / blood. Tumor Necrosis Factor-alpha / antagonists & inhibitors
Genetic Alliance.
consumer health - Arthritis
.
Genetic Alliance.
consumer health - Rheumatoid arthritis
.
MedlinePlus Health Information.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Rheumatoid Arthritis
.
Hazardous Substances Data Bank.
Infliximab
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19473561.001).
[ISSN]
0392-856X
[Journal-full-title]
Clinical and experimental rheumatology
[ISO-abbreviation]
Clin. Exp. Rheumatol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Leptin; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein; B72HH48FLU / Infliximab
31.
Bourdon C, Hojna S, Jordan M, Bérubé J, Kren V, Pravenec M, Liu P, Arab S, Pausová Z:
Genetic locus on rat chromosome 20 regulates diet-induced adipocyte hypertrophy: a microarray gene expression study.
Physiol Genomics
; 2009 Jun 10;38(1):63-72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In response to HFD, body weight, fat pad weights, adipocyte size, and
serum leptin levels
increased significantly more in SHR.1N than SHR.
Microarray gene expression profiles [Affymetrix, 15,923 genes and expressed sequence tags (ESTs)] showed that multiple genes of molecular pathways involved in lipogenesis were downregulated to a similar
level
in both strains, whereas genes involved in fatty acid oxidation and energy dissipation were upregulated less in SHR.1N than SHR.
MedlinePlus Health Information.
consumer health - Dietary Fats
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Hypertension. 2000 Jul;36(1):14-9
[
10904006.001
]
[Cites]
Nature. 2008 Aug 21;454(7207):961-7
[
18719582.001
]
[Cites]
Cell. 2001 Sep 7;106(5):563-73
[
11551504.001
]
[Cites]
JAMA. 2002 Jan 16;287(3):356-9
[
11790215.001
]
[Cites]
Diabetes. 2002 Jun;51(6):1876-83
[
12031976.001
]
[Cites]
Nucleic Acids Res. 2001 May 1;29(9):e45
[
11328886.001
]
[Cites]
JAMA. 2003 Jan 1;289(1):76-9
[
12503980.001
]
[Cites]
J Biol Chem. 2003 Apr 4;278(14):11888-96
[
12529376.001
]
[Cites]
Cell. 2003 Apr 18;113(2):159-70
[
12705865.001
]
[Cites]
Hypertension. 2003 May;41(5):1047-55
[
12654711.001
]
[Cites]
J Clin Invest. 2003 Dec;112(12):1796-808
[
14679176.001
]
[Cites]
Physiol Rev. 2004 Jan;84(1):277-359
[
14715917.001
]
[Cites]
Science. 2004 May 28;304(5675):1301-5
[
15166374.001
]
[Cites]
Am J Physiol Regul Integr Comp Physiol. 2004 Jul;287(1):R112-9
[
15001430.001
]
[Cites]
Nature. 2004 Sep 9;431(7005):200-5
[
15306821.001
]
[Cites]
Cell. 1982 May;29(1):53-60
[
7105184.001
]
[Cites]
Biochem J. 1988 Feb 1;249(3):765-9
[
3355496.001
]
[Cites]
Mol Endocrinol. 1988 May;2(5):395-403
[
2901666.001
]
[Cites]
J Hypertens. 1989 Mar;7(3):217-21
[
2708818.001
]
[Cites]
Science. 1993 Jan 1;259(5091):87-91
[
7678183.001
]
[Cites]
J Clin Invest. 1995 Jul;96(1):158-62
[
7615786.001
]
[Cites]
J Clin Invest. 1995 Dec;96(6):2914-23
[
8675663.001
]
[Cites]
Diabetes. 1997 Sep;46(9):1468-72
[
9287048.001
]
[Cites]
Eur J Clin Invest. 1998 Jan;28(1):59-66
[
9502188.001
]
[Cites]
J Clin Invest. 1998 Jul 15;102(2):412-20
[
9664083.001
]
[Cites]
J Clin Invest. 2004 Dec;114(12):1752-61
[
15599400.001
]
[Cites]
J Biol Chem. 2005 Apr 22;280(16):15493-6
[
15746100.001
]
[Cites]
Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):31-4
[
15936931.001
]
[Cites]
Biol Cell. 2005 Jul;97(7):479-86
[
15966863.001
]
[Cites]
FASEB J. 2005 Sep;19(11):1567-9
[
16009704.001
]
[Cites]
Am J Hypertens. 2005 Oct;18(10):1271-5
[
16202847.001
]
[Cites]
Annu Rev Cell Dev Biol. 2005;21:247-69
[
16212495.001
]
[Cites]
Obes Res. 2005 Dec;13(12):2122-31
[
16421346.001
]
[Cites]
Curr Opin Nephrol Hypertens. 2006 Mar;15(2):173-8
[
16481885.001
]
[Cites]
Cell Metab. 2006 Mar;3(3):223-9
[
16517409.001
]
[Cites]
Exp Hematol. 2006 Aug;34(8):1106-14
[
16863918.001
]
[Cites]
Biochem J. 2006 Sep 1;398(2):153-68
[
16898874.001
]
[Cites]
Nature. 2006 Dec 14;444(7121):847-53
[
17167472.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4401-6
[
17360536.001
]
[Cites]
Int J Obes (Lond). 2007 Jun;31(6):1004-13
[
17130847.001
]
[Cites]
J Lipid Res. 2007 Dec;48(12):2751-61
[
17872589.001
]
[Cites]
FEBS Lett. 2008 Jan 9;582(1):117-31
[
18037376.001
]
[Cites]
Mol Endocrinol. 2008 May;22(5):1023-31
[
18202144.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E356-67
[
18492779.001
]
[Cites]
Curr Hypertens Rep. 1999 Feb-Mar;1(1):42-50
[
10981041.001
]
(PMID = 19383622.001).
[ISSN]
1531-2267
[Journal-full-title]
Physiological genomics
[ISO-abbreviation]
Physiol. Genomics
[Language]
ENG
[Grant]
United States / Howard Hughes Medical Institute / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Dietary Fats; 0 / Leptin
[Other-IDs]
NLM/ PMC2696153
32.
Horoz M, Aslan M, Koylu AO, Bolukbas C, Bolukbas FF, Selek S, Erel O:
The relationship between leptin level and oxidative status parameters in hemodialysis patients.
Artif Organs
; 2009 Jan;33(1):81-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The relationship between
leptin level
and oxidative status parameters in hemodialysis patients.
Both
serum leptin level
and oxidative stress are increased in hemodialysis (HD) patients.
In the present study, we aimed to investigate whether there is association between oxidative status and
leptin level
in HD patients.
Serum leptin level
, total peroxide (TP)
level
, total antioxidant capacity (TAC), and oxidative stress index (OSI) were determined.
Serum leptin level
, TP
level
, and OSI were significantly higher in HD patients than controls (all P < 0.001) while TAC was lower (P < 0.001).
In HD patients,
serum leptin level
was significantly correlated with TP
level
and OSI (r = 0.372, P < 0.001 and r = 0.409, P < 0.001, respectively).
The correlation of
serum leptin level
with TP
level
and OSI remained statistically significant after adjusting for age, gender, and body-fat percentage (r = 0.446, P < 0.001 and r = 0.463, P < 0.001, respectively).
Hyperleptinemia seems to be associated with increased oxidative stress in HD patients, and this association may provide better understanding about the disorders related to either elevated
serum leptin levels
and/or increased oxidative stress in HD patients.
[MeSH-major]
Leptin
/ blood. Oxidative Stress. Renal Dialysis
MedlinePlus Health Information.
consumer health - Dialysis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19178446.001).
[ISSN]
1525-1594
[Journal-full-title]
Artificial organs
[ISO-abbreviation]
Artif Organs
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antioxidants; 0 / Leptin; 0 / Peroxides
33.
Shabat S, Nyska M, Eintacht S, Lis M, Bogomolni A, Berner Y, Kestanbaum-Shainkin R:
Serum leptin level in geriatric patients with hip fractures: possible correlation to biochemical parameters of bone remodeling.
Arch Gerontol Geriatr
; 2009 Mar-Apr;48(2):250-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Serum leptin level
in geriatric patients with hip fractures: possible correlation to biochemical parameters of bone remodeling.
Since
leptin
was suggested to be involved in bone remodeling, its possible involvement in fracture formation/prevention was evaluated, by determination of
serum leptin level
in geriatric population with hip fracture, and evaluation the relationships with biochemical parameters of bone remodeling.
Serum leptin level
of this total population distributed between 1 and 134ng/ml.
40% of patients were in the normal range of our laboratory (10-40ng/ml), 40% had decreased
leptin level
(<10ng/ml) and 20% had higher
leptin level
(>40ng/ml).
No correlation was detected between
serum leptin level
and vitamin D-25(OH)D3, which was under normal range in 60% of the patients.
Leptin
also did not correlate to ICTP
level
, which was high in 80% of the patients, suggesting an extensive bone resorption in this population.
Evaluation of
leptin level
in female versus male suggests that
leptin level
is higher in females than males also in this age (28.4ng/ml vs. 14.4ng/ml, p<0.001).
The higher
leptin levels
in women was accompanied by higher
serum levels
of glucose, albumin, Ca, cholesterol, Na and FT4.
Comparison of 50 patients with the lowest
leptin levels
(mean of 3.4ng/ml) to 50 patients with highest
leptin levels
(mean of 34ng/ml), did not indicate differences in both 25(OH)D3 and ICTP between these two populations in spite of the highly significant difference in
leptin levels
.
The high range of
serum leptin
concentration in these geriatric patients with hip fracture of both sexes, and the absence of any correlation between
leptin
and the tested parameters of bone resorption and Ca metabolism, teleopeptide
type
I collagen (ICTP) and 25(OH)D3, does not support a direct massive involvement of
serum leptin
in hip fracture of the very old population.
[MeSH-major]
Bone Remodeling / physiology. Hip Fractures / blood.
Leptin
/ blood
[MeSH-minor]
Aged. Aged, 80 and over. Biomarkers / blood. Calcifediol / blood. Case-Control Studies. Cohort Studies. Collagen
Type
I. Dihydroxycholecalciferols / blood. Female. Humans. Male. Peptide Fragments / blood. Peptides. Procollagen / blood. Sex Distribution
MedlinePlus Health Information.
consumer health - Hip Injuries and Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18359113.001).
[ISSN]
1872-6976
[Journal-full-title]
Archives of gerontology and geriatrics
[ISO-abbreviation]
Arch Gerontol Geriatr
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Biomarkers; 0 / Collagen Type I; 0 / Dihydroxycholecalciferols; 0 / Leptin; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; P6YZ13C99Q / Calcifediol
34.
Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A:
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Leuk Lymphoma
; 2006 Sep;47(9):1818-21
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's
lymphoma
.
Although numerous options are available for patients with recurrent low-grade non-Hodgkin's
lymphoma
(NHL), responses are rarely durable.
We previously conducted a phase I trial of fludarabine and paclitaxel in the treatment of recurrent low-grade
lymphoma
.
Twenty-two (78%) patients had grade 1 or 2 follicular
lymphoma
, and six patients (21%) had
small lymphocytic lymphoma
.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, Non-Hodgkin / drug therapy
[MeSH-minor]
Adult. Aged. Female. Humans. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ drug therapy.
Lymphoma
, Follicular / drug therapy. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Rate. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
FLUDARABINE
.
Hazardous Substances Data Bank.
TAXOL
.
Hazardous Substances Data Bank.
VIDARABINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17064994.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article
[Publication-country]
England
[Chemical-registry-number]
FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; P88XT4IS4D / Paclitaxel
35.
Biggar RJ, Christiansen M, Rostgaard K, Smedby KE, Adami HO, Glimelius B, Hjalgrim H, Melbye M:
Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma.
Int J Cancer
; 2009 Jun 1;124(11):2616-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunoglobulin subclass
levels
in patients with non-Hodgkin
lymphoma
.
Allergy/atopy has been suggested to protect against non-Hodgkin
lymphoma
(NHL) and specific IgE
levels
are decreased in patients with NHL.
We speculated that all immunoglobulin subclass
levels
might be downregulated in NHL and examined
levels
of IgM, IgD, IgA, IgE, IgG and IgG(4) in 200 NHL patients and 200 age- and sex-matched controls.
Patients with B-
cell
NHL of many types had consistently lower median immunoglobulin subclass
levels
than controls.
In every subclass except IgD, about 10-15% of B-
cell
NHL patients had absolute
levels
below the 2.5 percentile of controls.
Subclass
levels
correlated with each other and many patients had more than one significantly low
level
.
Levels
were lowest for IgG(4) and IgE.
Patients with chronic
lymphocytic
leukemia/
small lymphocytic lymphoma
had especially low total IgE
levels
.
In other B-
cell
NHL types, total IgE
levels
were decreased to a similar extent as other immunoglobulin subclasses.
In conclusion, low IgE
levels
are only part of a more generalized loss of immunoglobulins of all subtypes in a wide variety of B-
cell
NHL types.
Low immunoglobulin
levels
appear to be a consequence of B-
cell
NHL presence, and we speculate about molecular mechanisms that could reduce all immunoglobulin subclasses in B-
cell
NHL.
[MeSH-major]
Immunoglobulins /
classification
[MeSH-minor]
Adolescent. Adult. Aged. Antigens, CD80 / blood. Female. Humans. Immunoglobulin E / blood. Immunoglobulin G / blood. Immunoglobulin M / blood.
Lymphoma
, Non-Hodgkin / immunology. Male. Middle Aged
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19235925.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD80; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins; 37341-29-0 / Immunoglobulin E
36.
Kuriakose P:
Targeted therapy for hematologic malignancies.
Cancer Control
; 2005 Apr;12(2):82-90
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In addition, the use of
small
molecules against specific
cell
surface receptors, enzymes, and proteins has become an important strategy in the treatment of such disorders.
Nevertheless, additional studies are needed to determine where and when such management fits into a therapeutic regimen for any given
disorder
, whether upfront or as salvage therapy, alone or in combination with chemotherapy (concurrent or sequential).
[MeSH-minor]
Humans. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ drug therapy. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology.
Lymphoma
, Non-Hodgkin / drug therapy.
Lymphoma
, Non-Hodgkin / immunology. Multiple Myeloma / drug therapy. Multiple Myeloma / immunology. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ drug therapy. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ immunology. Radioimmunotherapy
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15855891.001).
[ISSN]
1073-2748
[Journal-full-title]
Cancer control : journal of the Moffitt Cancer Center
[ISO-abbreviation]
Cancer Control
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Immunologic Factors
[Number-of-references]
129
37.
Mao J, Yang T, Gu Z, Heird WC, Finegold MJ, Lee B, Wakil SJ:
aP2-Cre-mediated inactivation of acetyl-CoA carboxylase 1 causes growth retardation and reduced lipid accumulation in adipose tissues.
Proc Natl Acad Sci U S A
; 2009 Oct 13;106(41):17576-81
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
FACC1KO mice showed prenatal growth retardation; after weaning, however, their weight gain was comparable to that of wild-
type
(WT) mice on a normal diet.
In addition, there was about a 30% decrease in
serum
insulin-like growth factor I (IGF1), and while the
serum leptin level
was decreased by about 50%, it did not counteract the osteopenic effects of IGF1 on the bone.
Fatty acid analyses of mutant bone lipids revealed relatively higher
levels
of C18:2n-6 and C18:3n-3 and lower
levels
of their elongation C20 homologs than that of WT cohorts, leading to lower
levels
of C20 homologs and bone development.
MedlinePlus Health Information.
consumer health - Growth Disorders
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 1964 Feb;239:375-80
[
14169133.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92
[
10359843.001
]
[Cites]
Expert Opin Ther Targets. 2005 Apr;9(2):267-81
[
15934915.001
]
[Cites]
Cell Metab. 2005 Feb;1(2):107-19
[
16054052.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12011-6
[
16103361.001
]
[Cites]
Cell Mol Life Sci. 2005 Aug;62(16):1784-803
[
15968460.001
]
[Cites]
Mol Cell Biol. 2006 Feb;26(3):1063-76
[
16428458.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8552-7
[
16717184.001
]
[Cites]
J Bone Miner Res. 2006 Sep;21(9):1350-8
[
16939393.001
]
[Cites]
Transgenic Res. 2006 Oct;15(5):647-53
[
16952017.001
]
[Cites]
Endocrinology. 2006 Oct;147(10):4753-61
[
16857753.001
]
[Cites]
Bioorg Med Chem Lett. 2007 Mar 15;17(6):1803-7
[
17234407.001
]
[Cites]
Gastroenterology. 2007 May;132(6):2103-15
[
17498506.001
]
[Cites]
Cell. 2007 Aug 10;130(3):456-69
[
17693256.001
]
[Cites]
Nat Med. 2008 Mar;14(3):299-305
[
18297084.001
]
[Cites]
Cell. 2000 Jan 21;100(2):197-207
[
10660043.001
]
[Cites]
Annu Rev Physiol. 2000;62:413-37
[
10845097.001
]
[Cites]
Endocr Rev. 2000 Aug;21(4):393-411
[
10950158.001
]
[Cites]
Endocrinology. 2000 Dec;141(12):4436-41
[
11108252.001
]
[Cites]
Dev Biol. 2001 Jan 1;229(1):141-62
[
11133160.001
]
[Cites]
Prog Lipid Res. 2001 Jan-Mar;40(1-2):125-48
[
11137570.001
]
[Cites]
Trends Endocrinol Metab. 2000 Oct;11(8):327-32
[
10996528.001
]
[Cites]
Science. 2001 Mar 30;291(5513):2613-6
[
11283375.001
]
[Cites]
Biochem J. 2001 Aug 15;358(Pt 1):127-35
[
11485560.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):138-43
[
11756679.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7515-20
[
12810950.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7
[
14660788.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3258-63
[
14978271.001
]
[Cites]
Methods Enzymol. 1975;35:59-65
[
235706.001
]
[Cites]
J Biol Chem. 1983 Sep 25;258(18):11074-81
[
6136512.001
]
[Cites]
Annu Rev Biochem. 1983;52:537-79
[
6137188.001
]
[Cites]
J Biol Chem. 1985 May 25;260(10):6318-23
[
2860106.001
]
[Cites]
J Biol Chem. 1988 May 5;263(13):6447-53
[
2896193.001
]
[Cites]
Cell. 1993 Oct 8;75(1):73-82
[
8402902.001
]
[Cites]
Genes Dev. 1993 Dec;7(12B):2609-17
[
8276243.001
]
[Cites]
Nature. 1994 Dec 1;372(6505):425-32
[
7984236.001
]
[Cites]
Gene. 1995 Mar 10;154(2):271-5
[
7890176.001
]
[Cites]
Brain Res Dev Brain Res. 1997 Feb 20;98(2):197-203
[
9051261.001
]
[Cites]
Annu Rev Nutr. 1997;17:77-99
[
9240920.001
]
[Cites]
Nature. 1998 Oct 22;395(6704):763-70
[
9796811.001
]
[Cites]
Genes Dev. 1999 Apr 15;13(8):1025-36
[
10215629.001
]
[Cites]
J Nutr Biochem. 2004 Nov;15(11):651-6
[
15590268.001
]
(PMID = 19805143.001).
[ISSN]
1091-6490
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
ENG
[Grant]
United States / NIGMS NIH HHS / GM / R01 GM063115; United States / NIGMS NIH HHS / GM / GM-63115
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA Primers; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / aminoglycoside N1-acetyltransferase; EC 6.4.1.2 / Acetyl-CoA Carboxylase
[Other-IDs]
NLM/ PMC2762677
38.
Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P:
Lymphoma--emerging realities in sub-Saharan Africa.
Transfus Apher Sci
; 2010 Apr;42(2):141-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lymphoma
--emerging realities in sub-Saharan Africa.
Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the
lymphoma
reclassification project.
Median age was 55.2 years 61% were males, 10% had Hodgkin
lymphoma
and, overall, constitutional symptoms were present in 20%.
Median survival in hairy
cell
leukaemia (n=14), chronic
lymphocytic
leukaemia-
small lymphocytic lymphoma
(n=103), Hodgkin (n=41) and follicular
lymphoma
(n=59) was not reached at the time of analysis and exceeded 36 months.
This was followed by 32 months for those with mantle
cell
(n=7), splenic (n=2) and extranodal marginal
cell
(n=11), 24 months for T-
cell
lymphomas
(n=24), 20 months for
diffuse
large B-
cell
variants (n=88) but only 12 months for the aggressive tumours exemplified by Burkitt (n=7) and lymphoblastic subtypes (n=6).
The remaining 36 patients had to be excluded because numbers were too
small
for statistical analysis or unreliable staging.
In contrast gender, staging by Rye or Rai
classification
, retroviral infection and prior treatment with radiotherapy were without effect.
Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy
cell
leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin
lymphoma
treated according to the German study group protocols (p=0.0004).
Corresponding figures for chronic
lymphocytic
leukaemia-
small lymphocytic lymphoma
were 82% (p=0.0006), follicular
lymphoma
71% (p=0.060), peripheral T-
cell lymphoma
43% (p=0.0156),
diffuse
large B-
cell lymphoma
39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle
cell
, splenic and extra nodal marginal
cell
lymphomas
22% (p=0.2023).
Outcome argues in favour of patient management by a multidisciplinary team implicit in which are standardised protocols for
diagnosis
, staging and treatment.
Under these circumstances the
well
recognized centre effect applies when results approximate those from first world reference centres.
[MeSH-major]
Lymphoma
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2010. Published by Elsevier Ltd.
(PMID = 20149748.001).
[ISSN]
1473-0502
[Journal-full-title]
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
[ISO-abbreviation]
Transfus. Apher. Sci.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
39.
Gogas H, Trakatelli M, Dessypris N, Terzidis A, Katsambas A, Chrousos GP, Petridou ET:
Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.
Ann Oncol
; 2008 Feb;19(2):384-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Melanoma risk in association with
serum leptin levels
and lifestyle parameters: a case-control study.
BACKGROUND: Solar radiation has been identified
as a
principal factor for the causation of melanoma, whereas changing lifestyle patterns associated with obesity and diabetes might also contribute to the increasing incidence of the malignancy.
No study has investigated the role of
leptin
, a hormone whose
levels
increase in obesity and which has also been related to cancer.
Anthropometrical measures were also recorded and blood samples were obtained for determination of
serum leptin levels
.
RESULTS: An excess melanoma risk was observed for sun sensitive individuals and those with high circulating
levels
of
leptin
(OR: 1.56, 95% confidence interval 1.07-2.28, P = 0.02), after controlling for obesity indices, diabetes mellitus and education.
CONCLUSIONS: Melanoma risk was found to be positively associated with
serum leptin levels
and inversely with healthy lifestyle factors.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17925285.001).
[ISSN]
1569-8041
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Leptin
40.
Rao SN, Gurumurthy GP, Gururajan P, Arumugam SB, Saibabu, Kirthivasan V, Cherian KM:
Clinical and biochemical parameters in relation to serum leptin levels in South Indian children and adolescents.
Indian J Pediatr
; 2010 May;77(5):555-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical and biochemical parameters in relation to
serum leptin levels
in South Indian children and adolescents.
OBJECTIVE: To investigate the relationship between
serum leptin
and lipid profile in South Indian School children and adolescents, and to evaluate the role of
serum leptin
in obese, overweight and congenital heart diseased children and adolescents; in South Indian population and its correlation with anthropometric and biochemical parameters.
Anthropometric variables, lipid profile, fasting
serum
glucose were analyzed by autoanalyser and
serum leptin
by ELISA.
RESULTS:
Serum leptin levels
were significantly elevated in obese and overweight children than in control children (36.88+/-18.60ng/mL, 20.64+/-11.18ng/mL vs 7.97+/-2.79ng/mL; p value <0.001), and decreased in congenital heart diseased children than in control children (6.20+/-4.23 ng/mL vs 7.97+/-2.79ng/mL; p value <0.005).
CONCLUSIONS: This study provides a good relationship between
serum leptin levels
and anthropometric and biochemical parameters, such as total cholesterol, triglycerides and LDL-cholesterol.
We observed negative correlation between
serum leptin
and fasting glucose
levels
and HDL-cholesterol
levels
were found to be non-significant among the groups.
Further studies with large sample size are needed to ascertain the relationship between
serum leptin
and lipid profile in different groups of children and adolescents.
[MeSH-major]
Heart Defects, Congenital / blood.
Leptin
/ blood. Lipids / blood. Obesity / blood. Overweight / blood
MedlinePlus Health Information.
consumer health - Congenital Heart Defects
.
MedlinePlus Health Information.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Obesity in Children
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Invest. 1997 Aug 15;100(4):808-13
[
9259579.001
]
[Cites]
J Clin Invest. 2000 May;105(9):1243-52
[
10791999.001
]
[Cites]
Obes Res. 2003 Apr;11(4):532-40
[
12690082.001
]
[Cites]
Eur J Clin Nutr. 2007 Jun;61(6):719-26
[
17164827.001
]
[Cites]
Ann Intern Med. 1997 Jan 1;126(1):26-31
[
8992920.001
]
[Cites]
Int J Cardiol. 2003 Nov;92(1):93-7
[
14602223.001
]
[Cites]
Eur J Epidemiol. 2001;17(10):911-6
[
12188009.001
]
[Cites]
J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13
[
8923837.001
]
[Cites]
J Intern Med. 1999 Oct;246(4):409-18
[
10583712.001
]
[Cites]
Obes Res. 2005 Aug;13(8):1476-84
[
16129731.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Jul;82(7):2148-52
[
9215286.001
]
[Cites]
Indian Pediatr. 2007 Apr;44(4):257-62
[
17468520.001
]
[Cites]
Pediatrics. 2005 Apr;115(4):e500-3
[
15741351.001
]
[Cites]
Indian J Pediatr. 2006 Jul;73(7):593-6
[
16877853.001
]
[Cites]
Pediatrics. 1996 Aug;98(2 Pt 1):201-3
[
8692618.001
]
(PMID = 20401706.001).
[ISSN]
0973-7693
[Journal-full-title]
Indian journal of pediatrics
[ISO-abbreviation]
Indian J Pediatr
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Chemical-registry-number]
0 / Biomarkers; 0 / Leptin; 0 / Lipids
41.
Dedeoğlu EN, Erenus M, Yörük P:
Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women.
Fertil Steril
; 2009 Feb;91(2):425-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of hormone therapy and tibolone on body composition and
serum leptin levels
in postmenopausal women.
OBJECTIVE: To compare the changes in body composition and in
leptin levels
in postmenopausal women receiving hormone therapy (HT) or tibolone.
MAIN OUTCOME MEASURE(S): Anthropometric indices,
leptin levels
, tissue fat percentage, total fat, and lean mass measurements were performed at baseline and after 6 months.
RESULT(S): The
serum leptin levels
were in strong correlation with the total fat percentage and total fat mass at baseline.
Untreated women had weight gain and a gradual decrease in
leptin levels
.
Women receiving HT had significantly increased
leptin levels
.
Women in the tibolone group, however, had a significant decrease in
leptin levels
accompanied by decreased total fat mass, fat percentage, and increased total lean mass.
The changes in
leptin levels
were more pronounced in lean women.
CONCLUSION(S): Postmenopausal women tend to gain weight accompanied with a reduction in
leptin
concentrations.
Hormone therapy administration increases
leptin levels
while maintaining body weight and body fat distribution, whereas tibolone use decreases
leptin levels
, total fat percentage, and total fat mass.
[MeSH-major]
Adiposity / drug effects. Estrogen Replacement Therapy. Estrogens, Conjugated (USP) / therapeutic use.
Leptin
/ blood. Medroxyprogesterone Acetate / therapeutic use. Norpregnenes / therapeutic use. Postmenopause. Weight Gain / drug effects
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18249383.001).
[ISSN]
1556-5653
[Journal-full-title]
Fertility and sterility
[ISO-abbreviation]
Fertil. Steril.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
0 / Estrogens, Conjugated (USP); 0 / Leptin; 0 / Norpregnenes; C2QI4IOI2G / Medroxyprogesterone Acetate; FF9X0205V2 / tibolone
42.
Li L, Gao Y, Zhang LL, He DL:
Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells.
Cancer Biol Ther
; 2008 Nov;7(11):1787-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in
leptin
-mediated proliferation of renal
cell
carcinoma Caki-2 cells.
Serum leptin levels
are often elevated in obese people.
Leptin
has been reported to act
as a
mitogenic agent and promote renal cancer
cell
proliferation, whereas the detailed mechanisms still remain to be elucidated.
The purpose of this study is to investigate the proliferation and mobility effects in
leptin
-treated Caki-2 renal
cell
carcinoma and analyze the alterations of
leptin
-inducible STAT3 pathways and mitogenic signaling ERK pathways.
Our results indicate the constitutive expression of
leptin
receptor could not be upregulated upon the stimulation of
leptin
in Caki-2 cells.
Leptin
increases the proliferation and mobility capabilities of Caki-2 cells via upregulating the expression of both phosphor-ERK and phosphor-STAT3 and these two pathways could be partially abolished by inhibition of the activation of JAK-STAT3 and completely abrogated by inhibition of ERK1/2 pathways.
Our results also suggest that mitogenic actions of
leptin
are not the consequence of altered its receptor expression; whereas the cellular proliferation appears to be working through the cross-talking of JAK-STAT3 and ERK1/2 pathways in renal
cell
carcinoma caki-2 cells.
[MeSH-major]
Carcinoma, Renal
Cell
/ metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation. Janus Kinase 1 / metabolism.
Leptin
/ metabolism. STAT3 Transcription Factor / metabolism
[MeSH-minor]
Cell
Line, Tumor.
Cell
Proliferation. Flow Cytometry. Humans. Kidney Neoplasms / metabolism. MAP Kinase Signaling System. Obesity / metabolism. Protein Kinase C / metabolism. Signal Transduction
Genetic Alliance.
consumer health - Renal cell carcinoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18787400.001).
[ISSN]
1555-8576
[Journal-full-title]
Cancer biology & therapy
[ISO-abbreviation]
Cancer Biol. Ther.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Leptin; 0 / STAT3 Transcription Factor; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
43.
Xu LP, Huang XJ, Liu DH, Chen YH, Shi HX, Chen DB:
[A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
Zhonghua Nei Ke Za Zhi
; 2007 Dec;46(12):996-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem
cell
transplantation].
OBJECTIVE: To study the risk factors and clinical characteristics of post transplantation lymphoproliferative disorders (PTLD) after hematopoietic stem
cell
transplantation (HSCT).
PTLD was diagnosed on the basis of finding
diffuse
hyperplasia characterized by invasion of other organ structure with disorganization of the nodal structure in
lymph
nodes.
If pathological investigation was not possible, PTLD was diagnosed by the presence of fever,
lymph
node enlargement and/or EBV viral load, which could not be explained by other causes.
The morphology of biopsy appeared as
small B
-
lymphocytic lymphoma
; there was no response to chemotherapy and the patients died.
One patient recovered by reducing immunosuppressive drug therapy combined with MP and one patient recovered by reducing immunosuppressive/antivirus therapy and donor
lymphocyte
infusion.
[MeSH-major]
Hematopoietic Stem
Cell
Transplantation / adverse effects. Lymphoproliferative Disorders /
diagnosis
. Lymphoproliferative Disorders / etiology
Genetic Alliance.
consumer health - Transplantation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18478915.001).
[ISSN]
0578-1426
[Journal-full-title]
Zhonghua nei ke za zhi
[ISO-abbreviation]
Zhonghua Nei Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / HLA Antigens
44.
Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, Lank E, Bottomley B, Lopez-Fernandez J, Ferraz-Amaro I, Dattani MT, Ercan O, Myhre AG, Retterstol L, Stanhope R, Edge JA, McKenzie S, Lessan N, Ghodsi M, De Rosa V, Perna F, Fontana S, Barroso I, Undlien DE, O'Rahilly S:
Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.
N Engl J Med
; 2007 Jan 18;356(3):237-47
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical and molecular genetic spectrum of congenital deficiency of the
leptin
receptor.
BACKGROUND: A single family has been described in which obesity results from a mutation in the
leptin
-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined.
Serum leptin levels
were within the range predicted by the elevated fat mass in these subjects.
Their clinical features were less severe than those of subjects with congenital
leptin
deficiency.
Circulating
levels
of
leptin
were not disproportionately elevated, suggesting that
serum leptin
cannot be used
as a
marker for
leptin
-receptor deficiency.
Congenital
leptin
-receptor deficiency should be considered in the differential
diagnosis
in any child with hyperphagia and severe obesity in the absence of developmental delay or dysmorphism.
[MeSH-major]
Metabolism, Inborn Errors /
diagnosis
. Metabolism, Inborn Errors / genetics. Obesity / genetics. Receptors,
Cell
Surface / deficiency. Receptors,
Cell
Surface / genetics
[MeSH-minor]
Adult. Age of Onset. Basal Metabolism. Body Composition. Child.
Diagnosis
, Differential. Female. Genotype. Humans. Hyperphagia / blood. Hyperphagia / complications. Hyperphagia / genetics. Hypogonadism / blood. Hypogonadism / complications. Hypogonadism / genetics. Immunologic Deficiency Syndromes / blood. Immunologic Deficiency Syndromes / complications. Immunologic Deficiency Syndromes / genetics.
Leptin
/ blood.
Lymphocyte
Count. Male. Mutation. Pedigree. Phenotype. Receptors,
Leptin
Genetic Alliance.
consumer health - Leptin receptor deficiency
.
Genetics Home Reference.
consumer health - leptin receptor deficiency
.
Genetics Home Reference.
consumer health - LEPR gene
.
MedlinePlus Health Information.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Obesity in Children
.
COS Scholar Universe.
author profiles
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
SciCrunch.
OMIM: Data: Gene Annotation
.
SciCrunch.
Clinical Genomic Database: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2007 Massachusetts Medical Society.
[Cites]
Diabetes. 2000 Aug;49(8):1347-52
[
10923636.001
]
[Cites]
Clin Endocrinol (Oxf). 2006 Jun;64(6):667-71
[
16712669.001
]
[Cites]
Int J Obes Relat Metab Disord. 2002 May;26(5):640-6
[
12032747.001
]
[Cites]
Obes Rev. 2001 Feb;2(1):29-36
[
12119634.001
]
[Cites]
J Clin Invest. 2002 Oct;110(8):1093-103
[
12393845.001
]
[Cites]
N Engl J Med. 2003 Mar 20;348(12):1085-95
[
12646665.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6
[
15070752.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Oct;89(10):4821-6
[
15472169.001
]
[Cites]
Am J Clin Nutr. 1979 Mar;32(3):607-29
[
420153.001
]
[Cites]
Am J Clin Nutr. 1982 May;35(5 Suppl):1169-75
[
7081099.001
]
[Cites]
Am J Clin Nutr. 1991 Dec;54(6):963-9
[
1957828.001
]
[Cites]
Eur J Clin Nutr. 1993 Oct;47(10):724-34
[
8269887.001
]
[Cites]
Diabet Med. 1995 Jan;12(1):30-5
[
7712700.001
]
[Cites]
Arch Dis Child. 1995 Jul;73(1):25-9
[
7639544.001
]
[Cites]
J Pediatr. 1995 Oct;127(4):571-7
[
7562278.001
]
[Cites]
Biochem Biophys Res Commun. 1997 Apr 7;233(1):248-52
[
9144432.001
]
[Cites]
Nature. 1997 Jun 26;387(6636):903-8
[
9202122.001
]
[Cites]
Nat Genet. 1997 Jul;16(3):303-6
[
9207799.001
]
[Cites]
Nat Genet. 1998 Mar;18(3):213-5
[
9500540.001
]
[Cites]
Nature. 1998 Mar 26;392(6674):398-401
[
9537324.001
]
[Cites]
Am J Physiol. 1998 Apr;274(4 Pt 2):R985-90
[
9575960.001
]
[Cites]
Nat Genet. 1998 Jun;19(2):155-7
[
9620771.001
]
[Cites]
Nature. 1998 Aug 27;394(6696):897-901
[
9732873.001
]
[Cites]
Baillieres Clin Endocrinol Metab. 1998 Jul;12(2):297-314
[
10083898.001
]
[Cites]
N Engl J Med. 1999 Sep 16;341(12):879-84
[
10486419.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Oct;84(10):3686-95
[
10523015.001
]
[Cites]
Annu Rev Med. 2005;56:443-58
[
15660521.001
]
[Cites]
J Clin Endocrinol Metab. 2005 Mar;90(3):1849-55
[
15598687.001
]
[Cites]
J Clin Endocrinol Metab. 2005 Mar;90(3):1871-87
[
15598688.001
]
[Cites]
Nature. 2001 Nov 1;414(6859):34-5
[
11689931.001
]
(PMID = 17229951.001).
[ISSN]
1533-4406
[Journal-full-title]
The New England journal of medicine
[ISO-abbreviation]
N. Engl. J. Med.
[Language]
eng
[Grant]
Italy / Telethon / / GJT04008; United Kingdom / Wellcome Trust / / 077016; United Kingdom / Wellcome Trust / / 068086; United Kingdom / Medical Research Council / / G0502115; United Kingdom / Wellcome Trust / / 067457; United Kingdom / Wellcome Trust / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human
[Other-IDs]
NLM/ PMC2670197; NLM/ UKMS4351
45.
Gui W, Zhao ZQ, Zhang Z, Guo YR, Zhang QH, Su W:
[Analysis of pathological type and clinical features of lymphoma cell leukemia].
Zhonghua Xue Ye Xue Za Zhi
; 2009 Oct;30(10):662-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Analysis of pathological
type
and clinical features of
lymphoma cell
leukemia].
OBJECTIVE: To analyze the pathological
type
and clinical features of patients with
lymphoma cell
leukemia (LML).
METHODS: According to the 2008 WHO
classification
of tumors of hematopoietic and lymphoid tissue, the pathological
type
and clinical features of 127 LML cases were analyzed retrospectively.
The incidence in frequent order of them was B-lymphoblastic
lymphoma
, CLL/
small lymphocytic lymphoma
(
SLL
) and T-lymphoblastic
lymphoma
.
The LML of T and
B cell
subtypes were 45 and 74, respectively.
Eighty one patients presented LML at the same time of the NHL
diagnosis
and 46 during the course (1 - 88 months) of disease.
The clinical manifestations of LBL and
SLL
patients differed from that of ALL and CLL patients.
[MeSH-minor]
Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans.
Lymphoma
, Non-Hodgkin / pathology. Male. Middle Aged. Retrospective Studies. Young Adult
MedlinePlus Health Information.
consumer health - Acute Lymphocytic Leukemia
.
MedlinePlus Health Information.
consumer health - Chronic Lymphocytic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19954660.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
46.
Halldórsdóttir AM, Zehnbauer BA, Burack WR:
Application of BIOMED-2 clonality assays to formalin-fixed paraffin embedded follicular lymphoma specimens: superior performance of the IGK assays compared to IGH for suboptimal specimens.
Leuk Lymphoma
; 2007 Jul;48(7):1338-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Application of BIOMED-2 clonality assays to formalin-fixed paraffin embedded follicular
lymphoma
specimens: superior performance of the IGK assays compared to IGH for suboptimal specimens.
The BIOMED-2 PCR-based immunoglobulin gene rearrangement assays have quickly become the most commonly used laboratory method for detection of B-
cell
clonality.
When studying paired cases of follicular
lymphoma
(FL) from individual patients, we used these assays to assess clonality in 40 formalin-fixed paraffin-embedded (FFPE) specimens from 19 patients diagnosed with FL.
The high failure rate of the IGH assays for this set of FFPE
lymphomas
cannot be explained by systematic problems with DNA extraction or amplification because the same IGH assays resulted in a low failure rate (3/32, 9%) for FFPE
small lymphocytic lymphoma
/chronic
lymphocytic
leukemia specimens and for fresh frozen FL specimens (1/6, 17%).
Furthermore, in a second validation set of 13 FFPE follicular
lymphoma
the failure rate was 9/13 (69%).
Therefore, the BIOMED-2 IGH assay did not perform
well
on FFPE follicular
lymphoma
specimens, and the IGK assay may be superior for assessing clonality when no fresh/frozen tissue is available.
[MeSH-major]
B-
Lymphocytes
/ pathology. Clone Cells / pathology. Immunoglobulin Heavy Chains / genetics. Immunoglobulin kappa-Chains / genetics.
Lymphoma
, Follicular / pathology
Genetic Alliance.
consumer health - Follicular Lymphoma
.
Biospecimen Research Database.
Biospecimen Research Database
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17613763.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin kappa-Chains
47.
Matheny M, Zhang Y, Shapiro A, Tümer N, Scarpace PJ:
Central overexpression of leptin antagonist reduces wheel running and underscores importance of endogenous leptin receptor activity in energy homeostasis.
Am J Physiol Regul Integr Comp Physiol
; 2009 Nov;297(5):R1254-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Central overexpression of
leptin
antagonist reduces wheel running and underscores importance of endogenous
leptin
receptor activity in energy homeostasis.
We used recombinant adeno-associated virus (rAAV)-mediated gene delivery to overexpress a mutant of rat
leptin
yielding a protein that acts
as a
neutral
leptin
receptor antagonist.
Leptin
antagonist overexpression was confirmed by examination of mRNA
levels
in the hypothalamus.
The degree of antagonist overexpression was sufficient to partially block signal transducer and activator of transcription 3 (STAT3) phosphorylation due to administration of an acute submaximal dose of
leptin
.
In contrast, when
leptin
was overexpressed in the hypothalamus, WR activity was increased by greater than twofold.
At death, adiposity and
serum leptin levels
were greater in the antagonist group.
These data indicate that submaximal central
leptin
receptor blockade promotes obesity and diminishes WR activity.
These findings underscore the critical role of unrestrained
leptin
receptor activity in long-term energy homeostasis and suggest that even minor disruption of
leptin
receptor function can promote obesity.
COS Scholar Universe.
author profiles
.
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 2000 Apr 6;404(6778):661-71
[
10766253.001
]
[Cites]
J Clin Invest. 1995 Sep;96(3):1658-63
[
7657836.001
]
[Cites]
J Clin Invest. 2000 Jun;105(12):1827-32
[
10862798.001
]
[Cites]
Regul Pept. 2001 Jun 15;99(2-3):69-77
[
11384767.001
]
[Cites]
Neuroscience. 2001;104(4):1111-7
[
11457594.001
]
[Cites]
Neuropharmacology. 2002 Mar;42(4):548-61
[
11955525.001
]
[Cites]
Obes Rev. 2000 Oct;1(2):87-94
[
12119990.001
]
[Cites]
Endocrinology. 2002 Aug;143(8):3026-35
[
12130569.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8878-83
[
9238071.001
]
[Cites]
Am J Physiol. 1997 Jul;273(1 Pt 1):E226-30
[
9252501.001
]
[Cites]
Diabetes. 1997 Nov;46(11):1782-5
[
9356026.001
]
[Cites]
Nat Genet. 1998 Mar;18(3):213-5
[
9500540.001
]
[Cites]
Endocrinology. 1998 Sep;139(9):3681-90
[
9724018.001
]
[Cites]
Nature. 1998 Oct 22;395(6704):763-70
[
9796811.001
]
[Cites]
J Biol Chem. 1999 Jun 18;274(25):17541-4
[
10364187.001
]
[Cites]
Nat Biotechnol. 2004 Dec;22(12):1583-7
[
15568020.001
]
[Cites]
Diabetologia. 2005 Jun;48(6):1075-83
[
15864530.001
]
[Cites]
J Virol. 2006 Feb;80(4):1874-85
[
16439543.001
]
[Cites]
J Pharmacol Exp Ther. 2007 Feb;320(2):706-12
[
17082312.001
]
[Cites]
Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R868-74
[
17023670.001
]
[Cites]
Front Biosci. 2007;12:3531-44
[
17485319.001
]
[Cites]
Behav Brain Res. 2008 Mar 17;188(1):100-8
[
18063139.001
]
[Cites]
Diabetes. 2008 Mar;57(3):614-22
[
18086903.001
]
[Cites]
Endocrinology. 2008 Jun;149(6):3009-15
[
18308842.001
]
[Cites]
Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1370-5
[
18703413.001
]
[Cites]
Exp Biol Med (Maywood). 2002 Sep;227(8):587-600
[
12192100.001
]
[Cites]
Methods. 2002 Oct;28(2):158-67
[
12413414.001
]
[Cites]
Expert Opin Investig Drugs. 2003 Mar;12(3):373-8
[
12605561.001
]
[Cites]
Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1011-20
[
14557234.001
]
[Cites]
Obes Res. 2004 Jan;12(1):150-60
[
14742854.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6
[
15070752.001
]
[Cites]
Metabolism. 1977 Apr;26(4):371-80
[
846405.001
]
[Cites]
Q J Exp Physiol. 1987 Oct;72(4):549-59
[
3423201.001
]
[Cites]
Science. 1995 Jul 28;269(5223):543-6
[
7624777.001
]
[Cites]
Science. 1995 Jul 28;269(5223):546-9
[
7624778.001
]
[Cites]
Annu Rev Physiol. 2000;62:413-37
[
10845097.001
]
(PMID = 19726711.001).
[ISSN]
1522-1490
[Journal-full-title]
American journal of physiology. Regulatory, integrative and comparative physiology
[ISO-abbreviation]
Am. J. Physiol. Regul. Integr. Comp. Physiol.
[Language]
ENG
[Grant]
United States / NIA NIH HHS / AG / AG-26159; United States / NIA NIH HHS / AG / P30-AG-028740,
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Ion Channels; 0 / Leptin; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / Receptors, Leptin; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, rat; 0 / mitochondrial uncoupling protein
[Other-IDs]
NLM/ PMC2777784
48.
Benetti-Pinto CL, Castro N, Grassiotto Oda R, Garmes HM:
Leptin and adiponectin blood levels in women with premature ovarian failure and age- and weight-matched women with normal menstrual cycles.
Menopause
; 2010 Jan-Feb;17(1):174-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Leptin
and adiponectin blood
levels
in women with premature ovarian failure and age- and weight-matched women with normal menstrual cycles.
OBJECTIVE: The aim of this study was to evaluate
leptin
and adiponectin blood
levels
in women with premature ovarian failure (POF) and women with a normal menstrual cycle.
Serum leptin levels
were significantly lower in G1 compared with G2 (8.8 +/- 12.2 and 12.2 +/- 9.7 ng/mL; P < 0.05).
Serum
adiponectin
levels
were similar in both groups.
Leptin levels
were positively correlated to weight (r = 0.38; P = 0.03) but were not correlated to BMI and age in women with POF (G1); in G2, they were positively correlated to BMI (r = 0.59; P = 0.0006), weight (r = 0.63; P = 0.0006), and age (r = 0.40; P = 0.02).
Adiponectin
levels
did not correlate to weight, BMI, or age in both groups.
CONCLUSIONS: These results suggest that gonadal function loss may decrease
leptin
circulating
levels
, independently from age and BMI.
[MeSH-major]
Adiponectin / blood.
Leptin
/ blood. Primary Ovarian Insufficiency / blood
Genetic Alliance.
consumer health - premature ovarian failure
.
MedlinePlus Health Information.
consumer health - Premature Ovarian Failure
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19609224.001).
[ISSN]
1530-0374
[Journal-full-title]
Menopause (New York, N.Y.)
[ISO-abbreviation]
Menopause
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Adiponectin; 0 / Leptin
49.
Ruhlen RL, Howdeshell KL, Mao J, Taylor JA, Bronson FH, Newbold RR, Welshons WV, vom Saal FS:
Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice.
Environ Health Perspect
; 2008 Mar;116(3):322-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Low phytoestrogen
levels
in feed increase fetal
serum
estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice.
RESULTS: In fetuses whose mothers consumed the low-phytoestrogen PMI 5K96 feed, we found a paradoxical significant elevation in endogenous
serum
estradiol, which was associated postnatally with adverse reproductive outcomes referred to as the "fetal estrogenization syndrome (FES)".
The low-phytoestrogen-fed males and females were lighter at birth, but, between weaning and adulthood, they became obese and developed abnormally high
serum leptin levels
; these males, but not females, showed impaired glucose regulation.
Genetic Alliance.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Obesity
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ESTRADIOL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2056-61
[
9050904.001
]
[Cites]
Environ Health Perspect. 2003 Jun;111(8):994-1006
[
12826473.001
]
[Cites]
Toxicol Ind Health. 1998 Jan-Apr;14(1-2):239-60
[
9460178.001
]
[Cites]
Environ Health Perspect. 1998 Jul;106(7):369-73
[
9637793.001
]
[Cites]
Epidemiol Rev. 1998;20(2):157-72
[
9919436.001
]
[Cites]
Exp Biol Med (Maywood). 2004 Dec;229(11):1127-35
[
15564439.001
]
[Cites]
J Nutr. 2005 May;135(5):1331-5
[
15867335.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 May 10;102(19):7014-9
[
15867144.001
]
[Cites]
Birth Defects Res A Clin Mol Teratol. 2005 Jul;73(7):478-80
[
15959888.001
]
[Cites]
Environ Res. 2006 Jan;100(1):50-76
[
16256977.001
]
[Cites]
Reprod Toxicol. 2006 Apr;21(3):307-12
[
16257506.001
]
[Cites]
Endocrinology. 2006 Jun;147(6 Suppl):S56-69
[
16690810.001
]
[Cites]
Lab Anim. 2007 Jan;41(1):1-18
[
17234046.001
]
[Cites]
Environ Health Perspect. 2007 Jun;115(6):902-8
[
17589598.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13056-61
[
17670942.001
]
[Cites]
Environ Health Perspect. 2007 Oct;115(10):1467-73
[
17938737.001
]
[Cites]
Environ Health Perspect. 2008 Mar;116(3):389-93
[
18335108.001
]
[Cites]
Nature. 1999 Oct 21;401(6755):763-4
[
10548101.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12729-34
[
11070086.001
]
[Cites]
J Nutr. 2001 Feb;131(2):354S-60S
[
11160560.001
]
[Cites]
Cancer Res. 2001 Jun 1;61(11):4325-8
[
11389053.001
]
[Cites]
Exp Biol Med (Maywood). 2001 Dec;226(11):978-81
[
11743132.001
]
[Cites]
Comp Med. 2003 Dec;53(6):607-15
[
14727808.001
]
[Cites]
Reprod Toxicol. 2004 May;18(3):399-406
[
15082075.001
]
[Cites]
J Anim Sci. 1989 Jul;67(7):1824-40
[
2670873.001
]
[Cites]
Biol Reprod. 1990 Nov;43(5):751-61
[
2291911.001
]
[Cites]
J Vet Diagn Invest. 1990 Oct;2(4):268-73
[
2151311.001
]
[Cites]
Endocrinology. 1992 Jun;130(6):3184-90
[
1375894.001
]
[Cites]
Biol Reprod. 1992 Nov;47(5):723-9
[
1477199.001
]
[Cites]
J Steroid Biochem Mol Biol. 1993 Feb;44(2):147-53
[
8382517.001
]
[Cites]
Biol Reprod. 1995 Nov;53(5):1198-207
[
8527526.001
]
[Cites]
Environ Health Perspect. 1995 Oct;103 Suppl 7:83-7
[
8593881.001
]
[Cites]
Clin Chem. 1996 Jun;42(6 Pt 1):955-64
[
8665689.001
]
[Cites]
Med Sci Monit. 2002 Dec;8(12):RA282-92
[
12503048.001
]
[Cites]
Clin Chem. 1997 May;43(5):850; author reply 852
[
9166244.001
]
(PMID = 18335098.001).
[ISSN]
0091-6765
[Journal-full-title]
Environmental health perspectives
[ISO-abbreviation]
Environ. Health Perspect.
[Language]
ENG
[Grant]
United States / NIEHS NIH HHS / ES / R01 ES011283; United States / NIGMS NIH HHS / GM / T32 GM008396; United States / NIEHS NIH HHS / ES / ES11283
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Leptin; 0 / Phytoestrogens; 4TI98Z838E / Estradiol
[Other-IDs]
NLM/ PMC2265041
[Keywords]
NOTNLM ; casein / estradiol / fat / glucose tolerance / leptin / metabolic syndrome / obesity / puberty / reproductive organs / soy
50.
Bhattacharya A, Rahman MM, McCarter R, O'Shea M, Fernandes G:
Conjugated linoleic acid and chromium lower body weight and visceral fat mass in high-fat-diet-fed mice.
Lipids
; 2006 May;41(5):437-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This effect was accompanied by decreased
serum leptin levels
in CLA-fed and CLA + Cr-fed mice, and by higher energy expenditure (EE) and oxygen consumption (OC) in CLA + Cr-fed mice.
Serum levels
of glucose, insulin, the pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6),
as well
as insulin resistance index (IRI), decreased with CLA, whereas CLA and Cr in combination had significant effects on insulin and IL-6 concentrations and IRI.
In summary, CLA + Cr decreased body weight and fat mass in high-fat-diet-fed mice, which may be associated with decreased
leptin levels
and higher EE and OC.
[MeSH-minor]
Adiponectin / blood. Analysis of Variance. Animals. Dietary Fats / administration & dosage. Dietary Fats / pharmacology. Energy Metabolism / drug effects.
Leptin
/ blood. Male. Mice. Mice, Inbred BALB C
MedlinePlus Health Information.
consumer health - Body Weight
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
CHROMIUM, ELEMENTAL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Obes Rev. 2005 Aug;6(3):247-58
[
16045640.001
]
[Cites]
Biochem Biophys Res Commun. 2004 Oct 15;323(2):679-84
[
15369804.001
]
[Cites]
Diabetes. 2000 Sep;49(9):1534-42
[
10969838.001
]
[Cites]
Am J Clin Nutr. 2004 Oct;80(4):887-95
[
15447895.001
]
[Cites]
Diabetes Res Clin Pract. 1996 Mar;31(1-3):27-35
[
8792099.001
]
[Cites]
Lipids Health Dis. 2005 Jan 10;4:3
[
15642120.001
]
[Cites]
Am J Clin Nutr. 2004 Jun;79(6 Suppl):1199S-1206S
[
15159257.001
]
[Cites]
Biosci Biotechnol Biochem. 2002 Apr;66(4):916-20
[
12036077.001
]
[Cites]
JAMA. 2004 Jun 16;291(23):2847-50
[
15199035.001
]
[Cites]
Int J Obes Relat Metab Disord. 2003 Apr;27(4):522-9
[
12664086.001
]
[Cites]
J Nutr Biochem. 2004 Nov;15(11):680-7
[
15590272.001
]
[Cites]
Wei Sheng Yan Jiu. 2000 Nov;29(6):370-1
[
12520958.001
]
[Cites]
J Biomed Mater Res. 1996 Dec;32(4):655-61
[
8953156.001
]
[Cites]
Biochim Biophys Acta. 2002 Apr 15;1581(3):89-99
[
12020636.001
]
[Cites]
J Lipid Res. 2002 Sep;43(9):1400-9
[
12235171.001
]
[Cites]
J Endocrinol. 1998 Oct;159(1):165-72
[
9795354.001
]
[Cites]
Am J Clin Nutr. 2004 Jun;79(6):1118-25
[
15159244.001
]
[Cites]
Aging (Milano). 1997 Feb-Apr;9(1-2):73-9
[
9177588.001
]
[Cites]
Nutr Rev. 1998 Sep;56(9):266-70
[
9763876.001
]
[Cites]
J Nutr. 2005 May;135(5):1124-30
[
15867292.001
]
[Cites]
Exp Clin Endocrinol Diabetes. 2005 Feb;113(2):67-79
[
15772897.001
]
[Cites]
Metabolism. 1998 Apr;47(4):396-400
[
9550535.001
]
[Cites]
Diabetologia. 2004 Jun;47(6):1016-9
[
15168020.001
]
[Cites]
Am J Physiol. 1998 Sep;275(3 Pt 2):R667-72
[
9728060.001
]
[Cites]
Am J Clin Nutr. 2004 Jun;79(6 Suppl):1153S-1158S
[
15159250.001
]
[Cites]
Diabetes Care. 2002 Sep;25(9):1516-21
[
12196420.001
]
[Cites]
J Nutr Sci Vitaminol (Tokyo). 2004 Dec;50(6):416-21
[
15895517.001
]
[Cites]
Am J Clin Nutr. 2004 Jun;79(6 Suppl):1169S-1174S
[
15159253.001
]
[Cites]
Am J Clin Nutr. 2004 Jun;79(6 Suppl):1164S-1168S
[
15159252.001
]
[Cites]
Lipids. 2002 Jul;37(7):725-8
[
12216844.001
]
[Cites]
Diabetes. 2002 Jul;51(7):2037-44
[
12086931.001
]
[Cites]
Annu Rev Nutr. 2002;22:505-31
[
12055356.001
]
[Cites]
J Bone Miner Res. 2003 Jul;18(7):1206-16
[
12854830.001
]
[Cites]
J Dairy Sci. 1995 Nov;78(11):2358-65
[
8747326.001
]
[Cites]
Nat Med. 1995 Nov;1(11):1155-61
[
7584987.001
]
[Cites]
Diabetes Obes Metab. 2001 Aug;3 Suppl 1:S11-9
[
11685824.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Apr 11;303(3):795-9
[
12670481.001
]
[Cites]
Lipids. 1997 Aug;32(8):853-8
[
9270977.001
]
[Cites]
Prog Lipid Res. 2004 Nov;43(6):553-87
[
15522764.001
]
[Cites]
J Am Coll Nutr. 2005 Jun;24(3):200-9
[
15930486.001
]
[Cites]
Public Health Nutr. 2004 Feb;7(1A):123-46
[
14972057.001
]
[Cites]
Lipids. 2001 Jul;36(7):669-74
[
11521964.001
]
[Cites]
Nutrition. 1999 Sep;15(9):720-2
[
10467621.001
]
[Cites]
J Biol Chem. 2005 Nov 18;280(46):38445-56
[
16155293.001
]
[Cites]
JAMA. 1999 Oct 27;282(16):1519-22
[
10546690.001
]
[Cites]
Nature. 2000 Apr 6;404(6778):635-43
[
10766250.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E527-33
[
12736161.001
]
[Cites]
J Nutr. 2003 Jun;133(6):1793-9
[
12771319.001
]
[Cites]
Diabetes Res Clin Pract. 1995 Jun;28(3):179-84
[
8529496.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Jun;89(6):2665-71
[
15181039.001
]
[Cites]
J Nutr. 2000 Oct;130(10 ):2471-7
[
11015475.001
]
[Cites]
Am J Clin Nutr. 2004 Jun;79(6 Suppl):1132S-1136S
[
15159246.001
]
[Cites]
Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2057-65
[
11080069.001
]
[Cites]
Am J Clin Nutr. 1985 May;41(5 Suppl):1132-45
[
3993620.001
]
[Cites]
J Nutr. 2002 Oct;132(10):2995-8
[
12368384.001
]
[Cites]
Nature. 1999 Dec 23-30;402(6764):860-1
[
10622250.001
]
[Cites]
Diabetes. 2001 May;50(5):1149-57
[
11334420.001
]
[Cites]
Nutrition. 2003 Jan;19(1):30-5
[
12507636.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2000 Mar;278(3):E563-9
[
10710512.001
]
[Cites]
Am J Clin Nutr. 1981 Dec;34(12):2670-8
[
7032273.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Oct 17;310(2):562-6
[
14521947.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6207-12
[
15833818.001
]
[Cites]
Am J Vet Res. 1997 Jun;58(6):594-600
[
9185964.001
]
[Cites]
Int J Obes. 1991 Sep;15 Suppl 2:109-15
[
1794931.001
]
[Cites]
Obes Res. 2003 Mar;11(3):368-72
[
12634431.001
]
[Cites]
J Nutr. 2005 Apr;135(4):778-84
[
15795434.001
]
[Cites]
Metabolism. 1992 Jul;41(7):768-71
[
1619996.001
]
[Cites]
Diabetes Care. 1994 Dec;17(12):1449-52
[
7882815.001
]
[Cites]
Diabet Med. 2000 Sep;17(9):684-5
[
11051290.001
]
[Cites]
Nutrition. 2004 Nov-Dec;20(11-12):1008-17
[
15561492.001
]
[Cites]
Biochem Biophys Res Commun. 1998 Mar 27;244(3):678-82
[
9535724.001
]
[Cites]
Diabetologia. 1985 Jul;28(7):412-9
[
3899825.001
]
[Cites]
Lipids. 1999 Mar;34(3):235-41
[
10230716.001
]
(PMID = 16933788.001).
[ISSN]
0024-4201
[Journal-full-title]
Lipids
[ISO-abbreviation]
Lipids
[Language]
eng
[Grant]
United States / NIA NIH HHS / AG / AG023648; United States / NIA NIH HHS / AG / AG027562
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Adiponectin; 0 / Dietary Fats; 0 / Leptin; 0 / Linoleic Acids, Conjugated; 0R0008Q3JB / Chromium
51.
Chen L, Li J, Zheng W, Zhang Y, Wu Y, Li L, Qian S, Xu W:
The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia.
Leuk Lymphoma
; 2007 Sep;48(9):1785-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The prognostic evaluation of CLLU1 expression
levels
in 50 Chinese patients with chronic
lymphocytic
leukemia.
Chronic
lymphocytic
leukemia (CLL) is characterized by the relentless accumulation of monoclonal B cells with the appearance of
small
mature
lymphocytes
and a characteristic CD5 and CD19 co-expression immunophenotype.
To investigate CLLU1 expression in CLL and explore the relationship between CLLU1 expression and alternative prognostic markers, we measured CLLU1 expression
levels
by semiquantitative RT-PCR in a cohort of 50 Chinese patients with CLL.
The expression
levels
of CLLU1 were significantly increased in B + C CLL patients at Binet stage compared with those at Binet stage A (P = 0.005).
Patients with unmutated IgVH genes expressed higher
levels
of CLLU1 than did those with IgVH mutations (P < 0.05).
[MeSH-major]
Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ genetics.
Neoplasm
Proteins / genetics
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Leuk Lymphoma. 2007 Sep;48(9):1665-6
[
17786698.001
]
(PMID = 17786715.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / CLLU1 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Neoplasm Proteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38
52.
Al Maskari MY, Alnaqdy AA:
Correlation between Serum Leptin Levels, Body Mass Index and Obesity in Omanis.
Sultan Qaboos Univ Med J
; 2006 Dec;6(2):27-31
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Correlation between
Serum Leptin Levels
, Body Mass Index and Obesity in Omanis.
OBJECTIVE: To ascertain the relationship between
serum leptin levels
and related variables (weight, Body Mass Index (BMI) and fat percentage) in a group of Omani obese and non-obese healthy subjects.
METHODS:
Leptin levels
were assessed in
serum
samples from 35 obese Omanis and 20 non-obese healthy subjects.
RESULTS: There was a significant difference (p< 0.001) in
serum leptin
between the obese group (34.78 + 13.96 ng/ml) and the control non-obese subjects (10.6 ± 4.2 ng/ml).
Leptin levels
were higher in females compared to males.
There was a significantly positive correlation between
leptin levels
in obese subjects with weight (p=0.002), body fat percentage (p=0.0001) and BMI (p=0.001).
CONCLUSIONS: We concluded that
serum leptin levels
are higher in the Omani obese group and correlate positively with body fatness and obesity.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7
[
8784109.001
]
[Cites]
J Clin Endocrinol Metab. 1997 May;82(5):1632-4
[
9141562.001
]
[Cites]
J Clin Invest. 1997 May 15;99(10):2398-404
[
9153282.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Dec;82(12):4144-8
[
9398729.001
]
[Cites]
J Clin Endocrinol Metab. 1998 Jun;83(6):2149-55
[
9626154.001
]
[Cites]
Kidney Int. 1998 Oct;54(4):1267-75
[
9767543.001
]
[Cites]
Horm Res. 1998;50(6):297-302
[
9973668.001
]
[Cites]
Adv Physiol Educ. 2003 Dec;27(1-4):70-7
[
12760843.001
]
[Cites]
Diabet Med. 2002 Nov;19(11):954-7
[
12421434.001
]
[Cites]
J Clin Endocrinol Metab. 1996 Sep;81(9):3419-23
[
8784108.001
]
[Cites]
Ann Saudi Med. 2000 Mar;20(2):113-8
[
17322705.001
]
[Cites]
Diabetes. 2002 Jun;51(6):1980-5
[
12031989.001
]
[Cites]
Physiol Res. 2001;50(5):443-59
[
11702849.001
]
[Cites]
Atherosclerosis. 2001 Aug;157(2):495-503
[
11472752.001
]
[Cites]
Cesk Fysiol. 2001 Feb;50(1):25-30
[
11268559.001
]
[Cites]
East Mediterr Health J. 1999 Jan;5(1):14-20
[
10793776.001
]
[Cites]
Nutrition. 1999 Nov-Dec;15(11-12):829-33
[
10575656.001
]
[Cites]
J Mol Endocrinol. 1999 Apr;22(2):173-84
[
10194520.001
]
[Cites]
Int J Obes Relat Metab Disord. 1999 Feb;23 Suppl 1:22-8
[
10193858.001
]
[Cites]
Nat Med. 1995 Nov;1(11):1155-61
[
7584987.001
]
[Cites]
Nature. 1994 Dec 1;372(6505):425-32
[
7984236.001
]
[Cites]
N Engl J Med. 1996 Feb 1;334(5):292-5
[
8532024.001
]
[Cites]
Diabet Med. 1995 Dec;12(12):1122-5
[
8750224.001
]
(PMID = 21748132.001).
[ISSN]
2075-051X
[Journal-full-title]
Sultan Qaboos University medical journal
[ISO-abbreviation]
Sultan Qaboos Univ Med J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Oman
[Other-IDs]
NLM/ PMC3074914
[Keywords]
NOTNLM ; Body Mass Index / Body weight / Leptin / Obesity / Oman
53.
Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC:
Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.
Leuk Lymphoma
; 2009 Dec;50(12):1977-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of motexafin gadolinium in a phase II trial in refractory chronic
lymphocytic
leukemia.
Chronic
lymphocytic
leukemia (CLL) cells are susceptible to oxidative stress.
A phase II trial administered MGd 5 mg/kg/day IV for 5 days every 3 weeks until disease progression to patients with previously treated CLL and
small lymphocytic lymphoma
.
[MeSH-major]
Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ drug therapy. Metalloporphyrins / therapeutic use
[MeSH-minor]
Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 17 / genetics. Drug Administration Schedule. Drug Resistance,
Neoplasm
. Female. Flow Cytometry. Humans. Immunoblotting. In Situ Hybridization, Fluorescence. Male. Middle Aged. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / metabolism. Treatment Outcome
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19860624.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Metalloporphyrins; 6433A42F4F / motexafin gadolinium; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
54.
Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L, Colao A, Nappi C:
Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women.
Menopause
; 2007 Jan-Feb;14(1):38-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of estrogen-progestin therapy on
serum levels
of RANKL, osteoprotegerin, osteocalcin,
leptin
, and ghrelin in postmenopausal women.
OBJECTIVE: The aim of this study was to evaluate the effects of estrogen-progestin therapy on
serum levels
of receptor-activating nuclear factor kappabeta ligand (RANKL), osteoprotegerin, osteocalcin,
leptin
, and ghrelin in a cross-sectional study of 99 healthy postmenopausal women conducted at the Menopause Clinic of our department.
Serum leptin levels
were significantly lower in group B than in group A, whereas ghrelin was significantly higher in group B than in group A.
Similarly, although several reports suggest that
leptin
and ghrelin are involved in bone metabolism, we could not detect any important correlation of these two hormones with bone metabolism or bone status in treated and untreated postmenopausal women.
[MeSH-minor]
Administration, Cutaneous. Bone Density / drug effects. Cross-Sectional Studies. Female. Finger Phalanges / ultrasonography. Ghrelin. Humans.
Leptin
/ blood. Middle Aged. Osteocalcin / blood. Osteoporosis / prevention & control. Peptide Hormones / blood. Receptors,
Leptin
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Menopause. 2007 Jan-Feb;14(1):7-9
[
17194959.001
]
(PMID = 17075432.001).
[ISSN]
1072-3714
[Journal-full-title]
Menopause (New York, N.Y.)
[ISO-abbreviation]
Menopause
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Estrogens; 0 / Ghrelin; 0 / Leptin; 0 / Osteoprotegerin; 0 / Peptide Hormones; 0 / Progestins; 0 / RANK Ligand; 0 / Receptors, Leptin; 0 / leptin receptor, human; 104982-03-8 / Osteocalcin
55.
Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F:
Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.
Obes Surg
; 2009 Sep;19(9):1313-23
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adipokine
serum levels
are related to liver histology in severely obese patients undergoing bariatric surgery.
BACKGROUND:
Leptin
, adiponectin, and resistin are adipokines linked to the development of insulin resistance, which plays a central role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
We aimed to define adipokine
serum levels
in severely obese patients undergoing bariatric surgery and to correlate these with anthropometric and metabolic variables, liver function tests, and histopathological parameters of NAFLD and nonalcoholic steatohepatitis (NASH).
Serum leptin
, adiponectin, and resistin
levels
were measured, and histology was assessed using Brunt's and Kleiner's scoring systems.
RESULTS: Waist/hip ratio was significantly higher in men (p = 0.0001), and
leptin
(p = 0.036) and adiponectin (p = 0.0001)
serum levels
were higher in women.
In NAFLD patients,
serum
adiponectin was negatively correlated with activity grade and fibrosis stage, resistin was negatively correlated with steatosis grade (p = 0.033), while
leptin
was not related to histology.
Leptin
/adiponectin ratio showed positive association with stage (p = 0.044).
In the subgroup of NASH patients, adiponectin was negatively correlated only with stage (p = 0.01), while there was no correlation between
leptin
, resistin, or
leptin
/adiponectin and histology.
CONCLUSIONS:
Serum
adiponectin and resistin
levels
are related to liver histology in bariatric patients and may be indicative of the histological severity of NAFLD and the extent of hepatic steatosis, respectively.
Serum leptin levels
are not informative of underlying liver histology in severely obese patients.
MedlinePlus Health Information.
consumer health - Hepatitis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Chem. 1972 Jun;18(6):499-502
[
4337382.001
]
[Cites]
Am J Gastroenterol. 1999 Sep;94(9):2467-74
[
10484010.001
]
[Cites]
Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S15-21
[
17331160.001
]
[Cites]
Hepatology. 2003 Apr;37(4):917-23
[
12668987.001
]
[Cites]
Hepatology. 2004 Jul;40(1):46-54
[
15239085.001
]
[Cites]
Am J Gastroenterol. 2006 Nov;101(11):2629-40
[
16952281.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Dec;91(12):5122-5
[
16968796.001
]
[Cites]
Dig Dis Sci. 2008 Apr;53(4):1088-92
[
17934820.001
]
[Cites]
Nutr Rev. 2007 Jun;65(6 Pt 2):S57-63
[
17605315.001
]
[Cites]
Hepatology. 2008 Feb;47(2):484-92
[
18220286.001
]
[Cites]
Curr Opin Clin Nutr Metab Care. 2008 May;11(3):267-74
[
18403923.001
]
[Cites]
Expert Rev Mol Diagn. 2007 Mar;7(2):195-205
[
17331066.001
]
[Cites]
Surg Endosc. 2007 Sep;21(9):1593-9
[
17294310.001
]
[Cites]
Hepatology. 2002 Aug;36(2):403-9
[
12143049.001
]
[Cites]
Clin Endocrinol (Oxf). 2006 Jun;64(6):679-83
[
16712671.001
]
[Cites]
Curr Opin Lipidol. 2006 Apr;17(2):170-5
[
16531754.001
]
[Cites]
Gastroenterology. 2006 Sep;131(3):934-45
[
16952562.001
]
[Cites]
Hepatology. 2005 Jun;41(6):1313-21
[
15915461.001
]
[Cites]
Obes Surg. 2005 Feb;15(2):228-37
[
15802066.001
]
[Cites]
Gastroenterology. 2006 May;130(6):1848-52
[
16697746.001
]
[Cites]
Obes Surg. 2008 Nov;18(11):1430-7
[
18500507.001
]
[Cites]
Am J Gastroenterol. 2003 Dec;98(12):2771-6
[
14687831.001
]
[Cites]
Liver Int. 2006 Mar;26(2):151-6
[
16448452.001
]
[Cites]
Obes Surg. 2005 Mar;15(3):310-5
[
15826462.001
]
[Cites]
J Hepatol. 2006 Oct;45(4):600-6
[
16899321.001
]
[Cites]
Mediators Inflamm. 2006;2006(6):34295
[
17392582.001
]
[Cites]
JAMA. 2001 May 16;285(19):2486-97
[
11368702.001
]
[Cites]
J Hepatol. 2008;48 Suppl 1:S104-12
[
18304679.001
]
[Cites]
Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21
[
18081738.001
]
[Cites]
Hepatology. 2005 Aug;42(2):490-2
[
15977205.001
]
[Cites]
Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi
[
17544979.001
]
[Cites]
Obes Surg. 2006 Oct;16(10):1351-8
[
17059746.001
]
[Cites]
J Hepatol. 2004 Dec;41(6):943-9
[
15582127.001
]
[Cites]
J Clin Endocrinol Metab. 2005 Jun;90(6):3498-504
[
15797948.001
]
[Cites]
Obes Surg. 2006 Dec;16(12):1584-93
[
17217634.001
]
[Cites]
Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112
[
16447287.001
]
[Cites]
Scand J Gastroenterol. 2008;43(9):1128-36
[
18609175.001
]
[Cites]
Hepatogastroenterology. 2007 Jul-Aug;54(77):1512-6
[
17708287.001
]
[Cites]
Hepatology. 2003 May;37(5):1202-19
[
12717402.001
]
[Cites]
Hepatology. 2007 Aug;46(2):582-9
[
17661414.001
]
[Cites]
Hepatology. 2007 Sep;46(3):716-22
[
17659597.001
]
[Cites]
Gut. 2005 Jan;54(1):117-21
[
15591515.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Apr;89(4):1844-8
[
15070954.001
]
[Cites]
Am J Gastroenterol. 2007 Feb;102(2):399-408
[
17311652.001
]
[Cites]
Obes Surg. 2000 Aug;10(4):378-9
[
11202981.001
]
[Cites]
Gastroenterology. 2008 May;134(6):1682-98
[
18471547.001
]
[Cites]
Med Clin North Am. 2007 Nov;91(6):1125-49, ix
[
17964913.001
]
[Cites]
J Appl Physiol (1985). 1988 Feb;64(2):529-34
[
3372410.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Mar;91(3):1081-6
[
16394091.001
]
[Cites]
J Hepatol. 2008 May;48(5):829-34
[
18321606.001
]
[Cites]
Scand J Gastroenterol. 2006 May;41(5):566-72
[
16638699.001
]
[Cites]
Am J Gastroenterol. 2007 Sep;102(9):1931-8
[
17511754.001
]
[Cites]
J Pediatr Endocrinol Metab. 2004 Aug;17(8):1069-75
[
15379417.001
]
[Cites]
Curr Opin Gastroenterol. 2007 Mar;23(2):193-8
[
17268250.001
]
[Cites]
Hepatology. 2005 Nov;42(5):1175-83
[
16231364.001
]
[Cites]
Eur J Endocrinol. 2005 Jan;152(1):113-8
[
15762194.001
]
[Cites]
Am J Clin Pathol. 2007 Nov;128(5):837-47
[
17951208.001
]
[Cites]
Diabetologia. 1985 Jul;28(7):412-9
[
3899825.001
]
(PMID = 19693638.001).
[ISSN]
0960-8923
[Journal-full-title]
Obesity surgery
[ISO-abbreviation]
Obes Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Adipokines
56.
Srivastava RK, Krishna A:
Adiposity associated rise in leptin impairs ovarian activity during winter dormancy in Vespertilionid bat, Scotophilus heathi.
Reproduction
; 2007 Jan;133(1):165-76
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adiposity associated rise in
leptin
impairs ovarian activity during winter dormancy in Vespertilionid bat, Scotophilus heathi.
The aim of the study was to evaluate the seasonal variation in
serum leptin levels
in a natural population of the female bat, Scotophilus heathi and their relationship to the changes in the body mass,
serum
insulin
level
, and ovarian activity.
Circulating
leptin level
varied significantly over the season and correlated positively with the changes in body mass, and circulating insulin and androstenedione (A4)
levels
.
Circulating
leptin
concentrations showed two peaks; one coincides with the maximum fat accumulation prior to winter dormancy, whereas the second shorter peak coincides with late pregnancy.
The in vivo study in S. heathi showed that the increased circulating
leptin level
during winter dormancy coincides with the decreased expression of ovarian steroidogenic acute regulatory (StAR) protein, and low circulating estradiol (E2)
level
.
At the same time, increased circulating
leptin level
coincides with increased expression of ovarian insulin receptor and high circulating A4
level
.
The low circulating
leptin level
during preovulatory period coincides with the increase in StAR protein but decrease in insulin receptor protein.
The in vitro study confirmed the in vivo observations of inhibitory effect of
leptin
on LH induced StAR expression and E2 production, whereas the stimulatory effect of
leptin
(high dose) on LH induced expression of insulin receptor protein and A4 production.
However, pharmacological dose of
leptin
produced inhibitory effect on the expression of insulin receptor protein.
The results of the present study thus suggest that high circulating
leptin level
during winter dormancy promotes adiposity and impairs ovarian activity by suppressing StAR-mediated E2 production
as well
as by enhancing insulin receptor-mediated A4 synthesis thereby contributing anovulatory condition of delayed ovulation in S. heathi.
[MeSH-major]
Adiposity / physiology. Chiroptera / metabolism. Hibernation / physiology.
Leptin
/ blood. Ovary / metabolism
Hazardous Substances Data Bank.
ESTRADIOL
.
Hazardous Substances Data Bank.
PROGESTERONE
.
Hazardous Substances Data Bank.
ANDROSTENEDIONE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17244743.001).
[ISSN]
1470-1626
[Journal-full-title]
Reproduction (Cambridge, England)
[ISO-abbreviation]
Reproduction
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Insulin; 0 / Leptin; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; 409J2J96VR / Androstenedione; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; EC 2.7.10.1 / Receptor, Insulin
57.
Farfsing A, Engel F, Seiffert M, Hartmann E, Ott G, Rosenwald A, Stilgenbauer S, Döhner H, Boutros M, Lichter P, Pscherer A:
Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.
Leukemia
; 2009 Nov;23(11):2018-26
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gene knockdown studies revealed CCDC50
as a
candidate gene in mantle
cell lymphoma
and chronic
lymphocytic
leukemia.
The two B-
cell
non-Hodgkin's
lymphoma
entities, chronic
lymphocytic
leukemia (CLL) and mantle
cell lymphoma
(MCL), show recurrent chromosomal gains of 3q25-q29, 12q13-q14 and 18q21-q22.
The aim of this study was to identify genes, located within these gained regions, which control
cell
death and
cell
survival of MCL and CLL cancer cells.
Blood samples collected from 18 patients with CLL and 6 patients with MCL,
as well
as 6
cell
lines representing both malignancies were analyzed by gene expression profiling.
We performed a limited RNA interference screening with these candidates to identify genes affecting
cell
survival.
CCDC50 (coiled coil domain containing protein 50), SERPINI2 and SMARCC2 mediated a reduction of
cell
viability in primary CLL cells
as well
as in
cell
lines.
[MeSH-major]
Intracellular Signaling Peptides and Proteins / genetics. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ genetics.
Lymphoma
, Mantle-
Cell
/ genetics. RNA,
Small
Interfering
[MeSH-minor]
Bone Marrow Cells / cytology.
Cell
Line, Tumor.
Cell
Survival / physiology. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Genetic Testing. Genomics. Humans. Kidney / cytology. NF-kappa B / metabolism.
Neoplasm
Proteins / genetics. Protein Structure, Tertiary. Serpins / genetics. Transcription Factors / genetics. Transfection
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19641524.001).
[ISSN]
1476-5551
[Journal-full-title]
Leukemia
[ISO-abbreviation]
Leukemia
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / CCDC50 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / SERPINI2 protein, human; 0 / SMARCC2 protein, human; 0 / Serpins; 0 / Transcription Factors
58.
Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ:
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
J Clin Oncol
; 2006 May 20;24(15):2343-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-
cell
transplantation.
PATIENTS AND METHODS: An electronic database search of patients with chronic
lymphocytic
leukemia (CLL)/
small lymphocytic lymphoma
(
SLL
) who presented at The University of Texas M.D.
RESULTS: Of the 3,986 patients with CLL/
SLL
, 204 patients (5.1%) had possible RS, and 148 patients (3.7%) had biopsy- or fine-needle aspiration-proven RS.
A total of 20 patients underwent stem-
cell
transplantation (SCT).
[MeSH-major]
Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ therapy.
Lymphoma
, Non-Hodgkin / therapy
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Cell
Transformation, Neoplastic. Combined Modality Therapy. Disease Progression. Female. Health Status Indicators. Humans. Immunologic Factors / therapeutic use. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Risk. Rituximab. Stem
Cell
Transplantation. Survival Analysis. Treatment Outcome
Genetic Alliance.
consumer health - Transplantation
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16710033.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
59.
Zemanová M, Petruzelka L, Pazdrová G, Haluzík M, Novák F, Svobodník A:
[Changes in leptin, leptin receptor and fatty acids levels during chemoradiotherapy for oesophageal cancer].
Cas Lek Cesk
; 2005;144(12):811-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Changes in
leptin
,
leptin
receptor and fatty acids
levels
during chemoradiotherapy for oesophageal cancer].
Leptin
, a protein produced by adipocytes, is an important signalling molecule in energy regulation, metabolism of fatty acids and it can also augment tumour growth of various cancer
cell
lines.
METHODS AND RESULTS: In this study we examined the nutritional status (pre-treatment weight-loss, actual weight, body mass index),
serum levels
of
leptin
, soluble
leptin
receptor, TNF-alpha, IGF-1 and plasma phosphatidyl-cholin fatty acids before the beginning of treatment, after the onset of treatment and shortly before its completion.
Concomitant chemoradiation led to transient elevation of
serum leptin level
despite the weight loss during chemoradiotherapy.
[MeSH-major]
Esophageal Neoplasms / blood. Fatty Acids / blood.
Leptin
/ blood. Receptors,
Cell
Surface / blood
[MeSH-minor]
Adult. Aged. Combined Modality Therapy. Female. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Phosphatidylcholines / chemistry. Receptors,
Leptin
. Tumor Necrosis Factor-alpha / analysis. Weight Loss
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16389753.001).
[ISSN]
0008-7335
[Journal-full-title]
Casopís lékar̆ů c̆eských
[ISO-abbreviation]
Cas. Lek. Cesk.
[Language]
cze
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Czech Republic
[Chemical-registry-number]
0 / Fatty Acids; 0 / Leptin; 0 / Phosphatidylcholines; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / Tumor Necrosis Factor-alpha; 0 / leptin receptor, human; 67763-96-6 / Insulin-Like Growth Factor I
60.
Korotkova M, Gabrielsson BG, Holmäng A, Larsson BM, Hanson LA, Strandvik B:
Gender-related long-term effects in adult rats by perinatal dietary ratio of n-6/n-3 fatty acids.
Am J Physiol Regul Integr Comp Physiol
; 2005 Mar;288(3):R575-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We have previously shown that the ratio of n-6 to n-3 polyunsaturated fatty acids (PUFA) in the maternal diet affects
serum leptin levels
and growth of the suckling pups.
The aim of the present study was to investigate the long-term effects of various ratios of the dietary n-6 and n-3 PUFA during the perinatal period on
serum leptin
, insulin, and triacylglycerol,
as well
as body growth in the adult offspring.
At 3 wk of age, the n-6/n-3 PUFA ratios in the
serum
phospholipids of the offspring were 2.5, 8.3, and 17.5, respectively.
At the 28th postnatal wk, mean body weight and fasting insulin
levels
were significantly increased in the rats fed the n-6/n-3 diet perinatally compared with the other groups.
The systolic blood pressure and
serum
triacylglycerol
levels
were only increased in adult male rats of the same group.
MedlinePlus Health Information.
consumer health - Seniors' Health
.
Hazardous Substances Data Bank.
CHOLESTEROL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Am J Physiol Regul Integr Comp Physiol. 2006 Nov;291(5):R1564
(PMID = 15699360.001).
[ISSN]
0363-6119
[Journal-full-title]
American journal of physiology. Regulatory, integrative and comparative physiology
[ISO-abbreviation]
Am. J. Physiol. Regul. Integr. Comp. Physiol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Fatty Acids; 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6; 0 / Insulin; 0 / Phospholipids; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
61.
Pauwels NS, Bracke KR, Maes T, Pilette C, Joos GF, Brusselle GG:
The role of interleukin-6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease.
Exp Lung Res
; 2010 Oct;36(8):469-83
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Increased
levels
of interleukin-6 (IL-6) have been demonstrated in sputum and
serum
of COPD patients.
Wild-
type
(WT) and IL-6 knockout (KO) mice were exposed subacutely (4 weeks) and chronically (24 weeks) to air or cigarette smoke (CS).
Subacute and chronic CS exposure significantly increased pulmonary IL-6 mRNA expression in lung tissue and IL-6 protein
levels
in bronchoalveolar lavage fluid of WT mice.
Remarkably, air-exposed IL-6 KO mice have lower body weight,
serum leptin levels
, and adipose tissue mass compared to air-exposed WT mice.
[MeSH-minor]
Adipose Tissue, White / drug effects. Adipose Tissue, White / metabolism. Animals. Bronchoalveolar Lavage Fluid / cytology.
Cell
Count. Cytokines / genetics. Cytokines / metabolism. Disease Models, Animal. Gene Expression / drug effects.
Leptin
/ genetics.
Leptin
/ metabolism.
Lymphocytes
/ drug effects.
Lymphocytes
/ metabolism.
Lymphocytes
/ pathology. Male. Mice. Mice, Knockout. RNA, Messenger / metabolism. Smoking / adverse effects. Tobacco Smoke Pollution / adverse effects
MedlinePlus Health Information.
consumer health - COPD
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20939756.001).
[ISSN]
1521-0499
[Journal-full-title]
Experimental lung research
[ISO-abbreviation]
Exp. Lung Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Cytokines; 0 / Interleukin-6; 0 / Leptin; 0 / RNA, Messenger; 0 / Tobacco Smoke Pollution
62.
Aurangzeb B, Leach ST, Lemberg DA, Day AS:
Nutritional status of children with coeliac disease.
Acta Paediatr
; 2010 Jul;99(7):1020-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: The nutritional status of newly diagnosed CD was assessed by anthropometry, Bioelectrical Impedance and
serum leptin levels
, and contrasted to age and gender matched controls.
Mean height and weight for age, other nutritional parameters and
serum leptin
did not differ between the groups.
Serum leptin
correlated with BMI in both groups.
Variations in nutrition (under to overnutrition) may be seen at
diagnosis
, without relationship to the presence of symptoms.
Leptin levels
were not altered specifically in the setting of CD.
[MeSH-minor]
Adolescent. Anthropometry. Case-Control Studies. Child. Child, Preschool. Electric Impedance. Female. Humans. Infant.
Leptin
/ blood. Male. Nutrition Assessment
MedlinePlus Health Information.
consumer health - Celiac Disease
.
MedlinePlus Health Information.
consumer health - Child Nutrition
.
MedlinePlus Health Information.
consumer health - Toddler Nutrition
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20178518.001).
[ISSN]
1651-2227
[Journal-full-title]
Acta paediatrica (Oslo, Norway : 1992)
[ISO-abbreviation]
Acta Paediatr.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Norway
[Chemical-registry-number]
0 / Leptin
63.
Akinci M, Kosova F, Cetin B, Aslan S, Ari Z, Cetin A:
Leptin levels in thyroid cancer.
Asian J Surg
; 2009 Oct;32(4):216-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Leptin levels
in thyroid cancer.
BACKGROUND:
Leptin
has physiological roles in multiple systems, and has possible effects on several carcinogenesis steps.
The aim of this study was to investigate the
leptin levels
in thyroid papillary carcinoma (TPC) patients.
TPC patients had a bilateral total thyroidectomy operation and their
leptin levels
were measured before and 20 days after the operation.
RESULTS:
Serum leptin levels
of TPC patients were higher than in control group subjects (21.15 +/- 14.12 ng/mL vs. 9.89 +/- 0.21 ng/mL, p < 0.05).
The
leptin levels
decreased after total thyroidectomy (13.92 +/- 10.55 ng/mL) compared to prethyroidectomy
levels
(22.94 +/- 14.67 ng/mL) in 34 patients who came to the follow-up visit (p < 0.05).
However, the decreased post-thyroidectomy
levels
of
leptin
were still statistically significantly higher than the control group
levels
.
Multivariate regression analysis showed that the
leptin levels
in TPC patients were not related to age, menopausal status or pathologic occult status but were directly related to the cancer group.
CONCLUSION:
Leptin levels
were elevated in thyroid cancer, decreased after total thyroidectomy, and might be associated with thyroid papillary carcinogenesis.
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19892624.001).
[ISSN]
0219-3108
[Journal-full-title]
Asian journal of surgery
[ISO-abbreviation]
Asian J Surg
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Leptin
64.
Jaleel F, Jaleel A, Aftab J, Rahman MA:
Leptin and blood lipid levels in postmenopausal diabetic women with and without complication of ischemic heart disease.
Med Sci Monit
; 2006 Sep;12(9):CR382-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Leptin
and blood lipid
levels
in postmenopausal diabetic women with and without complication of ischemic heart disease.
BACKGROUND: Recent studies have provided evidence that
leptin
has significant effects on vascular development and repair.
The aim was to determine the
levels
of
leptin
and lipid profile in diabetic postmenopausal women with and without the complication of ischemic heart disease and to develop correlation between them.
Moreover, the relationship between
leptin levels
and extent of ischemic changes were determined.
The first group comprised normal healthy controls, the second diabetic
type
2 patients with no history of ischemic heart disease (I1ID), and the third diabetic patients with IHD.
Serum leptin levels
were determined by a Kit obtained from DRG and samples were analyzed on ELISA.
RESULTS: The results show that
leptin
and
serum
lipid
levels
increased significantly in diabetic patients with IHD compared with diabetic patients without IHD
as well
as normal subjects.
Moreover; the sertum
leptin level
increased significantly in the diabetic patients with IHD who had positive findings in myocardial perfusion scan compared with those having negative findings.
CONCLUSIONS: Hyperleptinemia in diabetic patients shows that
leptin
contributes to the development of cardiovascular disease in diabetic patients.
[MeSH-major]
Diabetes Mellitus,
Type
2 / blood. Hyperlipidemias / complications.
Leptin
/ blood. Myocardial Ischemia / etiology. Postmenopause / blood
Genetic Alliance.
consumer health - Heart Disease
.
MedlinePlus Health Information.
consumer health - Diabetes Type 2
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16940932.001).
[ISSN]
1234-1010
[Journal-full-title]
Medical science monitor : international medical journal of experimental and clinical research
[ISO-abbreviation]
Med. Sci. Monit.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Poland
[Chemical-registry-number]
0 / Leptin; 0 / Lipids
65.
Jalil A, Amir S, Majeed R, Jalil F:
Circulating leptin levels in elderly subjects with and without cerebrovasular disease.
J Coll Physicians Surg Pak
; 2010 May;20(5):350-1
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Circulating
leptin levels
in elderly subjects with and without cerebrovasular disease.
Serum
concentrations of
leptin
was investigated in 40 patients with ischemic stroke, in context of the size of the lesion and also in 40 non-diseased controls, matched according to age, gender and waist hip ratio.
Serum leptin
concentrations were determined in ng/ml with ELISA and computer tomography (CT) scan was performed in patients to estimate lesion size in cms.
Serum leptin
concentrations were found to be significantly higher (p < 0.001) in stroke patients (51.61+1.39), compared with controls (37.76+1.207).
Moreover, positive correlation (r=0.93) existed between
serum leptin level
and infarction size in patients with stroke.
[MeSH-major]
Cerebrovascular Disorders / blood.
Leptin
/ blood
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20642935.001).
[ISSN]
1022-386X
[Journal-full-title]
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
[ISO-abbreviation]
J Coll Physicians Surg Pak
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Pakistan
[Chemical-registry-number]
0 / Blood Glucose; 0 / Leptin
66.
Flanagan MB, Sathanoori M, Surti U, Soma L, Swerdlow SH:
Cytogenetic abnormalities detected by fluorescence in situ hybridization on paraffin-embedded chronic lymphocytic leukemia/small lymphocytic lymphoma lymphoid tissue biopsy specimens.
Am J Clin Pathol
; 2008 Oct;130(4):620-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cytogenetic abnormalities detected by fluorescence in situ hybridization on paraffin-embedded chronic
lymphocytic
leukemia/
small lymphocytic lymphoma
lymphoid tissue biopsy specimens.
Cytogenetic fluorescence in situ hybridization (FISH) panels are a major prognostic tool in chronic
lymphocytic
leukemia/
small lymphocytic lymphoma
(CLL/
SLL
), but few data exist on using paraffin-embedded extramedullary tissue biopsy specimens for these purposes.
Isolated whole nuclei were extracted from 20 paraffin-embedded tissue biopsy specimens with CLL/
SLL
and analyzed using a standard CLL FISH panel.
Cytogenetic FISH studies using paraffin-embedded tissue biopsy specimens in CLL/
SLL
had a high yield and, with 1 exception, demonstrated a profile similar to cases diagnosed in PB/BM.
[MeSH-major]
Chromosome Aberrations. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ genetics. Paraffin Embedding
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18794056.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
67.
Ioannou GN, Weiss NS, Kearney DJ:
Is Helicobacter pylori seropositivity related to body mass index in the United States?
Aliment Pharmacol Ther
; 2005 Mar 15;21(6):765-72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Helicobacter pylori infection may decrease
serum
ghrelin and increase gastric
leptin levels
, which may, in turn, decrease body mass index.
METHODS:
Serum
H. pylori and cytotoxin-associated gene product A (CagA) antibody
levels
were measured on 6724 adult participants of the third National Health and Nutrition Examination Survey (1988-91).
We also investigated whether H. pylori/cytotoxin-associated gene product A antibody status was associated with fasting
serum leptin levels
.
RESULTS: H. pylori/CagA antibody status was not associated with obesity (body mass index > or = 30 kg/m(2)) [adjusted odds ratio (OR) 1.2, 95% CI: 0.9-1.6 comparing (+/+) to (-/-) and adjusted OR 1.1, 95% CI: 0.8-1.5 comparing (+/-) to (-/-)], overweight (body mass index 25 to <30 kg/m(2)) [adjusted OR 1.0, 95% CI: 0.7-1.2 comparing (+/+) to (-/-) and adjusted OR 1.0, 95% CI: 0.8-1.3 comparing (+/-) to (-/-)], or fasting
serum leptin level
in the USA population.
CONCLUSIONS: H. pylori seropositivity and CagA antibody status are not associated with body mass index or fasting
serum leptin level
.
[MeSH-minor]
Adult. Aged. Antigens, Bacterial / blood. Bacterial Proteins / blood. Enzyme-Linked Immunosorbent Assay. Epidemiologic Methods. Female. Humans.
Leptin
/ blood. Male. Middle Aged. Obesity / blood. Obesity / epidemiology. Obesity / ethnology. United States / epidemiology
MedlinePlus Health Information.
consumer health - Helicobacter Pylori Infections
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15771763.001).
[ISSN]
0269-2813
[Journal-full-title]
Alimentary pharmacology & therapeutics
[ISO-abbreviation]
Aliment. Pharmacol. Ther.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Leptin; 0 / cagA protein, Helicobacter pylori
68.
Axelsson J, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P, Bárány P:
Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
Am J Kidney Dis
; 2005 Oct;46(4):628-34
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Body fat mass and
serum leptin levels
influence epoetin sensitivity in patients with ESRD.
Furthermore, the adipokine
leptin
stimulates human erythroid development in vitro.
In the present study, we investigate the impact of fat mass and
leptin level
on epoetin sensitivity in patients with ESRD.
Body composition was analyzed by dual-energy X-ray absorptiometry and correlated with
serum
markers of inflammation and
leptin
(analyzed by enzyme-linked immunosorbent assays),
as well
as with epoetin dose, in international units administered per week (IU/wk).
To correct for differences in body mass and hemoglobin (Hb)
levels
, epoetin sensitivity was approximated as epoetin/Hb ratio, ie, epoetin dose per unit of Hb (IU/wk/g/dL) and epoetin/Hb/kg ratio, ie, epoetin dose per unit of Hb and kilogram of patient body weight (IU/wk/Hb/kg).
The 3 groups had significantly different
serum levels
of high-sensitivity C-reactive protein (hsCRP; median, 8.6 versus 3.1 and 8.0 mg/L, respectively; P < 0.05), neopterin (median, 112.4 versus 94.3 and 96.1 ng/L, respectively; P < 0.05), and IL-6 (median, 6.8 versus 4.1 and 6.5 ng/mL, respectively; P < 0.05).
Significant between-group differences also were found in fat mass and
leptin levels
(median, 14.8 versus 10.5 and 7.9 ng/mL, respectively; P = 0.02).
In univariate analyses, significant relationships between epoetin sensitivity indices,
leptin levels
, and
levels
of the inflammatory markers hsCRP and IL-6 were found.
In a multivariate stepwise regression model, log ferritin, parathyroid hormone, log
leptin
, log IL-6, and polycystic kidney disease were significantly associated with the epoetin/Hb ratio.
CONCLUSION: The present study shows that
leptin level
may be a predictor of epoetin sensitivity.
Although truncal fat is associated with secretion of proinflammatory cytokines, this secretion appears not to have inhibitory effects on epoetin sensitivity in the presence of high
leptin levels
.
[MeSH-major]
Adipose Tissue / pathology. Anemia / drug therapy. Body Composition. Erythropoiesis / drug effects. Erythropoietin / analogs & derivatives. Kidney Failure, Chronic / complications.
Leptin
/ blood
MedlinePlus Health Information.
consumer health - Anemia
.
MedlinePlus Health Information.
consumer health - Kidney Failure
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DARBEPOETIN ALFA
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Am J Kidney Dis. 2006 Feb;47(2):371; author reply 372
[
16431269.001
]
(PMID = 16183417.001).
[ISSN]
1523-6838
[Journal-full-title]
American journal of kidney diseases : the official journal of the National Kidney Foundation
[ISO-abbreviation]
Am. J. Kidney Dis.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Hemoglobins; 0 / Interleukin-6; 0 / Leptin; 11096-26-7 / Erythropoietin; 15UQ94PT4P / Darbepoetin alfa; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins
69.
Farmer PL, Bailey DJ, Burns BF, Day A, LeBrun DP:
The reliability of lymphoma diagnosis in small tissue samples is heavily influenced by lymphoma subtype.
Am J Clin Pathol
; 2007 Sep;128(3):474-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The reliability of
lymphoma
diagnosis
in
small
tissue samples is heavily influenced by
lymphoma
subtype.
A specific pathologic
diagnosis
is important in
malignant
lymphoma
because the diverse disease subtypes require tailored approaches to clinical management.
Reliance on
small
samples obtained with cutting needles has been advocated
as a
less invasive alternative to using larger, excised samples.
Although published studies have demonstrated the safety and apparent sufficiency of this approach in informing clinical care, none have systematically determined the accuracy of pathologic
lymphoma
subtyping based on very
small
samples.
We used a tissue microarray representing 67 cases of
malignant
lymphoma
and 17 samples of nonneoplastic lymphoid tissue to model
lymphoma
diagnosis
in
small
samples.
Overall, 73.8% of the cases were diagnosed with
a level
of confidence deemed sufficient for directing clinical management; 85.9% of these diagnoses were accurate.
Small cell
lymphomas
with highly distinctive immunophenotypes, including
small lymphocytic
, mantle
cell
, and T-lymphoblastic
lymphoma
, were recognized most consistently and accurately in the
small
samples.
In contrast, follicular
lymphoma
and marginal zone
lymphoma
were especially difficult.
Our results indicate that the reliability of
lymphoma
diagnoses based on
small
samples is heavily influenced by
lymphoma
subtype.
[MeSH-major]
Lymphoma
/
diagnosis
. Tissue Array Analysis / methods
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17709322.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
70.
Lin TS:
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Clin Lymphoma Myeloma
; 2008 Aug;8 Suppl 4:S137-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Novel agents in chronic
lymphocytic
leukemia: efficacy and tolerability of new therapies.
Alkylating agents and purine analogues have been the mainstays of therapy for chronic
lymphocytic
leukemia (CLL) for decades.
(1) the alkylator bendamustine, (2) the cyclin-dependent kinase inhibitor flavopiridol, (3) the immunomodulating drug lenalidomide, (4) the bcl-2 antisense oligonucleotide oblimersen, and (5) the Bcl-2
small
-molecule inhibitor obatoclax.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ drug therapy
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
Bendamustine
.
Hazardous Substances Data Bank.
THALIDOMIDE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18952544.001).
[ISSN]
1557-9190
[Journal-full-title]
Clinical lymphoma & myeloma
[ISO-abbreviation]
Clin Lymphoma Myeloma
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Flavonoids; 0 / Nitrogen Mustard Compounds; 0 / Piperidines; 0 / Pyrroles; 0 / Thionucleotides; 0 / obatoclax; 45AD6X575G / alvocidib; 4Z8R6ORS6L / Thalidomide; 85J5ZP6YSL / oblimersen; 981Y8SX18M / Bendamustine Hydrochloride; F0P408N6V4 / lenalidomide
[Number-of-references]
30
71.
Chiu BC, Soni L, Gapstur SM, Fought AJ, Evens AM, Weisenburger DD:
Obesity and risk of non-Hodgkin lymphoma (United States).
Cancer Causes Control
; 2007 Aug;18(6):677-85
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Obesity and risk of non-Hodgkin
lymphoma
(United States).
OBJECTIVE: Few studies have explored the potential association between body mass index (BMI) and non-Hodgkin
lymphoma
(NHL) according to histologic subtypes, or have evaluated BMI at different periods in the subject's life, and the results of these studies have been inconsistent.
Obesity at ages 40-49 years was also associated with a higher risk of
small lymphocytic lymphoma
(OR=4.5; 95% CI=1.5-13.3),
diffuse
large B-
cell
NHL (OR=1.8; 95% CI=0.9-3.9) and follicular NHL (OR=1.8; 95% CI=0.9-3.5).
Obesity at ages 40-49 years is also associated with a higher risk of NHL overall, and particularly
small lymphocytic
, follicular, and
diffuse
large B-
cell
NHL.
[MeSH-major]
Body Mass Index.
Lymphoma
, Non-Hodgkin / etiology. Obesity / complications
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Obesity
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
MedlinePlus Health Information.
consumer health - Obesity
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17484069.001).
[ISSN]
0957-5243
[Journal-full-title]
Cancer causes & control : CCC
[ISO-abbreviation]
Cancer Causes Control
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
72.
Bi R, Lin DM, Han YL, Lu J, Xue LY, Zheng S, Wang MR, Lü N:
[Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma].
Zhonghua Bing Li Xue Za Zhi
; 2009 Nov;38(11):733-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Application of interphase fluorescence in situ hybridization in the
diagnosis
of
lymphoma
].
OBJECTIVE: To investigate the feasibility of interphase FISH in the routine clinicopathological practice and its values in the differential
diagnosis
of
lymphomas
.
METHODS: A total of 74 fresh tissue samples clinically suspicious of
lymphoma
were investigated by FISH using three probes including IgH/bcl-2, IgH/CCND1 and API2/MALT1, corresponding the translocation t(14;18), t(11;14) and t(11;18) respectively.
The results of FISH were analyzed and compared with the histopathologic
diagnosis
.
RESULTS: Histological evaluation eventually confirmed that there were 62 cases of
lymphoma
and 12 cases of reactive lymphoid processes.
The translocations were detected in 7 cases in 62 cases of
lymphoma
: 3 demonstrated t(14;18) including 2 cases of follicular
lymphomas
and 1 nodular sclerosing Hodgkin
lymphoma
.
Four cases had t(11;14) including mantle
cell lymphoma
(2 cases), follicular
lymphoma
(1 case) and
small cell lymphoma
(1 case).
Amplification or loss of regional genes was seen more often in
malignant
than in the benign cases.
CONCLUSION: Interphase FISH offers useful ancillary technology that plays an important role in differential
diagnosis
and
classification
of
lymphoma
.
[MeSH-major]
In Situ Hybridization, Fluorescence / methods.
Lymphoma
/
diagnosis
. Translocation, Genetic
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18.
Diagnosis
, Differential. Female. Hodgkin Disease /
diagnosis
. Hodgkin Disease / genetics. Hodgkin Disease / pathology. Humans. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/
diagnosis
. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ genetics. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ pathology.
Lymphoma
, Follicular /
diagnosis
.
Lymphoma
, Follicular / genetics.
Lymphoma
, Follicular / pathology.
Lymphoma
, Large B-
Cell
,
Diffuse
/
diagnosis
.
Lymphoma
, Large B-
Cell
,
Diffuse
/ genetics.
Lymphoma
, Large B-
Cell
,
Diffuse
/ pathology.
Lymphoma
, Mantle-
Cell
/
diagnosis
.
Lymphoma
, Mantle-
Cell
/ genetics.
Lymphoma
, Mantle-
Cell
/ pathology.
Lymphoma
, Non-Hodgkin /
diagnosis
.
Lymphoma
, Non-Hodgkin / genetics.
Lymphoma
, Non-Hodgkin / pathology. Male. Middle Aged. Young Adult
MedlinePlus Health Information.
consumer health - Lymphoma
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20079011.001).
[ISSN]
0529-5807
[Journal-full-title]
Zhonghua bing li xue za zhi = Chinese journal of pathology
[ISO-abbreviation]
Zhonghua Bing Li Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
73.
Hirosawa M, Minata M, Harada KH, Hitomi T, Krust A, Koizumi A:
Ablation of estrogen receptor alpha (ERalpha) prevents upregulation of POMC by leptin and insulin.
Biochem Biophys Res Commun
; 2008 Jun 27;371(2):320-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ablation of estrogen receptor alpha (ERalpha) prevents upregulation of POMC by
leptin
and insulin.
Ovariectomized diabetic (AFO) and nondiabetic (B6FO) mice had significantly lower food intake and elevated
serum leptin levels
.
ERaKOAkt and ERaKO mice also increased
serum leptin
concentrations, while hypoinsulinemia was observed in ERaKOAkt and hyperinsulinemia in ERaKO mice.
RT-PCR showed a significant attenuation of POMC expression in both ERaKOAkt and ERaKO mice, irrespective of the elevated
leptin serum levels
or hyperinsulinemia, while elevated
serum leptin levels
in AFO and B6FO mice upregulated POMC gene expression.
These results indicate that ERalpha plays an essential role in
leptin
- and insulin-stimulated upregulation of the POMC gene.
[MeSH-major]
Estrogen Receptor alpha / physiology. Gene Expression Regulation. Hyperphagia / genetics. Insulin / metabolism.
Leptin
/ metabolism. Pro-Opiomelanocortin / genetics
MedlinePlus Health Information.
consumer health - Diabetes Medicines
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18439911.001).
[ISSN]
1090-2104
[Journal-full-title]
Biochemical and biophysical research communications
[ISO-abbreviation]
Biochem. Biophys. Res. Commun.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Estrogen Receptor alpha; 0 / Insulin; 0 / Leptin; 66796-54-1 / Pro-Opiomelanocortin
74.
Wang HC, Yang YK, Chen PS, Lee IH, Yeh TL, Lu RB:
Increased plasma leptin in antipsychotic-naïve females with schizophrenia, but not in males.
Neuropsychobiology
; 2007;56(4):213-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Increased plasma
leptin
in antipsychotic-naïve females with schizophrenia, but not in males.
BACKGROUND: Metabolic abnormalities, including insulin resistance and increased
leptin levels
, were noted in patients with schizophrenia who had received antipsychotics.
In this study, we examined the
leptin levels
of antipsychotic-naïve schizophrenic patients.
Serum leptin levels
of the healthy controls and antipsychotic-naïve patients were compared.
The relationships between
leptin level
and gender, Positive and Negative Syndrome Scale score, and duration of illness were analyzed by Spearman's correlation.
RESULTS: Compared with sex-, age- and BMI-matched subjects, the female schizophrenic patients had elevated
serum leptin levels
.
In the male patients, the results of this preliminary study also revealed a positive correlation between
leptin levels
and the Aggression Risk Profile subscale of the PANSS.
CONCLUSION: This preliminary study suggests possible gender-specific
leptin
dysregulation in antipsychotic-naïve schizophrenic patients.
[MeSH-major]
Leptin
/ blood. Schizophrenia / blood. Sex Characteristics
Genetic Alliance.
consumer health - Schizophrenia
.
MedlinePlus Health Information.
consumer health - Schizophrenia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2008 S. Karger AG, Basel.
(PMID = 18382119.001).
[ISSN]
1423-0224
[Journal-full-title]
Neuropsychobiology
[ISO-abbreviation]
Neuropsychobiology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Leptin
75.
Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M:
Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma.
J Urol
; 2006 Oct;176(4 Pt 1):1631-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Increased
serum leptin levels
and over expression of
leptin
receptors are associated with the invasion and progression of renal
cell
carcinoma.
PURPOSE:
Leptin
, an adipocyte derived cytokine that is closely associated with obesity, was recently shown to be involved in carcinogenesis and cancer progression.
Because obesity is a significant risk factor for renal
cell
carcinoma, we investigated the link between
leptin
and the development of renal
cell
carcinoma.
MATERIALS AND METHODS: Associations between preoperative
serum leptin levels
and
leptin
receptor expression in tumor specimens and various clinicopathological parameters were analyzed in 57 patients with renal
cell
carcinoma.
RESULTS:
Serum leptin levels
were 1.2 to 16.2 ng/ml (mean 4.5).
Of 57 tumors 22 (38.6%) demonstrated high
leptin
receptor expression.
Serum leptin levels
were significantly higher in patients with vs without tumor specimen venous invasion (p = 0.030) and higher in patients with high vs low
leptin
receptor expression (p = 0.019).
There were significant associations between high
leptin
receptor expression and the presence of venous invasion (p = 0.013), histological
type
(p = 0.0076) and regional
lymph
node metastasis (p = 0.047).
Of 42 patients with N0M0 disease those with
serum leptin
5.0 ng/ml or more had significantly shorter progression-free survival than patients with lower
levels
(p = 0.0043).
Multivariate Cox proportional hazards model analysis demonstrated that higher
serum leptin
was an independent predictor of progression-free survival (p = 0.0406).
CONCLUSIONS:
Leptin
and
leptin
receptor could have a key role in the invasion of renal
cell
carcinoma and they could be valuable predictors of progression.
[MeSH-major]
Carcinoma, Renal
Cell
/ metabolism. Carcinoma, Renal
Cell
/ pathology. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology.
Leptin
/ blood. Receptors,
Cell
Surface / metabolism
[MeSH-minor]
Adult. Aged. Body Mass Index. Disease-Free Survival. Female. Humans. Male. Middle Aged.
Neoplasm
Invasiveness. Receptors,
Leptin
. Treatment Outcome
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16952705.001).
[ISSN]
0022-5347
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human
76.
Gharote HP, Mody RN:
Estimation of serum leptin in oral squamous cell carcinoma.
J Oral Pathol Med
; 2010 Jan;39(1):69-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Estimation of
serum leptin
in oral squamous
cell
carcinoma.
Leptin
, a homologous protein of cytokine family, is found to be decreased in
serum
with cachexia.
The purpose of this study was to compare
serum leptin levels
of oral squamous
cell
carcinoma patients with that of control group and correlate it with body mass index.
METHOD:
Serum
samples of 31 oral squamous
cell
carcinoma patients and that of 28 healthy individuals were subjected to evaluation of
serum leptin levels
(ng/ml) using enzyme-linked immunosorbent assay.
RESULTS: A significant reduction in
leptin level
of oral squamous
cell
carcinoma patients was observed.
Definite correlation between body mass index and
serum leptin
and also between
serum leptin levels
of various histopathological variants of oral squamous
cell
carcinoma was observed.
CONCLUSION: The results of this study suggest that evaluation of
serum leptin level
can provide status of cachexia in oral squamous
cell
carcinoma patients.
[MeSH-major]
Carcinoma, Squamous
Cell
/ blood.
Leptin
/ blood. Mouth Neoplasms / blood
[MeSH-minor]
Adult. Age Factors. Aged. Area Under Curve. Biomarkers / blood. Body Mass Index. Cachexia / blood. Female. Humans. Male. Middle Aged.
Neoplasm
Staging. ROC Curve. Sensitivity and Specificity. Sex Factors. Young Adult
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
Genetic Alliance.
consumer health - Oral squamous cell carcinoma
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19817969.001).
[ISSN]
1600-0714
[Journal-full-title]
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
[ISO-abbreviation]
J. Oral Pathol. Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Biomarkers; 0 / Leptin
77.
Mendoza-Núñez VM, Correa-Muñoz E, Garfias-Cruz EA, Sánchez-Rodriguez MA, Galván-Duarte RE, Retana-Ugalde R:
Hyperleptinemia as a risk factor for high blood pressure in the elderly.
Arch Pathol Lab Med
; 2006 Feb;130(2):170-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Hyperleptinemia
as a
risk factor for high blood pressure in the elderly.
CONTEXT: Studies have demonstrated that high
serum leptin levels
are associated with aging.
We measured
serum leptin levels
through the radioimmunoassay method.
RESULTS: The elderly subjects with HBP had significantly higher
leptin levels
than the healthy elderly subjects (P = .02).
Furthermore, in female elderly subjects we observed a statistically significant correlation between systolic blood pressure and
leptin
(r = 0.37, P = .003),
as well
as systolic blood pressure and age (r = 0.29, P = .02), but not with diastolic blood pressure.
In male elderly subjects, there was no correlation between
leptin
and systolic blood pressure or
leptin
and diastolic blood pressure.
[MeSH-major]
Hypertension / blood.
Leptin
/ blood
MedlinePlus Health Information.
consumer health - High Blood Pressure
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16454556.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Leptin
78.
Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z:
Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
PLoS One
; 2010;5(7):e11859
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic
lymphocytic
leukemia cells.
BACKGROUND: The receptor tyrosine kinase like orphan receptor (ROR)-1 gene is overexpressed in chronic
lymphocytic
leukemia (CLL).
METHODOLOGY/PRINCIPAL FINDINGS: Because IL-6 induced Stat3 phosphorylation and upregulated Ror1 protein
levels
in MM1 cells, we used these cells
as a
model.
Finally, like STAT3-siRNA in MM1 cells, STAT3-shRNA downregulated STAT3, ROR1, and STAT3-regulated genes and Stat3 and Ror1 protein
levels
in CLL cells.
[MeSH-major]
Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ metabolism. Receptor Tyrosine Kinase-like Orphan Receptors / metabolism. STAT3 Transcription Factor / metabolism
[MeSH-minor]
Blotting, Western.
Cell
Line.
Cell
Line, Tumor. Chromatin Immunoprecipitation. Electrophoretic Mobility Shift Assay. Genetic Vectors / genetics. Humans. Lentivirus / genetics. Mutagenesis, Site-Directed. Promoter Regions, Genetic. RNA,
Small
Interfering / genetics. RNA,
Small
Interfering / physiology. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Blood. 2010 Apr 8;115(14):2852-63
[
20154216.001
]
[Cites]
J Endocrinol. 2007 Apr;193(1):93-106
[
17400807.001
]
[Cites]
Nat Genet. 2000 Mar;24(3):275-8
[
10700182.001
]
[Cites]
Endocrinology. 2007 Sep;148(9):4226-37
[
17525119.001
]
[Cites]
Osteoporos Int. 2007 Dec;18(12):1683-92
[
17619808.001
]
[Cites]
Cancer Res. 2007 Dec 1;67(23):11291-9
[
18056455.001
]
[Cites]
Clin Cancer Res. 2008 Jan 15;14(2):396-404
[
18223214.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52
[
18287027.001
]
[Cites]
Blood. 2008 May 1;111(9):4681-9
[
18227347.001
]
[Cites]
Int J Cancer. 2008 Sep 1;123(5):1190-5
[
18546292.001
]
[Cites]
Leuk Lymphoma. 2008 Jul;49(7):1360-7
[
18604725.001
]
[Cites]
J Clin Pathol. 2008 Nov;61(11):1214-9
[
18765431.001
]
[Cites]
Trends Cell Biol. 2008 Nov;18(11):536-44
[
18848778.001
]
[Cites]
Blood. 2009 Jan 22;113(4):856-65
[
18796623.001
]
[Cites]
Bioorg Med Chem Lett. 2009 Feb 1;19(3):606-9
[
19121941.001
]
[Cites]
Int J Mol Med. 2009 Jun;23(6):763-9
[
19424602.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8695-700
[
19433805.001
]
[Cites]
Science. 2000 Mar 3;287(5458):1606-9
[
10733430.001
]
[Cites]
Genes Dev. 2000 Aug 1;14(15):1837-51
[
10921899.001
]
[Cites]
Immunity. 2000 Jul;13(1):15-24
[
10933391.001
]
[Cites]
Nat Genet. 2000 Aug;25(4):419-22
[
10932186.001
]
[Cites]
Nat Genet. 2000 Aug;25(4):423-6
[
10932187.001
]
[Cites]
Am J Hum Genet. 2000 Oct;67(4):822-31
[
10986040.001
]
[Cites]
J Biol Chem. 2001 Mar 2;276(9):6675-88
[
11053426.001
]
[Cites]
Oncogene. 2000 Dec 27;19(56):6613-26
[
11426647.001
]
[Cites]
J Exp Med. 2001 Dec 3;194(11):1639-47
[
11733578.001
]
[Cites]
J Immunol. 2002 Jan 1;168(1):466-74
[
11751994.001
]
[Cites]
Science. 2002 May 31;296(5573):1653-5
[
12040185.001
]
[Cites]
Blood. 2002 Nov 1;100(9):3311-8
[
12384432.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23
[
14973184.001
]
[Cites]
Science. 2004 Mar 5;303(5663):1483-7
[
15001769.001
]
[Cites]
FEBS Lett. 2004 Aug 27;573(1-3):202-6
[
15327998.001
]
[Cites]
J Biol Chem. 1992 Dec 25;267(36):26181-90
[
1334494.001
]
[Cites]
Blood. 1996 Aug 1;88(3):809-16
[
8704235.001
]
[Cites]
Science. 1996 Aug 9;273(5276):794-7
[
8670419.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9148-53
[
8799169.001
]
[Cites]
EMBO J. 1996 Oct 15;15(20):5616-26
[
8896455.001
]
[Cites]
J Clin Invest. 1997 Dec 15;100(12):3140-8
[
9399961.001
]
[Cites]
J Immunol. 1997 Dec 1;159(11):5206-10
[
9548458.001
]
[Cites]
Hematology. 2004 Aug;9(4):279-86
[
15621735.001
]
[Cites]
N Engl J Med. 2005 Feb 24;352(8):804-15
[
15728813.001
]
[Cites]
J Clin Invest. 2005 Mar;115(3):755-64
[
15711642.001
]
[Cites]
Nat Cell Biol. 2005 Jun;7(6):591-600
[
15864305.001
]
[Cites]
Br J Cancer. 2005 Jul 11;93(1):70-80
[
15970928.001
]
[Cites]
Dev Biol. 2006 Feb 1;290(1):81-91
[
16330017.001
]
[Cites]
Cancer Res. 2006 Jan 15;66(2):653-8
[
16423993.001
]
[Cites]
Mayo Clin Proc. 2006 Aug;81(8):1105-29
[
16901035.001
]
[Cites]
Int J Mol Med. 2007 Feb;19(2):273-8
[
17203201.001
]
[Cites]
Int J Mol Med. 2007 Apr;19(4):699-703
[
17334647.001
]
[Cites]
Blood. 2009 Nov 5;114(19):4179-85
[
19745069.001
]
(PMID = 20686606.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; EC 2.7.10.1 / Receptor Tyrosine Kinase-like Orphan Receptors
[Other-IDs]
NLM/ PMC2912280
79.
Caraway NP, Thomas E, Khanna A, Payne L, Zhang HZ, Lin E, Keating MJ, Katz RL:
Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival.
Cancer
; 2008 Oct 25;114(5):315-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with
small lymphocytic lymphoma
are useful for predicting survival.
BACKGROUND: Fine-needle aspiration (FNA) of
lymph
nodes is commonly used to assess disease progression in patients with
small lymphocytic lymphoma
(
SLL
).
Although cytologic features are helpful for diagnosing typical
SLL
and transformed large-
cell lymphoma
(tLCL),
SLL
in accelerated phase (SLLacc) is more difficult to diagnose.
Additional tests are needed to identify those patients who are transforming to a higher-grade
lymphoma
.
This study evaluated the use of a multicolor fluorescence in situ hybridization (FISH) probe panel specifically designed for chronic
lymphocytic
leukemia (CLL)/
SLL
and assessed the association between FISH findings and cytologic
diagnosis
, proliferation index, and risk of death.
METHODS: FNA specimens from 50 patients (32 men and 18 women; mean age, 57 years [range, 36-77 years]) with histologically confirmed CLL and/or
SLL
were evaluated in this study for chromosomal abnormalities of 11q22 (ATM), 12, 13q14.3, 13q34.3 (LAMP1), and 17p13.1 (p53) by using a multiprobe FISH kit.
The FISH findings were compared with the cytologic diagnoses (26
SLLs
, 12 SLLaccs, and 11 tLCLs), Ki-67 immunostaining, and risk of death.
CONCLUSIONS: FISH can be performed on FNA specimens from patients with a history of
SLL
/CLL.
Knowledge of genetic abnormalities from FNAs may be useful in deciding when and how to treat indolent or progressive
SLL
.
[MeSH-major]
Biopsy, Fine-Needle. Chromosome Aberrations. In Situ Hybridization, Fluorescence. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ genetics. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ mortality
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 American Cancer Society.
(PMID = 18683215.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Journal Article
[Publication-country]
United States
80.
Ly M, Belli E, Leobon B, Kortas C, Grollmüss OE, Piot D, Planché C, Serraf A:
Results of the double switch operation for congenitally corrected transposition of the great arteries.
Eur J Cardiothorac Surg
; 2009 May;35(5):879-83; discussion 883-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Segmental anatomy was {
SLL
} in all patients, dextrocardia in two patients, mesocardia in two patients.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19346135.001).
[ISSN]
1873-734X
[Journal-full-title]
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
[ISO-abbreviation]
Eur J Cardiothorac Surg
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
Germany
81.
Brito N, Fonseca M, Dinis I, Mirante A:
Metabolic factors in obesity.
J Pediatr Endocrinol Metab
; 2010 Jan-Feb;23(1-2):97-100
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Leptin
is an important hormone involved in the pathogenesis of obesity and has been under investigation
as a
risk marker for future complications. AIMS: 1.
To evaluate the relation between
serum leptin levels
and body mass index (BMI) and height.
2. To compare
leptin levels
in obese and non-obese children.
3. To evaluate the relation between
leptin levels
and insulin resistance index.
In the obese group we assessed sex, age, BMI SDS and height SDS for age and sex, and
serum levels
of glucose, insulin and
leptin
.
In the control group were obtained BMI SDS and height SDS for age and sex and
leptin levels
.
Leptin levels
showed a positive correlation with BMI SDS (r = 0.69; p < 0.001) and height SDS (r = 0.31; p < 0.001).
When comparing
leptin levels
between obese and non-obese groups, we found a significant difference in boys (50.7 +/- 27.3 versus 7.0 +/- 6.8 ng/ml; p < 0.001) and in girls (57.6 +/- 25.5 versus 16.5 +/- 10.3 ng/ml; p < 0.001).
In the nonobese group,
leptin levels
were lower in boys.
Leptin
showed a positive correlation with insulin resistance index in boys (r = 0.45, p = 0.05), but not in girls.
CONCLUSIONS: This study has confirmed a positive correlation between
leptin levels
and BMI SDS.
In obese children elevated
leptin
is associated with central resistance to its action.
The positive correlation of
leptin
with insulin resistance index may suggest a major role of
leptin
in insulin resistance.
[MeSH-major]
Blood Glucose / metabolism. Insulin Resistance.
Leptin
/ blood. Obesity / epidemiology. Obesity / metabolism
Genetic Alliance.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Blood Sugar
.
MedlinePlus Health Information.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Obesity in Children
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20432812.001).
[ISSN]
0334-018X
[Journal-full-title]
Journal of pediatric endocrinology & metabolism : JPEM
[ISO-abbreviation]
J. Pediatr. Endocrinol. Metab.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Blood Glucose; 0 / Insulin; 0 / Leptin
82.
Kastenbaum HA, Khalbuss WE, Felgar RE, Stoller R, Monaco SE:
The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology.
Cytojournal
; 2010;7:20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The spectrum of coincident entities with
small lymphocytic lymphoma
/chronic
lymphocytic
leukemia (
SLL
/CLL) diagnosed by cytology.
BACKGROUND: The cytologic
diagnosis
of
Small lymphocytic lymphoma
/chronic
lymphocytic
leukemia (
SLL
/CLL) often relies on finding a
small
lymphoid population with the characteristic immunoprofile by ancillary testing.
There are only a few reports of other processes identified with
SLL
/CLL.
The aim of this study was to review the fine needle aspiration (FNA) and touch prep (TP) diagnoses of
SLL
/CLL in order to identify any coincident entities.
MATERIALS AND METHODS: We retrospectively reviewed all FNA and TP cytology cases between January 2005 and May 2009 with
a diagnosis
of
SLL
/CLL to determine the presence of any coincident process.
Coincident entities were identified in nine cases (31%) and included seven (28%) neoplastic entities (Hodgkin
lymphoma
[HL], adenocarcinoma, squamous
cell
carcinoma, seminoma) and two (7%) non-neoplastic entities (infection and immunoglobulin containing cells).
Six cases (21%) suspicious for large
cell
transformation were also identified.
CONCLUSION: In our review of
SLL
/CLL, coincident entities were present in 31% of the cases and included a spectrum of non-neoplastic and neoplastic processes.
FC was the most frequently utilized ancillary test, but IHC provided important information by excluding a mantle
cell lymphoma
or confirming a coincident process.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20976208.001).
[ISSN]
1742-6413
[Journal-full-title]
CytoJournal
[ISO-abbreviation]
Cytojournal
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC2955352
[Keywords]
NOTNLM ; Chronic lymphocytic leukemia / SLL/CLL / cytopathology / small lymphocytic lymphoma
83.
Chang HH, Gean PW, Chou CH, Yang YK, Tsai HC, Lu RB, Chen PS:
C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients.
J Clin Psychopharmacol
; 2010 Oct;30(5):512-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar
disorder
patients.
BACKGROUND: Valproate (VPA) is a mood stabilizer for treating patients with bipolar
disorder
(BD).
RESULTS: The variation of GNB3 C825T showed an association with higher plasma total cholesterol (P = 0.037), triglyceride (P = 0.014), and
leptin
(P < 0.001)
levels
in BD patients treated with VPA.
After adjusting for age, sex, types of BDs, and
serum
concentration of VPA, the variation of GNB3 C825T remained significantly associated with the
levels
of
serum leptin
and body mass index (BMI; P < 0.001 and P = 0.030, respectively).
In addition, the GNB3 C825T showed significant drug-single-nucleotide polymorphism interactions with insulin
levels
(P = 0.033), triglyceride
levels
(P = 0.013),
leptin levels
(P = 0.013), and BMI (P = 0.018).
These results indicated that the T allele may be associated with lower
serum leptin levels
and BMI in BD patients treated with VPA.
[MeSH-major]
Alleles. Bipolar
Disorder
/ genetics. Bipolar
Disorder
/ metabolism. Heterotrimeric GTP-Binding Proteins / genetics. Polymorphism, Single Nucleotide / genetics. Protein Subunits / genetics. Valproic Acid / adverse effects
[MeSH-minor]
Adult. Body Mass Index. Female. Heterozygote Detection. Humans.
Leptin
/ blood. Male. Middle Aged. Young Adult
Genetic Alliance.
consumer health - Bipolar Disorder
.
MedlinePlus Health Information.
consumer health - Bipolar Disorder
.
Hazardous Substances Data Bank.
VALPROIC ACID
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20814328.001).
[ISSN]
1533-712X
[Journal-full-title]
Journal of clinical psychopharmacology
[ISO-abbreviation]
J Clin Psychopharmacol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / G-protein beta3 subunit; 0 / Leptin; 0 / Protein Subunits; 614OI1Z5WI / Valproic Acid; EC 3.6.5.1 / Heterotrimeric GTP-Binding Proteins
84.
Lin J, Yan GT, Gao XN, Liao J, Wang LH, Hao XH:
[Distribution of leptin expression and its effect on the recovery of sepsis-induced internal disorders].
Sichuan Da Xue Xue Bao Yi Xue Ban
; 2008 May;39(3):360-3, 417
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Distribution of
leptin
expression and its effect on the recovery of sepsis-induced internal disorders].
OBJECTIVE: To explore the distribution of
leptin
expression and the effect of sepsis on
leptin
protein and mRNA
levels
.
The mRNA expressions of
leptin
in those samples were determined by RT-PCR.
Radioimmunoassay was applied to measure
serum leptin
concentrations in each group at 12 h after injury, while RT-PCR was also used to detect
Leptin
mRNA expressions in hypothalamus, fat and lung after injury.
RESULTS:
Leptin
mRNA expressions were confirmed in all the above nine vital organs, with the highest in kidney but the lowest in testis.
The
serum leptin level
showed no significant difference between sham operation group and other four groups.
Compared with sham operation group, the
Leptin
mRNA
level
in CLP group decreased significantly in hypothalamus, fat and lung, while that in the other three groups showed different changes.
The effect of intralipid on
Leptin
mRNA expression was found to be a dual-direction pattern, with central stimulation but peripheral inhibition.
CONCLUSION:
Leptin
is widely expressed in multiple vital organs, and it may be a protective factor to promote recovery of sepsis-induced internal disorders.
[MeSH-major]
Gene Expression Profiling.
Leptin
/ physiology. Sepsis / physiopathology
MedlinePlus Health Information.
consumer health - Sepsis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18575315.001).
[ISSN]
1672-173X
[Journal-full-title]
Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
[ISO-abbreviation]
Sichuan Da Xue Xue Bao Yi Xue Ban
[Language]
chi
[Publication-type]
English Abstract; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Leptin; 0 / RNA, Messenger
85.
Nishimura H, Akiyama T, Monobe Y, Matsubara K, Igarashi Y, Abe M, Sugihara T, Sadahira Y:
Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma.
Mod Pathol
; 2010 Mar;23(3):439-49
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of sphingosine-1-phosphate receptor 1 in mantle
cell lymphoma
.
In this study, we evaluated sphingosine-1-phosphate receptor 1's suitability
as a
diagnostic marker for
malignant
lymphoma
by immunostaining formalin-fixed paraffin-embedded sections using
a well
-defined commercial anti-sphingosine-1-phosphate receptor 1 antibody.
Sphingosine-1-phosphate receptor 1 was strongly expressed on the surface of
small
lymphocytes
forming primary lymphoid follicles and in the mantle zone of secondary lymphoid follicles.
Microarray-based immunohistochemistry with tissue samples from 85 lymphoid malignancy cases demonstrated that sphingosine-1-phosphate receptor 1 was expressed on the surface of mantle
cell lymphoma
cells.
Strong expression was observed in all classical mantle
cell lymphoma
cases involving the
lymph
node (19 out of 19), gastrointestinal tract (10 out of 10), bone marrow (9 out of 9), and orbita (1 out of 1).
One aggressive variant of mantle
cell lymphoma
displayed a weaker membranous staining than classical mantle
cell lymphoma
in the
lymph
node and bone marrow.
In a cyclin D1-negative mantle
cell lymphoma
of the orbita, no conclusive result was obtained.
No cases of follicular
lymphoma
, marginal zone
lymphoma
, B lymphoblastic leukemia/
lymphoma
, or Burkitt's
lymphoma
showed any significant expression, whereas 2 out of 6 chronic
lymphocytic
leukemia/
small lymphocytic
lymphomas
in bone marrow, 1 out of 3 lymphoplasmacytic
lymphomas
in the
lymph
node, and 2 out of 37
diffuse
large B-
cell
lymphomas
exhibited staining.
A quantitative reverse transcription polymerase chain reaction-based analysis of mantle
cell lymphoma
lines revealed the sphingosine-1-phosphate receptor 1 mRNA expression
level
to be
well
correlated with the results of immunocytochemistry, flow cytometry, and western blotting.
Thus, sphingosine-1-phosphate receptor 1 immunohistochemistry may be useful in the histological
diagnosis
of mantle
cell lymphoma
with formalin-fixed and paraffin-embedded sections.
[MeSH-major]
Lymphoma
, Mantle-
Cell
/ metabolism. Receptors, Lysosphingolipid / metabolism
[MeSH-minor]
Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology.
Cell
Line, Tumor. Cyclin D1 / metabolism. Female. Humans.
Lymph
Nodes / metabolism.
Lymph
Nodes / pathology.
Lymphocytes
/ metabolism.
Lymphocytes
/ pathology. Male. Middle Aged. Tissue Array Analysis
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20081804.001).
[ISSN]
1530-0285
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / CCND1 protein, human; 0 / Receptors, Lysosphingolipid; 0 / S1PR1 protein, human; 136601-57-5 / Cyclin D1
86.
Kartal O, Inal V, Baysan O, Sağlam K:
[Relationship between serum leptin levels and left ventricular hypertrophy in obese hypertensive patients].
Anadolu Kardiyol Derg
; 2008 Oct;8(5):342-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Relationship between
serum leptin levels
and left ventricular hypertrophy in obese hypertensive patients].
[Transliterated title]
Sişman hipertansif hastalarda
leptin
düzeyleri ve sol ventrikül hipertrofisi ile ilişkisi.
OBJECTIVE: Previous studies showed relation between elevated
serum leptin levels
(
SLL
) and hypertension.
The aim of this study was to evaluate relationship between
SLL
and left ventricular hypertrophy (LVH) and body mass index (BMI) in obese hypertensive patients.
Hypertensive patients were classified as;
level
-I or
level
-II according to JNC-VII
classification
and as normal weighted (18-24.99 kg/m2), over weighted (25-26.99 kg/m2) and obese (27 kg/m2 and above) according to BMI's.
All the patients were evaluated by echocardiography and blood samples were withdrawn for determination
SLL
.
Logistic regression analysis was applied for the evaluation of relationship between
SLL
and clinical variables.
RESULTS: Mean
levels
of arterial blood pressure (ABP) of total 80 patients (36 males and 44 females) was 155+/-1.1/95.1+/-0.7 mmHg and the mean age was 48.9+/-1.3 years.
Patients with
level
I hypertension (n=32) had mean ABP of 149.7+/-0.5/90.9+/-0.6 mmHg and with
level
-II hypertension (n=48)--mean ABP 168.5+/-1.6/102.9+/-0.9 mmHg.
There were no differences in LVH incidence between hypertension
level
groups and BMI groups (p>0.05).
Serum leptin levels
were similar in patients with
level
I and
level
II hypertension (33.5+/-2.9 ng/ml and 37.3+/-3.6 ng/ml, respectively, p>0.05).
However,
leptin levels
were higher in obese patients as compared with normal and over weighted patients (40.9+/-3.2 ng/ml versus 28.5+/-3.6 ng/ml and 32.8+/-4.9 ng/ml, p<0.01).
Patients with LVH had significantly higher
levels
of
leptin as
compared with patients without LVH (51.40+/-5.1 ng/ml versus 28.30+/-4.20 ng/ml, p<0.05).
Logistic regression analysis demonstrated that
SLL
independently of blood pressure and BMI is related with LVH (OR--1.7, %95 CI--1.2-1.9, p<0.05).
CONCLUSION: Our study showed that elevated
serum leptin levels
are significantly related with LVH independently of body mass index and
level
of blood pressure.
Thus, elevated
SLLs
, independently of hypertension
level
and BMI
classification
, coexist with LVH.
Sympathetic activation or direct cardiac receptor activation or proliferative effects of
leptin
may be responsible for this coexistence.
[MeSH-major]
Hypertension / blood. Hypertrophy, Left Ventricular / blood. Hypertrophy, Left Ventricular / pathology.
Leptin
/ blood. Obesity / blood
MedlinePlus Health Information.
consumer health - High Blood Pressure
.
MedlinePlus Health Information.
consumer health - Obesity
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Anadolu Kardiyol Derg. 2008 Oct;8(5):347-9
[
18849225.001
]
(PMID = 18849224.001).
[ISSN]
1308-0032
[Journal-full-title]
Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
[ISO-abbreviation]
Anadolu Kardiyol Derg
[Language]
tur
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Turkey
[Chemical-registry-number]
0 / Leptin
87.
Baseggio L, Gazzo S, Callet-Bauchu E, Traverse-Glehen A, Thieblemont C, Bryon PA, Magaud JP, Berger F, Felman P:
An unusual case of indolent B-cell lymphoma with distinct chronic lymphocytic leukemia and marginal zone differentiation according to the site of involvement.
Leuk Lymphoma
; 2005 Sep;46(9):1369-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
An unusual case of indolent B-
cell lymphoma
with distinct chronic
lymphocytic
leukemia and marginal zone differentiation according to the site of involvement.
The immunological profile of lymphoproliferative disorders is usually conserved whatever the involved site, thus allowing a reliable
diagnosis
from peripheral blood analysis, especially in
small lymphocytic lymphoma
/chronic
lymphocytic lymphoma
(
SLL
/CLL).
Here we present a case wherein the cytology and immunophenotype of blood specimen and bone marrow argue in favor of
SLL
/CLL with a typical Matutes score (5/5), whereas the cyto-histology and immunophenotype of spleen specimen led to the
diagnosis
of splenic marginal zone B-
cell lymphoma
(SMZL).
Whereas these data suggested the presence of 2 B-
cell
clones, the study of the mutational status of IgVH gene in blood and spleen demonstrated the presence of a single clone, which likely developed simultaneously along two distinct ways of differentiation according to the anatomic site suggesting here the predominant role of a micro-environmental factor in
cell
differentiation.
Although rare, this kind of event must be kept in mind
as a
cause of discrepancies between diagnoses from different sites.
[MeSH-major]
Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ blood.
Lymphoma
, B-
Cell
/
diagnosis
[MeSH-minor]
Aged. Genes, Immunoglobulin. Humans. Immunophenotyping. Male. Mutation. Splenic Neoplasms /
diagnosis
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
Genetic Alliance.
consumer health - Indolent B cell lymphoma
.
Genetic Alliance.
consumer health - Leukemia, B-cell, chronic
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16109617.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
88.
Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Kumakiri J, Takeda S:
Influencing factors of adhesion development and the efficacy of adhesion-preventing agents in patients undergoing laparoscopic myomectomy as evaluated by a second-look laparoscopy.
Fertil Steril
; 2008 May;89(5):1247-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
INTERVENTION(S): Video tape recording was performed during the second-look laparoscopy (
SLL
) to evaluate the postoperative uterine wound adhesions and adhesions around the uterine adnexa.
MAIN OUTCOME MEASURE(S): Evaluation of adhesions at the uterine wound and of
de
novo adhesions of the uterine adnexa by
SLL
.
RESULT(S): The
SLL
revealed uterine surgical wound adhesions in 141 patients (37.9%) and
de
novo adhesions of the uterine adnexa in 33 patients (8.9%).
The results of analysis to determine the factors influencing the development of postoperative adhesions revealed that the diameter of the largest myoma, number of myomas, and
type
of adhesion-preventing agent used (except for fibrin sheath, which had no effect) influenced the incidence of postoperative adhesions at the surgical wound, but only the diameter of the largest myoma influenced the incidence of
de
novo adhesions of the uterine adnexa.
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Ovarian Disorders
.
MedlinePlus Health Information.
consumer health - Uterine Cancer
.
MedlinePlus Health Information.
consumer health - Uterine Fibroids
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18155700.001).
[ISSN]
1556-5653
[Journal-full-title]
Fertility and sterility
[ISO-abbreviation]
Fertil. Steril.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Cellulose, Oxidized; 0 / Fibrin Tissue Adhesive; 0 / INTERCEED
89.
Berger F, Traverse-Glehen A, Felman P, Callet-Bauchu E, Baseggio L, Gazzo S, Thieblemont C, Ffrench M, Magaud JP, Salles G, Coiffer B:
Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
Clin Lymphoma
; 2005 Mar;5(4):220-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone
lymphoma
: are they distinct or the same entity?
Waldenstrom's macroglobulinemia (WM) is considered in the World Health Organization
classification as
a clinical syndrome associated with monoclonal immunoglobulin (Ig) M secretion, mainly observed in patients with lymphoplasmacytic
lymphoma
(LPL) and occasionally with other
small B
-
cell
lymphomas
.
Some authors consider it a rare distinct lymphoproliferative
disorder
with primary bone marrow infiltration and IgM monoclonal gammopathy.
As LPL shares important
morphologic
and immunophenotypic overlaps with marginal zone B-
cell
lymphomas
(MZLs) in cases showing plasmacytic maturation, it remains unclear if they constitute unique or distinct entities.
Both diseases are composed of
lymphocytes
, lymphoplasmacytoid cells, and tumoral plasma cells with a surface (s) IgM-positive sIgD+/ cytoplasmic IgMpositive CD19+ CD20+ CD27+/ CD5 CD10 CD23 phenotype, without a specific marker.
Extranodal mucosa-associated lymphoid tissue (MALT)
lymphoma
, nodal MZL (NMZL), and splenic MZL (SMZL) are distinct entities displaying common
morphologic
, immunophenotypic, and genetic characteristics.
MALT
lymphoma
is clearly distinct from LPL, although bone marrow infiltration and IgM paraprotein are not rare.
[MeSH-major]
Antigens, CD. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/
classification
. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/ immunology.
Lymphoma
, B-
Cell
/ immunology.
Lymphoma
, B-
Cell
/ pathology. Waldenstrom Macroglobulinemia /
classification
. Waldenstrom Macroglobulinemia / immunology
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15794852.001).
[ISSN]
1526-9655
[Journal-full-title]
Clinical lymphoma
[ISO-abbreviation]
Clin Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / Immunoglobulin M
[Number-of-references]
38
90.
Bridgeford EC, Marini RP, Feng Y, Parry NM, Rickman B, Fox JG:
Gastric Helicobacter species as a cause of feline gastric lymphoma: a viable hypothesis.
Vet Immunol Immunopathol
; 2008 May 15;123(1-2):106-13
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gastric Helicobacter species
as a
cause of feline gastric
lymphoma
: a viable hypothesis.
Gastric Helicobacter spp. are associated with chronic inflammation and neoplastic transformation in humans
as well
as domestic and laboratory species.
The present study examined the association of Helicobacter heilmannii (Hhe) infection in pet cats with feline gastric mucosa associated lymphoid tissue (MALT)
lymphoma
.
Tissues were collected via gastric biopsy or at necropsy from 47 pet cats with clinical signs of gastrointestinal disease, including vomiting and inappetance, and classified as gastritis (14/47),
lymphoma
(31/37), or normal (2/47).
Tissues positive for argyrophilic organisms with Warthin-Starry stain (29/47) were assessed by fluorescent in situ hybridization (FISH) for the presence of Hhe strains 1-4
as well
as with a fifth probe that detected Helicobacter salomonis, Helicobacter bizzozeronii, or Helicobacter felis.
Interestingly, a significant association between Hhe status and
a diagnosis
of lymphoblastic or
lymphocytic lymphoma
was observed
as well
in a subset of 24 Warthin-Starry positive
lymphoma
cases: of lymphoblastic
lymphoma
cases, 13/17 were positive for Hhe (p<0.05; chi(2)=4.854).
The association found between a positive Hhe status with the presence of feline gastric
lymphoma
, especially lymphoblastic
lymphoma
, argues for the need to conduct prospective studies to better identify the frequency and strain distribution of Hhe infection in both healthy and clinically ill cats, particularly those cats with gastric
lymphoma
.
MedlinePlus Health Information.
consumer health - Helicobacter Pylori Infections
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Vet Sci. 2002 Jun;3(2):123-33
[
12441682.001
]
[Cites]
Aust Vet J. 2001 Jul;79(7):476-81
[
11549046.001
]
[Cites]
J Clin Microbiol. 2004 May;42(5):2144-51
[
15131182.001
]
[Cites]
J Pathol. 2004 Aug;203(4):896-903
[
15258991.001
]
[Cites]
Infect Immun. 1994 Jun;62(6):2367-74
[
8188360.001
]
[Cites]
Infect Immun. 1995 Jul;63(7):2674-81
[
7790084.001
]
[Cites]
Am J Pathol. 1995 Jul;147(1):217-22
[
7604881.001
]
[Cites]
Am J Pathol. 1997 Jul;151(1):273-80
[
9212752.001
]
[Cites]
J Clin Microbiol. 1998 Mar;36(3):634-7
[
9508286.001
]
[Cites]
J Clin Microbiol. 1998 May;36(5):1366-70
[
9574707.001
]
[Cites]
Scand J Gastroenterol. 1998 Aug;33(8):795-8
[
9754724.001
]
[Cites]
Blood Cells Mol Dis. 2005 Jan-Feb;34(1):6-16
[
15607694.001
]
[Cites]
Pathol Int. 2005 Jul;55(7):398-404
[
15982214.001
]
[Cites]
Am J Pathol. 2005 Sep;167(3):797-812
[
16127158.001
]
[Cites]
J Am Vet Med Assoc. 2005 Oct 1;227(7):1118-22
[
16220673.001
]
[Cites]
Gut. 2006 May;55(5):616-8
[
16299027.001
]
[Cites]
Infect Immun. 2007 Mar;75(3):1214-22
[
17194807.001
]
[Cites]
Am J Gastroenterol. 2007 Apr;102(4):725-30
[
17324128.001
]
[Cites]
Infect Immun. 2000 Feb;68(2):779-90
[
10639446.001
]
[Cites]
Am J Pathol. 2000 Feb;156(2):709-21
[
10666399.001
]
[Cites]
Gastroenterology. 2000 May;118(5):821-8
[
10784580.001
]
[Cites]
Gut. 2001 Mar;48(3):297-303
[
11171816.001
]
[Cites]
Vet Microbiol. 2001 Apr 2;79(3):253-65
[
11240103.001
]
[Cites]
Vet Pathol. 2001 Mar;38(2):173-83
[
11280373.001
]
[Cites]
J Clin Microbiol. 2001 Apr;39(4):1510-6
[
11283079.001
]
[Cites]
Vet Clin North Am Small Anim Pract. 2003 Sep;33(5):1083-98, vii
[
14552162.001
]
(PMID = 18387674.001).
[ISSN]
0165-2427
[Journal-full-title]
Veterinary immunology and immunopathology
[ISO-abbreviation]
Vet. Immunol. Immunopathol.
[Language]
ENG
[Grant]
United States / NIAID NIH HHS / AI / R01 AI037750-12; United States / NIAID NIH HHS / AI / R01 AI37750; United States / NIAID NIH HHS / AI / AI037750-12; United States / NCRR NIH HHS / RR / RR007036-20; United States / NIAID NIH HHS / AI / R01 AI037750-13; United States / NIAID NIH HHS / AI / AI037750-13; United States / NIAID NIH HHS / AI / R01 AI037750; United States / NIEHS NIH HHS / ES / P30 ES002109; United States / NCRR NIH HHS / RR / T32 RR007036; United States / NCRR NIH HHS / RR / T32 RR007036-20; United States / NCRR NIH HHS / RR / T32 RR07036
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
Netherlands
[Other-IDs]
NLM/ NIHMS95239; NLM/ PMC2653416
91.
de Larrinoa AF, del Cura J, Zabala R, Fuertes E, Bilbao F, Lopez JI:
Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma.
J Clin Ultrasound
; 2007 Jul-Aug;35(6):295-301
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Value of ultrasound-guided core biopsy in the
diagnosis
of
malignant
lymphoma
.
PURPOSE: Ultrasound-guided core needle biopsy for the
diagnosis
and management of
malignant lymphomas
is controversial and has not been accepted as an alternative to surgical biopsy.
METHODS: Over a 5-year period (2000-2004), ultrasound-guided core needle biopsies were performed in 102
malignant lymphomas
.
Five diagnostic categories were considered: large B-
cell
lymphomas
(LBCL),
small B
-
cell
lymphomas
(SBCL), Hodgkin's disease (HD), T
cell
lymphomas
, and miscellaneous.
SBCL (39), LBCL (36), HD (15), T
cell
lymphomas
(5), and miscellaneous (7) [including T
cell
-rich
B cell
(2), natural killer
cell
(1), Burkitt's
lymphoma
(1), and non-Hodgkin's
lymphoma
of the
B cell
type
,
NOS
(3)] were correctly diagnosed.
Three HDs, 1 natural killer
cell lymphoma
, 1 follicular
lymphoma
, and 1 LBCL were not correctly diagnosed.
CONCLUSIONS: Ultrasound-guided core needle biopsy is effective in the
diagnosis
of
malignant lymphomas
and can be used as the first diagnostic approach in selected clinical situations.
[MeSH-major]
Biopsy / methods.
Lymphoma
/
diagnosis
. Ultrasonography, Interventional
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Burkitt
Lymphoma
/
diagnosis
. Burkitt
Lymphoma
/ pathology. Female. Hodgkin Disease /
diagnosis
. Humans. Killer Cells, Natural / pathology. Leukemia,
Lymphocytic
, Chronic, B-
Cell
/
diagnosis
.
Lymph
Nodes / pathology.
Lymphoma
, B-
Cell
/
diagnosis
.
Lymphoma
, Follicular /
diagnosis
.
Lymphoma
, Large B-
Cell
,
Diffuse
/
diagnosis
.
Lymphoma
, T-
Cell
/
diagnosis
. Male. Middle Aged. Prospective Studies
MedlinePlus Health Information.
consumer health - Biopsy
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2007 Wiley Periodicals, Inc.
(PMID = 17486566.001).
[ISSN]
0091-2751
[Journal-full-title]
Journal of clinical ultrasound : JCU
[ISO-abbreviation]
J Clin Ultrasound
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
92.
Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G:
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
Clin Cancer Res
; 2005 Feb 15;11(4):1490-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
B-
cell
lymphomas
differ in their responsiveness to CpG oligodeoxynucleotides.
Synthetic CpG oligodeoxynucleotides are currently being tested in clinical trials for the therapy of different types of
B cell
non-Hodgkin's
lymphoma
.
However, there is only limited information on the CpG oligodeoxynucleotide sensitivity of primary
malignant
B cells of different non-Hodgkin's
lymphoma
entities.
Here we found that most B-
cell
malignancies except plasmacytoma respond to CpG oligodeoxynucleotides by up-regulating expression of costimulatory and antigen-presenting molecules, by increasing expression of CD20, and by proliferation.
In an in vitro analysis of 41 individual patient-derived primary tumor samples, B-
cell
chronic
lymphocytic
leukemia (B-CLL) and marginal zone
lymphoma
showed the strongest activation upon stimulation with CpG oligodeoxynucleotides.
Small lymphocytic lymphoma
, follicular
lymphoma
, mantle
cell lymphoma
, and large
cell lymphoma
showed an intermediate response.
Although CpG oligodeoxynucleotides induced proliferation in all CpG oligodeoxynucleotide-sensitive types of B-
cell
malignancies, proliferation was weaker than in normal B cells and at least for B-CLL was followed by increased apoptosis.
In conclusion, B-
cell
malignancies show significant differences in their responsiveness to CpG oligodeoxynucleotides.
Focusing clinical studies on patients with highly CpG oligodeoxynucleotide-sensitive B-
cell
malignancies may improve the clinical outcome of such trials.
[MeSH-major]
Lymphoma
, B-
Cell
/ drug therapy. Oligodeoxyribonucleotides / pharmacology
[MeSH-minor]
Adjuvants, Immunologic / pharmacology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Antigens, CD20 / immunology.
Cell
Proliferation / drug effects.
Cell
Survival / drug effects. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Membrane Glycoproteins / genetics. Middle Aged. Plasmacytoma / drug therapy. Plasmacytoma / genetics. Plasmacytoma / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors,
Cell
Surface / genetics. Rituximab. Time Factors. Toll-Like Receptor 9. Toll-Like Receptors. Tumor Cells, Cultured
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15746051.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adjuvants, Immunologic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / CPG-oligonucleotide; 0 / Membrane Glycoproteins; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / TLR9 protein, human; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab
93.
Xia D, Song Y, Li C, Zhang F, Wei M:
The change of serum leptin and its relationship with platelet membrane glycoprotein Ib in patients with coronary heart disease.
Front Med China
; 2007 Oct;1(4):352-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The change of
serum leptin
and its relationship with platelet membrane glycoprotein Ib in patients with coronary heart disease.
The aim of this paper was to investigate the change of
serum leptin
and its relationship with platelet membrane glycoprotein Ib (GP Ib) in patients with coronary heart disease (CHD).
Serum leptin
was detected by enzyme linked immunosorbent assay.
After correcting the differences of systolic blood pressure, body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting glucose, PPBS, fasting insulin and quantitative insulin sensitive index,
serum leptin level
in the CHD group was significantly higher than that in the control group (P < 0.05).
Single factor correlative analysis revealed that
serum leptin
in CHD patients was negatively correlated with the average fluorescence intensity of platelet membrane GP Ib (P < 0.05).
Multifactorial stepwise regression analysis showed that
serum leptin
in CHD patients was independently negatively correlated with the average fluorescence intensity of platelet membrane GP Ib (P < 0.05).
Logistic analysis demonstrated that
serum leptin
was independently correlated with the risk of CHD (P < 0.05).
The increase of
serum leptin
could affect blood platelet activation.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Curr Opin Pharmacol. 2005 Apr;5(2):160-4
[
15780825.001
]
[Cites]
Trends Cardiovasc Med. 2004 Jan;14(1):18-22
[
14720470.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Aug;89(8):3872-8
[
15292320.001
]
[Cites]
J Cell Biol. 2001 Aug 6;154(3):485-90
[
11489912.001
]
[Cites]
J Biol Chem. 2001 Jul 6;276(27):25096-100
[
11342529.001
]
[Cites]
FASEB J. 1999 Jul;13(10):1231-8
[
10385613.001
]
[Cites]
Med Hypotheses. 2006;67(1):82-6
[
16500036.001
]
[Cites]
Kobe J Med Sci. 2001 Jun;47(3):141-50
[
11729375.001
]
[Cites]
Int J Obes Relat Metab Disord. 2003 Jan;27(1):13-8
[
12532148.001
]
[Cites]
Eur Heart J. 2006 Oct;27(19):2294-9
[
16543250.001
]
[Cites]
Diabetes. 1999 Sep;48(9):1787-93
[
10480609.001
]
[Cites]
Circulation. 2001 Dec 18;104(25):3052-6
[
11748099.001
]
[Cites]
Nature. 1998 Feb 5;391(6667):591-4
[
9468137.001
]
[Cites]
Arterioscler Thromb Vasc Biol. 1998 Jun;18(6):928-33
[
9633933.001
]
[Cites]
Atherosclerosis. 2007 Apr;191(2):418-26
[
16712853.001
]
[Cites]
Blood. 1991 Feb 15;77(4):770-9
[
1704263.001
]
[Cites]
Diabetes Care. 1998 May;21(5):782-6
[
9589240.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E695-702
[
15886225.001
]
[Cites]
Neurosci Lett. 2000 Oct 27;293(2):107-10
[
11027845.001
]
[Cites]
Diabetes. 2003 Aug;52(8):2121-8
[
12882931.001
]
[Cites]
Coron Artery Dis. 2003 Feb;14(1):65-79
[
12629328.001
]
[Cites]
J Thromb Haemost. 2005 May;3(5):1042-9
[
15869602.001
]
[Cites]
J Clin Invest. 1997 Jul 15;100(2):270-8
[
9218503.001
]
[Cites]
Clin Exp Immunol. 2006 Mar;143(3):452-7
[
16487244.001
]
[Cites]
Int J Obes Relat Metab Disord. 2001 Oct;25(10):1471-3
[
11673768.001
]
[Cites]
Coron Artery Dis. 2003 Aug;14(5):357-63
[
12878900.001
]
[Cites]
Diabet Med. 2005 Mar;22(3):278-85
[
15717875.001
]
[Cites]
Angiology. 2006 May-Jun;57(3):267-72
[
16703186.001
]
(PMID = 24573923.001).
[ISSN]
1673-7342
[Journal-full-title]
Frontiers of medicine in China
[ISO-abbreviation]
Front Med China
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
94.
Shen XH, Tang QY, Huang J, Cai W:
Vitamin E regulates adipocytokine expression in a rat model of dietary-induced obesity.
Exp Biol Med (Maywood)
; 2010 Jan;235(1):47-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The aim of this study was to determine the effect of the antioxidant vitamin E (VE) on adiponectin and
leptin
expression in obese rats.
Blood and adipose tissues were then immediately collected; mRNA and protein
levels
of
leptin
and adiponectin were measured by realtime reverse transcription-polymerase chain reaction and Western blotting.
Biomarkers of oxidative stress, including
serum levels
of 8-epi-prostaglandin-F(2)alpha (8-epi-PGF(2)alpha) and glutathione peroxidase activity, were also examined.
Adiponectin and
leptin levels
were lower in the DIO group than in the control group.
VE intervention increased the expression of both
leptin
and adiponectin (P values < 0.05).
Association analysis showed that
serum leptin levels
correlated positively with body fat mass (r = 0.601, P < 0.05).
Both
serum leptin
and adiponectin
levels
were associated with the presence of
serum
8-epi-PGF2 alpha (
leptin
, r = 0.513, P < 0.05; adiponectin, r = -0.422, P < 0.05).
Administration of VE decreases
leptin
and adiponectin expression in obese rats.
[MeSH-major]
Adiponectin / blood. Adiponectin / genetics. Antioxidants / pharmacology.
Leptin
/ blood.
Leptin
/ genetics. Obesity / blood. Obesity / genetics. Vitamin E / pharmacology
MedlinePlus Health Information.
consumer health - Antioxidants
.
MedlinePlus Health Information.
consumer health - Obesity
.
MedlinePlus Health Information.
consumer health - Vitamin E
.
Gene Ontology.
gene/protein/disease-specific - Gene Ontology annotations from this paper
.
Hazardous Substances Data Bank.
PROSTAGLANDIN F2ALPHA
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20404018.001).
[ISSN]
1535-3699
[Journal-full-title]
Experimental biology and medicine (Maywood, N.J.)
[ISO-abbreviation]
Exp. Biol. Med. (Maywood)
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Adiponectin; 0 / Antioxidants; 0 / Biomarkers; 0 / DNA Primers; 0 / Dietary Fats; 0 / Leptin; 0 / RNA, Messenger; 1406-18-4 / Vitamin E; 27415-26-5 / 8-epi-prostaglandin F2alpha; B7IN85G1HY / Dinoprost; EC 1.11.1.9 / Glutathione Peroxidase
95.
Lassiter TL, Ryde IT, Levin ED, Seidler FJ, Slotkin TA:
Neonatal exposure to parathion alters lipid metabolism in adulthood: Interactions with dietary fat intake and implications for neurodevelopmental deficits.
Brain Res Bull
; 2010 Jan 15;81(1):85-91
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We assessed
serum leptin
and adiponectin, tumor necrosis factor-alpha (TNFalpha) in adipose tissues, and thiobarbituric acid reactive species (TBARS) in peripheral tissues and brain regions.
Neonatal parathion exposure uncoupled
serum leptin levels
from their dependence on body weight, suppressed adiponectin and elevated TNFalpha in white adipose tissue.
Our results are consistent with impaired fat utilization and prediabetes,
as well
as exposing a potential relationship between effects on fat metabolism and on synaptic function in the brain.
MedlinePlus Health Information.
consumer health - Dietary Fats
.
COS Scholar Universe.